2024/12/21 更新

写真a

カミムラ ヒロテル
上村 博輝
KAMIMURA Hiroteru
所属
医歯学総合病院 消化器内科 講師
職名
講師
▶ researchmapのプロフィールを表示
外部リンク

学位

  • 博士(医学) ( 2011年9月   新潟大学 )

研究キーワード

  • 肝病理

  • 急性肝不全

  • 消化器癌

  • 消化器内科

  • 肝栄養

  • 自己免疫性消化器疾患

  • 胆汁うっ滞

  • ウイルス性肝炎

  • 肝細胞癌

研究分野

  • ライフサイエンス / 消化器内科学

経歴

  • 新潟大学   医歯学総合病院 消化器内科   講師

    2022年6月 - 現在

  • 新潟大学   医歯学総合研究科   特任准教授

    2019年4月 - 2022年5月

  • 新潟大学   医歯学総合病院 消化器内科   特任助教

    2017年4月 - 2019年3月

  • 新潟大学   医学部   特任助手

    2015年11月 - 2017年3月

 

論文

  • Diffuse Large B-cell Lymphoma with Severe Lactic Acidosis and Liver Failure: A Case Report and Literature Review.

    Shun Yamazaki, Yusuke Watanabe, Kazuya Takahashi, Kentaro Tominaga, Satoshi Ikarashi, Takeshi Yokoo, Hiroteru Kamimura, Atsunori Tsuchiya, Shuji Terai

    Internal medicine (Tokyo, Japan)   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Among causes of liver failure, liver failure due to lymphocytic infiltration is rare. Unlike typical liver failure, some cases present with severe lactic acidosis and a poor prognosis. We herein report a case of diffuse large B-cell lymphoma with severe lactic acidosis and liver failure. We further discuss the characteristics of similar cases in the literature, suggesting that intrahepatic infiltration by hematological malignant cells should be considered as a differential diagnosis in the presence of severe lactic acidosis and liver failure. This study underscores the importance of early recognition and serves as a reference for future cases.

    DOI: 10.2169/internalmedicine.4450-24

    PubMed

    researchmap

  • Portal biliopathyにより胆管消失症候群を来したと考えられる一例

    木村 究, 上村 博輝, 渡邉 雄介, 五十嵐 聡, 土屋 淳紀, 寺井 崇二, 佐久間 康成, 大西 康晴, 眞田 幸弘, 脇屋 太一, 平田 雄大, 大豆生田 尚彦

    肝臓   65 ( Suppl.1 )   A301 - A301   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • ダサチニブ及びケルセチンは老化細胞除去剤としてMASHメダカモデルにおいて老化細胞を減少させ病態改善に寄与する

    阿部 寛幸, 弥久保 俊太, 渡邉 雄介, 木村 成宏, 横尾 健, 坂牧 僚, 上村 博輝, 土屋 淳紀, 上村 顕也, 寺井 崇二

    肝臓   65 ( Suppl.1 )   A514 - A514   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 【慢性肝臓病の克服を目指して】肝臓リハビリテーションと再生医療の開発状況

    上村 博輝, 土屋 淳紀, 寺井 崇二

    日本内科学会雑誌   113 ( 1 )   69 - 75   2024年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    researchmap

  • Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease. 国際誌

    Itsuo Nagayama, Kenya Kamimura, Takashi Owaki, Masayoshi Ko, Takuro Nagoya, Yuto Tanaka, Marina Ohkoshi, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Shuji Terai

    Hepatology international   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Insulin-like growth factor-1 (IGF-1) is involved in the pathology of non-alcoholic fatty liver disease (NAFLD) and ameliorates fatty infiltration in the liver. It is activated by growth hormone (GH); however, the role of GH-IGF-1 axis in NAFLD developmental phase has not been well identified. Therefore, in this study, we focused on the effect of IGF-1 in NAFLD pathology and GH excretion activation from the pituitary gland by peripheral autonomic neural pathways relaying liver-brain-gut pathway and by central neuropeptides. METHODS: GH and IGF-1 levels were assessed in wild-type and melanocortin-4 receptor knockout mice upon the development of diet-induced NAFLD. The contribution of the peripheral autonomic nervous system connecting the liver-brain-gut axis was assessed by its blockade using capsaicin and that of the central nervous system was assessed by the expression of hypothalamic brain-derived neurotrophic factor (BDNF) and corticotropin-releasing factor (CRH), which activates GH release from the pituitary gland. RESULTS: In the NAFLD mouse models, the levels of GH and IGF-1 increased (p < .05). Further, hepatic fatty infiltration was suppressed even under peripheral autonomic nervous system blockade (p < .001), which inhibited gastric ghrelin expression. In mice with peripheral autonomic nervous blockade, hypothalamic BDNF and CRH were inhibited (p < .05), resulting in GH and IGF-1 excretion, whereas other neuropeptides of somatostatin and cortistatin showed no changes. These complementary effects were canceled in melanocortin-4 receptor knockout mice, which diminished BDNF and CRH release control. CONCLUSIONS: Our study demonstrates that the release of IGF-1 by the nervous system is a key factor in maintaining the pathological homeostasis of NAFLD, suggesting its therapeutic potential.

    DOI: 10.1007/s12072-023-10601-1

    PubMed

    researchmap

  • Development and validation of machine learning model for predicting treatment responders in patients with primary biliary cholangitis. 国際誌

    Naruhiro Kimura, Kazuya Takahashi, Toru Setsu, Yusuke Horibata, Yusuke Kaneko, Haruka Miyazaki, Kohei Ogawa, Yuzo Kawata, Norihiro Sakai, Yusuke Watanabe, Hiroyuki Abe, Hiroteru Kamimura, Akira Sakamaki, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    Hepatology research : the official journal of the Japan Society of Hepatology   2023年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIMS: Ursodeoxycholic acid is the first-line treatment for primary biliary cholangitis, and treatment response is one of the factors predicting the outcome. To prescribe alternative therapies, clinicians might need additional information before deciphering the treatment response to ursodeoxycholic acid, contributing to a better patient prognosis. In this study, we developed and validated machine learning (ML) algorithms to predict treatment responses using pretreatment data. METHODS: This multicenter cohort study included collecting datasets from two data samples. Data 1 included 245 patients from 18 hospitals for ML development, and was divided into (i) training and (ii) development sets. Data 2 (iii: test set) included 51 patients from our hospital for validation. An extreme gradient boosted tree predicted the treatment response in the ML model. The area under the curve was used to evaluate the efficacy of the algorithm. RESULTS: Data 1 showed that patients complying with the Paris II treatment response had significantly lower serum alkaline phosphatase and total bilirubin levels than those who did not respond. Three factors, total bilirubin, total protein, and alanine aminotransferase levels were selected as essential variables for prediction. Data 2 showed that patients complying with the Paris II criteria had significantly high prothrombin time and low total bilirubin levels. The area under the curve of extreme gradient boosted tree was good for (ii) (0.811) and (iii) (0.856). CONCLUSIONS: We demonstrated the efficacy of ML in predicting the treatment response for patients with primary biliary cholangitis. Early identification of cases requiring additional treatment with our novel ML model may improve prognosis.

    DOI: 10.1111/hepr.13966

    PubMed

    researchmap

  • 多職種の肝炎医療コーディネーターとの連携による,院内におけるC型肝炎患者の拾い上げと紹介率向上の効果

    荒生 祥尚, 酒井 規裕, 薛 徹, 渡邉 雄介, 木村 成宏, 阿部 寛幸, 坂牧 僚, 上村 博輝, 横尾 健, 土屋 淳紀, 上村 顕也, 寺井 崇二

    肝臓   64 ( Suppl.2 )   A634 - A634   2023年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Machine learning prediction model for treatment responders in patients with primary biliary cholangitis. 国際誌

    Naruhiro Kimura, Kazuya Takahashi, Toru Setsu, Shu Goto, Suguru Miida, Nobutaka Takeda, Yuichi Kojima, Yoshihisa Arao, Kazunao Hayashi, Norihiro Sakai, Yusuke Watanabe, Hiroyuki Abe, Hiroteru Kamimura, Akira Sakamaki, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    JGH open : an open access journal of gastroenterology and hepatology   7 ( 6 )   431 - 438   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Treatment response to ursodeoxycholic acid may predict the prognosis of patients with primary biliary cholangitis (PBC). Recent studies have suggested the benefits of using machine learning (ML) to forecast complex medical predictions. We aimed to predict treatment response in patients with PBC using ML and pretreatment data. METHODS: We conducted a single-center retrospective study and collected data from 194 patients with PBC who were followed up for at least 12 months after treatment initiation. Patient data were analyzed with five ML models, namely random forest, extreme gradient boosting (XGB), decision tree, naïve Bayes, or logistic regression, to predict treatment response using the Paris II criteria. The established models were assessed using an out-of-sample validation. The area under the curve (AUC) was used to evaluate the efficacy of each algorithm. Overall survival and liver-related deaths were analyzed using Kaplan-Meier analysis. RESULTS: Compared to logistic regression (AUC = 0.595, P = 0.0219, 0.031 models), ML analyses showed significantly high AUC in the random forest (AUC = 0.84) and XGB (AUC = 0.83) models; however, the AUC was not significantly high for decision tree (AUC = 0.633) or naïve Bayes (AUC = 0.584) models. Kaplan-Meier analysis showed significantly improved prognoses in patients predicted to achieve the Paris II criteria by XGB (log-rank = 0.005 and 0.007). CONCLUSION: ML algorithms could improve treatment response prediction using pretreatment data, which could lead to better prognoses. In addition, the ML model using XGB could predict the prognosis of patients before treatment initiation.

    DOI: 10.1002/jgh3.12915

    PubMed

    researchmap

  • FDA,PMDAデータベース20年の副作用報告から報告形態による国際比較の解析

    上村 博輝, 酒井 規裕, 木村 成宏, 薛 徹, 土屋 淳紀, 寺井 崇二

    肝臓   64 ( Suppl.1 )   A412 - A412   2023年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 消化器疾患とビッグデータ インターネット普及による薬物関連有害事象報告の変遷 FDAの20年の副作用報告からの解析

    上村 博輝, 土屋 淳紀, 寺井 崇二

    日本消化器病学会雑誌   120 ( 臨増総会 )   A40 - A40   2023年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 急性肝不全に対する治療 内科,外科の立場から 新潟県での急性肝不全診療ネットワークの構築とOn line HD導入への取り組み

    薛 徹, 上村 博輝, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌明, 寺井 崇二

    肝臓   64 ( 2 )   92 - 93   2023年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Analysis of drug-induced liver-related adverse event trend reporting between 1997 and 2019. 国際誌

    Hiroteru Kamimura, Toru Setsu, Naruhiro Kimura, Makoto Miyazawa, Shota Kaneko, Kenya Kamimura, Atsunori Tsuchiya, Yoshihiro Uesawa, Shuji Terai

    Hepatology research : the official journal of the Japan Society of Hepatology   53 ( 6 )   556 - 568   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: This study aimed to analyze the current trends of drug-induced liver-related adverse events in the Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases. METHODS: The characteristics of implicated drugs were investigated by analyzing big data on drug-induced liver-related adverse events over the past 20 years in FAERS, comparing drug rankings between the JADER and FAERS databases, and calculating rankings of drugs inducing liver-related adverse events using the Medical Dictionary for Regulatory Activities Terminology. RESULTS: In the 452,272 cases registered in FAERS from 1997 to 2019, warfarin, paracetamol, and adalimumab were the drugs most related to DILI. In the 38,919 cases registered in the JADER from 2004 to 2019, sorafenib, nivolumab, and herbal extracts were the drugs most related to DILI. No associations were found between the top 30 drugs in either of the two databases. Notably, the number of drug-induced liver-related adverse event reports and total adverse events has sharply increased in recent years. CONCLUSIONS: Although liver-related adverse events are largely caused by host immunity and other constitutional factors, differences in primary diseases, countries, and historical backgrounds lead to differences in the number of reports. Securing an appropriate database and a mechanism to collect real-time information on the frequency of adverse drug reactions is warranted. This article is protected by copyright. All rights reserved.

    DOI: 10.1111/hepr.13883

    PubMed

    researchmap

  • Navitoclax improves acute-on-chronic liver failure by eliminating senescent cells in mice. 国際誌

    Yusuke Watanabe, Hiroyuki Abe, Naruhiro Kimura, Yoshihisa Arao, Natsuki Ishikawa, Maeda Yuichiro, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    Hepatology research : the official journal of the Japan Society of Hepatology   53 ( 5 )   460 - 472   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Acute-on-chronic liver failure (ACLF), a disease with poor prognosis, is reportedly caused by cellular senescence due to mitochondrial dysfunction. In this study, we described and analyzed the underlying mechanism of a novel approach for ACLF using ABT263/navitoclax (Navi) that selectively eliminates senescent cells. METHODS: Irradiation-induced senescent hepatocytes were used for in vitro evaluation of the effects of Navi on ACLF (n = 6 for each group). Lipopolysaccharide- and carbon tetrachloride-induced ACLF mouse model was used for in vivo evaluation of the effects of Navi administration compared with the control using one-way or two-way analysis of variance, followed by Student's t-test or Kruskal-Wallis test. The effects on the senescence-associated secretory phenotype (n = 8 for each group) and mitochondrial functions, including adenosine triphosphate concentration and membrane potential (n = 8 for each group), were investigated using real-time polymerase chain reaction, immunohistochemistry, and enzyme analysis. RESULTS: Navi eliminated irradiation-induced senescent hepatocytes in vitro, leading to non-senescent hepatocyte proliferation. Navi eliminated senescent cells in the liver in vivo, resulting in downregulation of mRNA expression of senescence-associated secretory phenotype factors, a decrease of liver enzymes, and upregulated proliferation of non-senescent cells in the liver. Regarding mitochondrial functional assessment in the liver, adenosine triphosphate concentration and membrane potential were upregulated after Navi administration in vitro and in vivo. CONCLUSIONS: Navi may ameliorate ACLF damage by eliminating senescent cells in the liver, downregulating senescence-associated secretory phenotype factors, and upregulating mitochondrial functions. We believe that this novel approach using Navi will pave the way for ACLF treatment.

    DOI: 10.1111/hepr.13879

    PubMed

    researchmap

  • HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma. 国際誌

    Chiyumi Oda, Kenya Kamimura, Osamu Shibata, Shinichi Morita, Yuto Tanaka, Toru Setsu, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Satoshi Kofuji, Toshifumi Wakai, Hiroshi Nishina, Shuji Terai

    Biochemistry and biophysics reports   32   101352 - 101352   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) accounts for 10%-20% of the total HCC numbers. Its clinical features include the occurrence in the younger generation, large tumors, and poor prognosis. The contribution of hepatitis B virus X (HBx) protein in hepatocytes during activation of various oncogenic pathways has been reported. We aimed to assess the possible association between HBx and Yes-associated protein (YAP) expression in the liver tissue and the clinical features of HBV-related HCC. Methods: The relationship between HBx and YAP expression was examined in vivo using HCC tumor and peritumor tissues (n = 55). The clinical information including tumor size, marker, and the prognosis was assessed with protein expressions. The in vitro gene expression analyses were conducted using HBx- and YAP-overexpressing HCC cell lines. Results: Among 19 cases of HBV-related, 17 cases of hepatitis C virus (HCV)-related, and 19 cases of nonviral-related HCC, the HBV-related tumor showed the largest size. The HBx-stained area in the tumor and peritumor tissue showed a significant correlation with tumor size and serum α-fetoprotein level. YAP expression was higher in HBV-related tumor tissue than in the peritumor tissue and HCV-related tumor. Additionally, HBx and YAP protein expressions are correlated and both expressions in the tumor contributed to the poor prognosis. An in vitro study demonstrated that HBx and YAP overexpression in the hepatocytes activate the various oncogenic signaling pathways. Conclusions: Our study demonstrated that YAP expression in the liver of HBV-infected patients might be the key factor in HBV-related HCC development and control of tumor-related features.

    DOI: 10.1016/j.bbrep.2022.101352

    PubMed

    researchmap

  • 小児NAFLD患者の背景疾患と移行医療への課題

    上村 博輝, 佐藤 毅昂, 山崎 文紗子, 坂牧 僚, 土屋 淳紀, 寺井 崇二, 長崎 啓祐, 齋藤 昭彦

    肥満研究   28 ( Suppl. )   290 - 290   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肥満学会  

    researchmap

  • 小児NAFLD患者の背景疾患と移行医療への課題

    上村 博輝, 佐藤 毅昂, 山崎 文紗子, 坂牧 僚, 土屋 淳紀, 寺井 崇二, 長崎 啓祐, 齋藤 昭彦

    肥満研究   28 ( Suppl. )   290 - 290   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肥満学会  

    researchmap

  • Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression.

    Norihiro Sakai, Kenya Kamimura, Hirotaka Miyamoto, Masayoshi Ko, Takuro Nagoya, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Hiroyuki Soki, Ayako Tokunaga, Tatsuo Inamine, Mikiro Nakashima, Hatsune Enomoto, Kazuki Kousaka, Hidehisa Tachiki, Kaname Ohyama, Shuji Terai

    Journal of gastroenterology   58 ( 1 )   53 - 68   2022年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: To establish a treatment option for liver fibrosis, the possibility of the drug repurposing theory was investigated, with a focus on the off-target effects of active pharmaceutical ingredients. METHODS: First, several active pharmaceutical ingredients were screened for their effects on the gene expression in the hepatocytes using chimeric mice with humanized hepatocytes. As per the gene expression-based screening assay for 36 medications, we assessed the mechanism of the antifibrotic effect of letrozole, a third-generation aromatase inhibitor, in mouse models of liver fibrosis induced by carbon tetrachloride (CCl4) and a methionine choline-deficient (MCD) diet. We assessed liver histology, serum biochemical markers, and fibrosis-related gene and protein expressions in the hepatocytes. RESULTS: A gene expression-based screening assay revealed that letrozole had a modifying effect on fibrosis-related gene expression in the hepatocytes, including YAP, CTGF, TGF-β, and CYP26A1. Letrozole was administered to mouse models of CCl4- and MCD-induced liver fibrosis and it ameliorated the liver fibrosis. The mechanisms involved the inhibition of the Yap-Ctgf profibrotic pathway following a decrease in retinoic acid levels in the hepatocytes caused by suppression of the hepatic retinol dehydrogenase, Hsd17b13 and activation of the retinoic acid hydrogenase, Cyp26a1. CONCLUSIONS: Letrozole slowed the progression of liver fibrosis by inhibiting the Yap-Ctgf pathway. The mechanisms involved the modification of the Hsd17b13 and Cyp26a1 expressions led to the suppression of retinoic acid in the hepatocytes, which contributed to the activation of Yap-Ctgf pathway. Because of its off-target effect, letrozole could be repurposed for the treatment of liver fibrosis. The third-generation aromatase inhibitor letrozole ameliorated liver fibrosis by suppressing the Yap-Ctgf pathway by partially modifying the Hsd17b13 and Cyp26a1 expressions, which reduced the retinoic acid level in the hepatocytes. The gene expression analysis using chimeric mice with humanized liver revealed that the mechanisms are letrozole specific and, therefore, may be repurposed for the treatment of liver fibrosis.

    DOI: 10.1007/s00535-022-01929-w

    PubMed

    researchmap

  • 肝硬変,肝癌治療薬の薬物関連有害事象報告の国際比較把握とその解釈による今後のマネージメント

    上村 博輝, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.3 )   A792 - A792   2022年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 慢性肝疾患におけるTGFβ3の発現と肝予備能との関連性についての検討

    阿部 寛幸, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 上村 博輝, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.2 )   A597 - A597   2022年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • アテゾリズマブ+ベバシズマブ併用療法の非奏効例におけるLate line移行時期についての検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.2 )   A582 - A582   2022年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • アテゾリズマブ+ベバシズマブ併用療法の非奏効例におけるLate line移行時期についての検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.2 )   A582 - A582   2022年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 慢性肝疾患におけるTGFβ3の発現と肝予備能との関連性についての検討

    阿部 寛幸, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 上村 博輝, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.2 )   A597 - A597   2022年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Effects of a selective PPARα modulator, sodium-glucose cotransporter 2 inhibitor, and statin on the myocardial morphology of medaka nonalcoholic fatty liver disease model. 国際誌

    Marina Ohkoshi-Yamada, Kenya Kamimura, Atsushi Kimura, Yuto Tanaka, Itsuo Nagayama, Shunta Yakubo, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai

    Biochemical and biophysical research communications   625   116 - 121   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic dysregulation and is linked with various cardiovascular complications, which often lead to poor prognostic outcomes. To develop a standard therapy for NAFLD and to urgently address its complications, the current study aimed to investigate the mechanisms of NAFLD-related heart disease and the therapeutic effects of drugs targeting various metabolic pathways. METHODS: To explore the mechanism of NAFLD-related heart disease, a medaka model of high-fat diet-induced NAFLD was utilized. The gross structural, histological, and inflammatory changes in the myocardium were evaluated in a time-dependent manner. In addition, the therapeutic effects of medicines used for NAFLD treatment including, selective peroxisome proliferator-activated receptor α modulator (SPPARMα, pemafibrate), sodium-glucose cotransporter 2 (SGLT2) inhibitor (tofogliflozin), and statin (pitavastatin), and their combinations on heart pathology were evaluated. To determine the mechanisms underlying the therapeutic effects, the expression of genes related to liver inflammation was assessed via whole transcriptome sequencing analysis. RESULTS: The fish with NAFLD-related heart injury presented with cardiomyocyte hypertrophy, which led to cardiac hypertrophy. This morphological change was caused by the infiltration of inflammatory cells, including macrophages and CD4- and CD8-positive lymphocytes, in the cardiac wall and the expression of transforming growth factor beta 1 in the cardiomyocytes. Further, the livers of the fish had upregulated expressions of senescence-associated secretory phenotype-related genes. Treatment with pemafibrate, tofogliflozin, and pitavastatin reduced these changes and, consequently, cardiomyopathy. CONCLUSION: Our results demonstrated that NAFLD-related heart disease was attributed to the senescence-associated secretory phenotype-induced inflammatory activity in the cardiac wall, which resulted in myocardial hypertrophy. Moreover, the effects of SPPARMα, SGLT2 inhibitor, and statin on NAFLD-related heart disease were evident in the medaka NAFLD model.

    DOI: 10.1016/j.bbrc.2022.07.117

    PubMed

    researchmap

  • 機械学習を用いた慢性心不全に続発した肝臓への障害(Cardiac Hepatopathy)の画像解析

    三井田 秀, 上村 博輝, 山崎 文紗子, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 薛 徹, 横尾 健, 坂牧 僚, 土屋 淳紀, 藤木 伸也, 猪又 孝元, 寺井 崇二

    日本門脈圧亢進症学会雑誌   28 ( 3 )   152 - 152   2022年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • Cumulative risk of developing a new symptom in patients with primary biliary cholangitis and its impact on prognosis. 国際誌

    Naruhiro Kimura, Toru Setsu, Yoshihisa Arao, Norihiro Sakai, Yusuke Watanabe, Hiroyuki Abe, Hiroteru Kamimura, Akira Sakamaki, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Akihiko Osaki, Kentarou Igarashi, Nobuo Waguri, Masahiko Yanagi, Toru Takahashi, Soichi Sugitani, Yuka Kobayashi, Masaaki Takamura, Akira Yoshikawa, Toru Ishikawa, Toshiaki Yoshida, Toshiaki Watanabe, Hitoshi Bannai, Tomoyuki Kubota, Kazuhiro Funakoshi, Hiroto Wakabayashi, So Kurita, Norio Ogata, Masashi Watanabe, Yuhsaku Mita, Shigeki Mori, Motoya Sugiyama, Toru Miyajima, Sumio Takahashi, Shuichi Sato, Kisei Ishizuka, Hironobu Ohta, Yutaka Aoyagi, Shuji Terai

    JGH open : an open access journal of gastroenterology and hepatology   6 ( 8 )   577 - 586   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background and Aim: Symptoms of primary biliary cholangitis (PBC) frequently impair one's quality of life (QOL). Nonetheless, with improved treatment, the prognosis of PBC also improves. QOL plays an important role in patients with PBC. In this study, we aimed to reevaluate the transition of new symptom development in PBC and its predictive factors. Methods: This retrospective multicenter study enrolled 382 patients with PBC for symptom analysis. The impact of a newly developed symptom on PBC prognosis was investigated by Kaplan-Meier analysis with propensity score matching and logistic progression analysis. Results: The cumulative risk of developing a new symptom after 10 and 20 years of follow-up was 7.6 and 28.2%, and specifically that of pruritus, which was the most common symptom, was 6.7 and 23.3%, respectively. In Cox hazard risk analysis, serum Alb level (hazard ratio [HR], 1.097; 95% confidence interval [CI], 1.033-1.165; P = 0.002), the serum D-Bil level (HR, 6.262; 95% CI, 2.522-15.553, P < 0.001), and Paris II criteria (HR, 0.435; 95% CI, 0.183-1.036; P = 0.037) were significant independent predictors of a new symptom. Kaplan-Meier analysis showed that the overall survival and liver-related death were not significant between patients with and without a new symptom. Conclusion: The cumulative risk of new symptom development is roughly 30% 20 years after diagnosis and could be predicted by factors including serum albumin levels, serum D-Bil level, and Paris II criteria.

    DOI: 10.1002/jgh3.12789

    PubMed

    researchmap

  • 機械学習を用いた慢性心不全に続発した肝臓への障害(Cardiac Hepatopathy)の画像解析

    三井田 秀, 上村 博輝, 山崎 文紗子, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 薛 徹, 横尾 健, 坂牧 僚, 土屋 淳紀, 藤木 伸也, 猪又 孝元, 寺井 崇二

    日本門脈圧亢進症学会雑誌   28 ( 3 )   152 - 152   2022年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • 肝性腹水が腹部コンパートメント症候群を介して腎機能へ与える影響の検討

    上村 博輝, 酒井 規裕, 小島 雄一, 川田 雄三, 渡邊 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 横尾 健, 坂牧 僚, 土屋 淳紀, 上村 顕也, 横山 純二, 寺井 崇二

    日本門脈圧亢進症学会雑誌   28 ( 2 )   199 - 203   2022年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    大量の肝性腹水が腹腔内圧の上昇をもたらし、腹部コンパートメント症候群を発症している状況を腹水前後の膀胱内圧測定、腎静脈流速測定を中心に検討した。対象症例は穿刺前後の膀胱内圧測定、腎静脈の流速測定等が可能であった腹水合併肝硬変8例。穿刺前後の膀胱内圧、尿潜血反応、腎機能、腎静脈流速等を経時的に観察した。末期肝硬変患者が肝腎症候群へ移行する過程で腹水による腹腔内圧の上昇が腎うっ血を併発させ、レニン-アンギオテンシン-アルドステロン系の亢進に関係する可能性が示唆された。(著者抄録)

    researchmap

  • 【肝性脳症の病態と治療】肝性脳症と腸内細菌 病態と治療

    坂牧 僚, 上村 顕也, 横山 邦彦, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 薛 徹, 阿部 寛幸, 上村 博輝, 横尾 健, 土屋 淳紀, 寺井 崇二

    消化器・肝臓内科   12 ( 1 )   68 - 72   2022年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • 肝性腹水が腹部コンパートメント症候群を介して腎機能へ与える影響の検討

    上村 博輝, 酒井 規裕, 小島 雄一, 川田 雄三, 渡邊 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 横尾 健, 坂牧 僚, 土屋 淳紀, 上村 顕也, 横山 純二, 寺井 崇二

    日本門脈圧亢進症学会雑誌   28 ( 2 )   199 - 203   2022年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    大量の肝性腹水が腹腔内圧の上昇をもたらし、腹部コンパートメント症候群を発症している状況を腹水前後の膀胱内圧測定、腎静脈流速測定を中心に検討した。対象症例は穿刺前後の膀胱内圧測定、腎静脈の流速測定等が可能であった腹水合併肝硬変8例。穿刺前後の膀胱内圧、尿潜血反応、腎機能、腎静脈流速等を経時的に観察した。末期肝硬変患者が肝腎症候群へ移行する過程で腹水による腹腔内圧の上昇が腎うっ血を併発させ、レニン-アンギオテンシン-アルドステロン系の亢進に関係する可能性が示唆された。(著者抄録)

    researchmap

  • The liver-gut peripheral neural axis and nonalcoholic fatty liver disease pathologies via hepatic serotonin receptor 2A. 国際誌

    Takashi Owaki, Kenya Kamimura, Masayoshi Ko, Itsuo Nagayama, Takuro Nagoya, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Takeki Sato, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, Shuji Terai

    Disease models & mechanisms   15 ( 7 )   2022年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Serotonin (5-HT) is one of the key bioamines of nonalcoholic fatty liver disease (NAFLD). Its mechanism via autonomic neural signal pathways remains unexplained; hence, we evaluated the involvement of 5-HT and related-signaling pathways via autonomic nerves in NAFLD. Diet-induced NAFLD animal models were developed using wild-type and melanocortin 4 receptor knockout (MC4RKO) mice, and the effects of autonomic neural axis on NAFLD physiology, 5-HT and its receptors (Htrs), and lipid metabolism-related genes were assessed applying hepatic nerve blockade. Hepatic neural blockade retarded the progression of NAFLD by reducing 5-HT in the small intestine, hepatic Htr2a, and hepatic lipogenic genes expression, and HTR2A antagonist reproduced these effects. The effects were milder in MC4RKO, and brain 5-HT and Htr2c expression did not correlate with peripheral neural blockade. Our study demonstrates that the autonomic liver-gut neural axis is involved in the etiology of diet-induced NAFLD and that 5-HT and HTR2A are key factors, implying that the modulation of the axis and use of HTR2A antagonists are potentially novel therapeutic strategies for NAFLD treatment.

    DOI: 10.1242/dmm.049612

    PubMed

    researchmap

  • Involvement of DNA Damage Response via the Ccndbp1-Atm-Chk2 Pathway in Mice with Dextran-Sodium-Sulfate-Induced Colitis. 国際誌

    Ryoko Horigome, Kenya Kamimura, Yusuke Niwa, Kohei Ogawa, Ken-Ichi Mizuno, Koichi Fujisawa, Naoki Yamamoto, Taro Takami, Tomoyuki Sugano, Akira Sakamaki, Hiroteru Kamimura, Masaaki Takamura, Shuji Terai

    Journal of clinical medicine   11 ( 13 )   2022年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The dextran sodium sulfate (DSS)-induced colitis mouse model has been widely utilized for human colitis research. While its mechanism involves a response to double-strand deoxyribonucleic acid (DNA) damage, ataxia telangiectasia mutated (Atm)-checkpoint kinase 2 (Chk2) pathway activation related to such response remains unreported. Recently, we reported that cyclin D1-binding protein 1 (Ccndbp1) activates the pathway reflecting DNA damage in its knockout mice. Thus, this study aimed to examine the contribution of Ccndbp1 and the Atm-Chk2 pathway in DSS-induced colitis. We assessed the effect of DSS-induced colitis on colon length, disease activity index, and histological score and on the Atm-Chk2 pathway and the subsequent apoptosis in Ccndbp1-knockout mice. DSS-induced colitis showed distal colon-dominant Atm and Chk2 phosphorylation, increase in TdT-mediated dUTP-biotin nick end labeling and cleaved caspase 3-positive cells, and histological score increase, causing disease activity index elevation and colon length shortening. These changes were significantly ameliorated in Ccndbp1-knockout mice. In conclusion, Ccndbp1 contributed to Atm-Chk2 pathway activation in the DSS-induced colitis mouse model, causing inflammation and apoptosis of mucosal cells in the colon.

    DOI: 10.3390/jcm11133674

    PubMed

    researchmap

  • Relative Dose Intensityに基づく高齢者レンバチニブ投与における全生存期間の検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A302 - A302   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Methotrexate-associated proliferative disorder in the lower esophagus extending to the gastroesophageal junction: A case report. 国際誌

    Yuki Hojo, Masafumi Takatsuna, Satoshi Ikarashi, Hiroteru Kamimura, Rika Kimura, Masaki Mito, Yusuke Watanabe, Yusuke Tani, Junji Yokoyama, Shuji Terai

    DEN open   2 ( 1 )   e14   2022年4月

     詳細を見る

    記述言語:英語  

    A 64-year-old woman was receiving oral methotrexate (MTX) for rheumatoid arthritis (RA) for 15 years. She underwent esophagogastroduodenoscopy because of discomfort in the chest. Endoscopic findings revealed an ulcer in the lower esophagus extending to the gastroesophageal junction (EGJ). The ulcer occupied half of the esophageal lumen and had a sharp and clear margin. Magnifying narrow-band imaging endoscopy revealed the deposition of white plaque, and there were few microvessels in the edge and bottom of the ulcer. Histologic examination of the biopsy specimens from the oral edge of the lesion revealed proliferation of atypical lymphoid cells (immunophenotype results: CD20 [+], CD3 [partially +], CD5 [-], and BCL-2 [-]]. The patient was diagnosed with methotrexate-associated lymphoproliferative disorder (MTX-LPD) and was advised to stop MTX intake. After 2 months of stopping MTX, the ulcer was found to be almost regressed and showed signs of healing. MTX-LPD in the lower esophagus extending to the EGJ is extremely rare. This case can help in expanding the understanding of esophageal MTX-LPD.

    DOI: 10.1002/deo2.14

    PubMed

    researchmap

  • Relative Dose Intensityに基づく高齢者レンバチニブ投与における全生存期間の検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A302 - A302   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝疾患の小児・成人移行期医療の課題-全人的ケアの確立を目指して 成人外来へ受診する可能性をもつ小児脂肪肝の特徴

    上村 博輝, 上村 顕也, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A169 - A169   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝疾患の画像情報による病態解明と診療応用 心不全患者が肝形態に及ぼす影響(Cardiac Hepatopathy)の画像による解析

    上村 博輝, 土屋 淳紀, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増総会 )   A223 - A223   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Cyclin D1 Binding Protein 1 Responds to DNA Damage through the ATM-CHK2 Pathway. 国際誌

    Yusuke Niwa, Kenya Kamimura, Kohei Ogawa, Chiyumi Oda, Yuto Tanaka, Ryoko Horigome, Masato Ohtsuka, Hiromi Miura, Koichi Fujisawa, Naoki Yamamoto, Taro Takami, Shujiro Okuda, Masayoshi Ko, Takashi Owaki, Atsushi Kimura, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai

    Journal of clinical medicine   11 ( 3 )   2022年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Cyclin D1 binding protein 1 (CCNDBP1) is considered a tumor suppressor, and when expressed in tumor cells, CCNDBP1 can contribute to the viability of cancer cells by rescuing these cells from chemotherapy-induced DNA damage. Therefore, this study focused on investigating the function of CCNDBP1, which is directly related to the survival of cancer cells by escaping DNA damage and chemoresistance. Hepatocellular carcinoma (HCC) cells and tissues obtained from Ccndbp1 knockout mice were used for the in vitro and in vivo examination of the molecular mechanisms of CCNDBP1 associated with the recovery of cells from DNA damage. Subsequently, gene and protein expression changes associated with the upregulation, downregulation, and irradiation of CCNDBP1 were assessed. The overexpression of CCNDBP1 in HCC cells stimulated cell growth and showed resistance to X-ray-induced DNA damage. Gene expression analysis of CCNDBP1-overexpressed cells and Ccndbp1 knockout mice revealed that Ccndbp1 activated the Atm-Chk2 pathway through the inhibition of Ezh2 expression, accounting for resistance to DNA damage. Our study demonstrated that by inhibiting EZH2, CCNDBP1 contributed to the activation of the ATM-CHK2 pathway to alleviate DNA damage, leading to chemoresistance.

    DOI: 10.3390/jcm11030851

    PubMed

    researchmap

  • Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. 国際誌

    Atsushi Kimura, Kenya Kamimura, Marina Ohkoshi-Yamada, Yoko Shinagawa-Kobayashi, Ryo Goto, Takashi Owaki, Chiyumi Oda, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai

    Biochemical and biophysical research communications   596   76 - 82   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Nonalcoholic steatohepatitis (NASH) is a disease entity with an increasing incidence, with involvement of several metabolic pathways. Various organs, including the liver, kidneys, and the vasculature, are damaged in NASH, indicating the urgent need to develop a standard therapy. Therefore, this study was conducted to investigate the effects of drugs targeting various metabolic pathways and their combinations on a high-fat diet (HFD)-induced NASH medaka model. METHODS: To investigate the effects of drugs on vascular structures, the NASH animal model was developed using the fli::GFP transgenic medaka fed with HFD at 20 mg/fish daily. The physiological changes, histological changes in the liver, vascular structures in the fin, and serum biochemical markers were evaluated in a time-dependent manner after treatment with selective peroxisome proliferator-activated receptor α modulator (pemafibrate), statin (pitavastatin), sodium-glucose cotransporter 2 inhibitor (tofogliflozin), and their combinations. Furthermore, to determine the mechanisms underlying the effects, whole transcriptome sequencing was conducted using medaka liver samples. RESULTS: Histological analyses revealed significant suppression of fat accumulation and fibrotic changes in the liver after treatment with drugs and their combinations. The expression levels of steatosis- and fibrosis-related genes were modified by the treatments. Moreover, the HFD-induced vascular damages in the fin exhibited milder changes after treatment with the drugs. CONCLUSION: The effects of treating various metabolic pathways on the medaka body, liver, and vascular structures of the NASH medaka model were evidenced. Moreover, to our knowledge, this study is the first to report whole genome sequence and gene expression evaluation of medaka livers, which could be helpful in clarifying the molecular mechanisms of drugs.

    DOI: 10.1016/j.bbrc.2022.01.086

    PubMed

    researchmap

  • Simultaneous muscular hemorrhages in two regions three years after successfully controlling refractory ascites using transjugular intrahepatic portosystemic shunt treatment: a case report.

    Hiroteru Kamimura, Michitaka Imai, Hiroyuki Abe, Aiko Yoshioka, Kanae Hirose, Noriko Ishihara, Toru Ishikawa, Shuji Terai

    Clinical journal of gastroenterology   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Various therapies and drugs have been developed to extend the life expectancy of patients with liver cirrhosis. The prolonged prognosis of cirrhotic patients may change the final cause of death in the future. Deep bleeding into the muscle is an uncommon but potentially life-threatening complication of liver cirrhosis. CASE REPORT: A 53-year-old man had undergone transjugular intrahepatic portosystemic shunt treatment for refractory ascites, which successfully controlled it for three years. However, he had started drinking again and experienced acute-on-chronic liver failure. He also had severe back pain. Abdominal computed tomography showed hyperdensities in the retroperitoneum and right pleural cavity. Despite blood infusion, he died from acute-on-chronic liver failure. A pathological autopsy revealed bleeding from the iliopsoas and right diaphragmatic muscle simultaneously, evident from the presence of red blood cells located between the muscle sheaths. Disruption of the small vessels in the skeletal muscle fibers was inferred. CONCLUSION: This is a critical case that underscores the significance of improving available knowledge based on the cause of final death of the patients with cirrhosis, who now have a good long-term prognosis owing to the latest medical developments.

    DOI: 10.1007/s12328-022-01591-y

    PubMed

    researchmap

  • Use of a Deep Learning Approach for the Sensitive Prediction of Hepatitis B Surface Antigen Levels in Inactive Carrier Patients. 国際誌

    Hiroteru Kamimura, Hirofumi Nonaka, Masaya Mori, Taichi Kobayashi, Toru Setsu, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    Journal of clinical medicine   11 ( 2 )   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Deep learning is a subset of machine learning that can be employed to accurately predict biological transitions. Eliminating hepatitis B surface antigens (HBsAgs) is the final therapeutic endpoint for chronic hepatitis B. Reliable predictors of the disappearance or reduction in HBsAg levels have not been established. Accurate predictions are vital to successful treatment, and corresponding efforts are ongoing worldwide. Therefore, this study aimed to identify an optimal deep learning model to predict the changes in HBsAg levels in daily clinical practice for inactive carrier patients. We identified patients whose HBsAg levels were evaluated over 10 years. The results of routine liver biochemical function tests, including serum HBsAg levels for 1, 2, 5, and 10 years, and biometric information were obtained. Data of 90 patients were included for adaptive training. The predictive models were built based on algorithms set up by SONY Neural Network Console, and their accuracy was compared using statistical analysis. Multiple regression analysis revealed a mean absolute percentage error of 58%, and deep learning revealed a mean absolute percentage error of 15%; thus, deep learning is an accurate predictive discriminant tool. This study demonstrated the potential of deep learning algorithms to predict clinical outcomes.

    DOI: 10.3390/jcm11020387

    PubMed

    researchmap

  • Longitudinal increase in albumin-bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis. 国際誌

    Akira Sakamaki, Masaaki Takamura, Norihiro Sakai, Yusuke Watanabe, Yoshihisa Arao, Naruhiro Kimura, Toru Setsu, Hiroyuki Abe, Takeshi Yokoo, Hiroteru Kamimura, Shunsuke Tsubata, Nobuo Waguri, Toru Ishikawa, Hirokazu Kawai, Soichi Sugitani, Tomomi Sato, Kazuhiro Funakoshi, Masashi Watanabe, Kentarou Igarashi, Kenya Kamimura, Atsunori Tsuchiya, Yutaka Aoyagi, Shuji Terai

    PloS one   17 ( 2 )   e0263464   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Due to the developments in the treatment for hepatitis, it is possible to prevent the progression of liver fibrosis and improve patients' prognosis even if it has already led to liver cirrhosis (LC). Consequently, a two-step study was conducted. To begin with, a retrospective study was conducted to identify the potential predictors of non-malignancy-related mortality from LC. Then, we prospectively analyzed the validity of these parameters as well as their association with patients' quality of life. In the retrospective study, 89 cases were included, and the multivariate Cox regression analysis indicated that age (P = 0.012), model for end-stage liver disease (MELD) score (P = 0.012), and annual rate of change of the albumin-bilirubin (ALBI) score (P < 0.001) were significantly associated with LC prognosis. In the prospective study, 70 patients were included, and the patients were divided into cirrhosis progression and non-progression groups. The univariate logistic regression analysis indicated the serum procollagen type III N-terminal peptide level (P = 0.040) and MELD score (P = 0.010) were significantly associated with the annual rate of change of the ALBI score. Furthermore, the mean Chronic Liver Disease Questionnaire score worsened from 5.3 to 4.9 in the cirrhosis progression group (P = 0.034). In conclusion, a longitudinal increase in the ALBI score is closely associated with non-malignancy-related mortality and quality of life.

    DOI: 10.1371/journal.pone.0263464

    PubMed

    researchmap

  • 脾動脈瘤破裂を契機にC型肝炎治療に至った肝硬変の1例

    北條 雄暉, 上村 博輝, 大脇 崇史, 木村 莉菓, 岩澤 貴宏, 渡邊 雄介, 高綱 将史, 五十嵐 聡, 高村 昌昭, 薛 徹, 荒生 祥尚, 堀井 陽祐, 佐藤 辰彦, 寺井 崇二

    肝臓   62 ( 11 )   749 - 755   2021年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    症例は50代の女性.30代でC型肝炎ウイルスへの感染を指摘されていたが治療に至らず,継続的な受診も行っていなかった.腹痛と意識消失を主訴に救急搬送され,脾動脈瘤破裂による出血性ショックと診断された.当院で脾動脈瘤塞栓術を施行し,術後経過は良好であった.外来にて直接作用型抗ウイルス薬を導入し,ウイルス学的著効を達成した.CT検査の普及により,脾動脈瘤の偶然の発見も増加していると報告されていて,今後本例のように肝臓以外の疾患での受診を契機に,ウイルス性肝炎や肝硬変の診断から治療に至る症例もある.C型肝炎の未治療者や未受検者,非認識受検者は国内に未だ数多く存在しており,脾動脈瘤に関する文献的考察と,新潟県で実施している肝炎患者の拾い上げの試みについても併せて記載し報告する.(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/default/link?pub_year=2021&ichushi_jid=J00263&link_issn=&doc_id=20211111030008&doc_link_id=1390852945233297152&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1390852945233297152&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

  • 脾動脈瘤破裂を契機にC型肝炎治療に至った肝硬変の1例

    北條 雄暉, 上村 博輝, 大脇 崇史, 木村 莉菓, 岩澤 貴宏, 渡邊 雄介, 高綱 将史, 五十嵐 聡, 高村 昌昭, 薛 徹, 荒生 祥尚, 堀井 陽祐, 佐藤 辰彦, 寺井 崇二

    肝臓   62 ( 11 )   749 - 755   2021年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Rare complication of hepatocellular carcinoma in Wilson's disease. 国際誌

    Marina Ohkoshi-Yamada, Kenya Kamimura, Hiroteru Kamimura, Shuji Terai

    JGH open : an open access journal of gastroenterology and hepatology   5 ( 10 )   1220 - 1222   2021年10月

     詳細を見る

    記述言語:英語  

    The complication of hepatocellular carcinoma (HCC) in Wilson's disease is rare. Wilson's disease treatment using D-penicillamine (DPA) is useful to prevent HCC occurrence; however, it also causes iron accumulation and synergistic radical formation in the liver, which may enhance carcinogenesis. Reported herein is a case of HCC in Wilson's disease treated with DPA for 36 years. The tumor was surgically resected and histologically diagnosed with moderately differentiated HCC surrounded by cirrhotic tissue with fatty infiltration. Rhodanine staining revealed a slight positively stained area in both tumor and surrounding tissues. Information obtained from this case and literature review highlight the feature of HCC in Wilson's disease.

    DOI: 10.1002/jgh3.12648

    PubMed

    researchmap

  • 原発性胆汁性胆管炎患者の予後を最もよく予想する治療反応性判定Criteriaについて

    木村 成宏, 高村 昌昭, 武田 信峻, 荒生 祥尚, 高綱 将史, 渡邉 雄介, 竹内 卓, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    日本消化器病学会雑誌   118 ( 臨増大会 )   A698 - A698   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 原発性胆汁性胆管炎患者の予後を最もよく予想する治療反応性判定Criteriaについて

    木村 成宏, 高村 昌昭, 武田 信峻, 荒生 祥尚, 高綱 将史, 渡邉 雄介, 竹内 卓, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    日本消化器病学会雑誌   118 ( 臨増大会 )   A698 - A698   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice. 国際誌

    Shunsuke Nojiri, Atsunori Tsuchiya, Kazuki Natsui, Suguru Takeuchi, Takayuki Watanabe, Yuichi Kojima, Yusuke Watanabe, Hiroteru Kamimura, Masahiro Ogawa, Satoko Motegi, Takahiro Iwasawa, Takeki Sato, Masaru Kumagai, Yui Ishii, Tomomi Kitayama, Yu-Tung Li, Yuya Ouchi, Takashi Shimbo, Masaaki Takamura, Katsuto Tamai, Shuji Terai

    Inflammation and regeneration   41 ( 1 )   28 - 28   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The liver has a high regenerative ability and can induce spontaneous regression of fibrosis when early liver damage occurs; however, these abilities are lost when chronic liver damage results in decompensated cirrhosis. Cell therapies, such as mesenchymal stem cell (MSC) and macrophage therapies, have attracted attention as potential strategies for mitigating liver fibrosis. Here, we evaluated the therapeutic effects of HMGB1 peptide synthesized from box A of high mobility group box 1 protein. Liver damage and fibrosis were evaluated using a carbon tetrachloride (CCl4)-induced cirrhosis mouse model. The effects of HMGB1 peptide against immune cells were evaluated by single-cell RNA-seq using liver tissues, and those against monocytes/macrophages were further evaluated by in vitro analyses. Administration of HMGB1 peptide did not elicit a rapid response within 36 h, but attenuated liver damage after 1 week and suppressed fibrosis after 2 weeks. Fibrosis regression developed over time, despite continuous liver damage, suggesting that administration of this peptide could induce fibrolysis. In vitro analyses could not confirm a direct effect of HMGB1 peptide against monocyte/macrophages. However, macrophages were the most affected immune cells in the liver, and the number of scar-associated macrophages (Trem2+Cd9+ cells) with anti-inflammatory markers increased in the liver following HMGB1 treatment, suggesting that indirect effects of monocytes/macrophages were important for therapeutic efficacy. Overall, we established a new concept for cell-free therapy using HMGB1 peptide for cirrhosis through the induction of anti-inflammatory macrophages.

    DOI: 10.1186/s41232-021-00177-4

    PubMed

    researchmap

  • 急性肝障害からの回復の予測バイオマーカーとしての血中セロトニン測定の意義

    薛 徹, 上村 顕也, 大脇 崇史, 荒生 祥尚, 横尾 健, 坂牧 僚, 上村 博輝, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   62 ( Suppl.2 )   A536 - A536   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma. 国際誌

    Takeki Sato, Atsunori Tsuchiya, Takashi Owaki, Masaru Kumagai, Satoko Motegi, Takahiro Iwasawa, Shunsuke Nojiri, Masahiro Ogawa, Suguru Takeuchi, Yusuke Watanabe, Yuzo Kawata, Hiroteru Kamimura, Shuji Terai

    Biochemical and biophysical research communications   566   36 - 44   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The number of patients with non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD) is increasing. This study elucidates the effect of both NASH and IBD on hepatocellular carcinoma (HCC) using a mouse model combining NASH and IBD. The melanocortin 4 receptor-deficient (Mc4r-KO) mice were divided into four groups with or without a high-fat diet (HFD) and with or without dextran sulfate sodium (DSS) to induce colitis, and the differences in liver damage and occurrence of HCC were analyzed. In the HFD + DSS group, the body weight, liver weight/body weight ratio, and serum levels of albumin and alanine aminotransferase were significantly lower than those in the HFD group. We further found that steatosis was significantly lower and lobular inflammation was significantly higher in the HFD + DSS group than those in the HFD group, and that individual steatosis and lobular inflammation state in the HFD + DSS mice varied. We detected HCC only in the HFD + DSS group, and mice with severe steatosis and mild colitis were found to be at high risk of HCC. Presently, the prediction of HCC is very difficult. In some cases, severe colitis reverses the fat accumulation due to appetite loss. Our findings clearly showed that severe steatohepatitis and mild colitis are simultaneously essential for the occurrence of HCC in patients with NASH and IBD.

    DOI: 10.1016/j.bbrc.2021.05.097

    PubMed

    researchmap

  • The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan. 国際誌

    Akira Sakamaki, Kenya Kamimura, Takeshi Yokoo, Akihiko Osaki, Seiichi Yoshikawa, Yoshihisa Arao, Toru Setsu, Hiroteru Kamimura, Nobuo Waguri, Manabu Takeuchi, Kazuhiro Funakoshi, Shuji Terai

    Medicine   100 ( 32 )   e26902   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    ABSTRACT: Gastrointestinal bleeding, hepatic encephalopathy (HE), and hepatocarcinogenesis are associated with the prognosis of patients with liver cirrhosis (LC). Proton pump inhibitors (PPIs) have been used to prevent bleeding, however the effects of PPIs on overall survival have not yet been elucidated. Therefore, this multicenter retrospective study aimed to assess the effect of PPI on the prognosis and HE occurrence of the patients with liver cirrhosis in Japan.A total of 456 patients diagnosed with LC at the 4 institutes during the study period (2010-2014) were assessed. PPI-treated and non-treated patients were compared using propensity score matching analysis. Primary and secondary endpoints of the study were set as the occurrence of HE and overall survival, respectively.A comparison of all cases showed a significantly poorer hepatic reserve function in the PPI-treated patients. The propensity-score matching analysis was performed and 120 PPI-treated patients were 1:1 matched with non-treated patients. The analysis revealed a higher incidence of HE in the PPI-treated than in the non-treated patients (P = .032; hazard ratio [HR], 2.162; 95% confidence interval [CI], 1.066-4.176), but the prognosis of PPI-treated patients was no worse than that of non-treated patients (P = .676; HR, 1.101; 95% CI, 0.702-1.726).This retrospective study showed that PPI administration for the patients with liver cirrhosis may partly be related to the increased incidence of HE but not worsen the patient prognosis.

    DOI: 10.1097/MD.0000000000026902

    PubMed

    researchmap

  • BRTO中に出血を来し、NBCAによるEISを併用し治療を完遂した十二指腸静脈瘤の1例

    前田 悠一郎, 荒生 祥尚, 小島 雄一, 川田 雄三, 渡邉 雄介, 薛 徹, 阿部 寛幸, 坂牧 僚, 上村 博輝, 横尾 健, 土屋 淳紀, 上村 顕也, 横山 純二, 寺井 崇二

    日本門脈圧亢進症学会雑誌   27 ( 3 )   134 - 134   2021年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • Rapid Onset of Weight Gain and Liver Dysfunction Successfully Treated With Nutrition and Exercise. 国際誌

    Hiroteru Kamimura, Masakazu Sano, Takanori Tsujimura, Yasunaga Takeda, Yuko Komoro, Junji Yokoyama, Shuji Terai

    Cureus   13 ( 7 )   e16530   2021年7月

     詳細を見る

    記述言語:英語  

    Physical inactivity is one of the causes of most metabolic syndromes. The incidence of metabolic syndrome is expected to increase in the near future because of the reduced opportunities for exercise caused by COVID-19. Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease. Changes in diet and lifestyle have led to a dramatic increase in the prevalence of NAFLD in the world. NAFLD is characterized by excessive triglyceride (TG) accumulation in the hepatocytes due to both increased inflow of free fatty acids and de novo hepatic lipogenesis. Thus far, no study quantitatively assessed the liver fat deposition after a rapid decline in physical activity. Herein, we describe a case of a 17-year-old Japanese boy with severe fat infiltration of the liver, due to a rapid decline in physical activity, treated at our facility. Our rehabilitation and nutritional support teams administered appropriate exercise and nutrition support to reduce weight and improve liver dysfunction. Our findings support dietary changes and exercise therapy to manage such cases.

    DOI: 10.7759/cureus.16530

    PubMed

    researchmap

  • 高齢者消化器がん化学療法〜高齢者のがん治療を安全・効果的に遂行するための取り組み 高齢肝細胞癌症例における分子標的治療薬の生存期間延長効果と予測因子の検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    日本高齢消化器病学会誌   24 ( 1 )   115 - 115   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本高齢消化器病学会  

    researchmap

  • Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan. 国際誌

    Naruhiro Kimura, Masaaki Takamura, Nobutaka Takeda, Yusuke Watanabe, Yoshihisa Arao, Masahumi Takatsuna, Suguru Takeuchi, Hiroyuki Abe, Toru Setsu, Hiroteru Kamimura, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    Hepatology international   15 ( 2 )   437 - 443   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Biochemical response to treatment in patients with primary biliary cholangitis (PBC) reflects prognosis. However, the best predictive criteria to detect biochemical response remain undetermined. In addition, because these criteria need > 6 months until definition, parameters that can estimate its results before initiating treatment are needed. METHODS: We conducted a single-center retrospective study on 196 patients with PBC, followed up for at least 12 months after initiating treatment. RESULTS: Kaplan-Meier analysis showed that Paris II (p = 0.002) and Rotterdam criteria (p = 0.001) could estimate the overall survival of PBC patients, whereas Paris II (p = 0.001), Rotterdam (p = 0.001), and Rochester criteria (p= 0.025) could estimate liver-related deaths. Cox hazard analysis revealed Paris II and Rotterdam criteria as significantly independent predictors of overall survival (hazard ratio (HR) 3.948, 95% CI 1.293-12.054, p = 0.016 and HR 6.040, 95% CI 1.969-18.527, p = 0.002, respectively) and liver-related deaths (HR 10.461, 95% CI 1.231-88.936, p = 0.032 and HR 10.824, 95% CI 1.252-93.572, p = 0.032, respectively). The results of Paris II criteria could be estimated by serum prothrombin time (Odds ratio (OR) 1.052, 95% CI 1.008-1.098, p = 0.021) and alanine transaminase level (OR 0.954, 95% CI 0.919-0.991, p = 0.014) whereas, those of Rotterdam criteria could be estimated by serum albumin level (OR 3.649, 95% CI 1.098-12.128, p = 0.035) at the time of diagnosis. CONCLUSIONS: This study highlights the best prediction criteria and pre-treatment parameters that facilitate the prognosis of PBC patients.

    DOI: 10.1007/s12072-021-10163-0

    PubMed

    researchmap

  • point shear wave elastographyを利用した肝線維化のheterogeneityの検証

    横尾 健, 杉田 萌乃, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    超音波医学   48 ( Suppl. )   S713 - S713   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本超音波医学会  

    researchmap

  • Successful treatment of positive-sense RNA virus coinfection with autoimmune hepatitis using double filtration plasmapheresis. 国際誌

    Hiroteru Kamimura, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    BMJ case reports   14 ( 3 )   2021年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Double filtration plasmapheresis (DFPP) is an apheretic technique that selectively removes high molecular weight substances using a plasma component filter. DFPP has been used to treat positive-sense RNA virus infections, mainly chronic hepatitis C virus (HCV) infection, because of its ability to directly eliminate viral particles from blood plasma from 2008 to about 2015, before direct-acting antiviral agents was marketed. This effect has been termed virus removal and eradication by DFPP. HCV is a positive-sense RNA virus similar to West Nile virus, dengue virus and the SARS and Middle East respiratory syndrome coronaviruses. SARS-CoV-2 is classified same viral species. These viruses are all classified in Family Flaviviridae which are family of single-stranded plus-stranded RNA viruses. Viral particles are 40-60 nm in diameter, enveloped and spherical in shape. We present a rare case of HCV removal where an RNA virus infection that copresented with virus-associated autoimmune hepatitis was eliminated using DFPP. Our results indicate that DFPP may facilitate prompt viraemia reduction and may have novel treatment applications for SARS-CoV-2, that is, use of therapeutic plasma exchange for fulminant COVID-19.

    DOI: 10.1136/bcr-2020-236984

    PubMed

    researchmap

  • Relationship between detection of hepatitis B virus in saliva and periodontal disease in hepatitis B virus carriers in Japan. 国際誌

    Hiroteru Kamimura, Jun Watanabe, Tomoyuki Sugano, Junji Kohisa, Hiroyuki Abe, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Shogo Okoshi, Yoshinari Tanabe, Ritsuo Takagi, Hirofumi Nonaka, Shuji Terai

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   27 ( 3 )   492 - 496   2021年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Although hepatitis B virus infection is well-described, the additional risk posed by oral bleeding in individuals with chronic hepatitis B virus infection has not been determined. This study aimed to determine the quantity of hepatitis B virus in the saliva of carriers in Japan, as a means of understanding the potential risk for horizontal transmission. METHODS: Saliva samples from 48 confirmed hepatitis B virus carriers were included in the analysis. Hepatitis B virus concentrations and the presence of occult blood as periodontal disease were evaluated in each sample. RESULTS: Hepatitis B surface antigen was identified in 46 of the 48 samples (98%), with hepatitis B virus DNA identified in 19 of the 48 saliva samples (40%). Occult blood was detected in 32 (67%) samples with the prevalence increasing as a function of age (r = 0.413; P = 0.003). There was a significantly positive correlation between hepatitis B virus DNA levels in the serum and saliva specimens (r = 0.895; P < 0.001). CONCLUSIONS: Occult blood in saliva was detected in most participants. The detection of hepatitis B virus DNA correlated positively with hepatitis B virus in the serum and occult blood in the saliva. Therefore, improved care of periodontal disease among older people is important for preventing horizontal transmission of hepatitis B virus.

    DOI: 10.1016/j.jiac.2020.10.028

    PubMed

    researchmap

  • Potential Effect of a Selective Peroxisome Proliferator-activated Receptor Alpha Modulator on Metabolic Dysfunction-associated Fatty Liver Disease.

    Hiroteru Kamimura, Atsushi Kimura, Shuji Terai

    Internal medicine (Tokyo, Japan)   60 ( 14 )   2165 - 2166   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.2169/internalmedicine.6906-20

    PubMed

    researchmap

  • Rare paraneoplastic syndromes in digestive systems caused by lung cancer. 国際誌

    Hiroteru Kamimura, Tomohiro Iwasaki, Kazunao Hayashi, Shuji Terai

    BMJ case reports   14 ( 2 )   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We observed a rare case of two different digestive paraneoplastic syndromes that improved with the treatment of the neoplasms. The first syndrome was chronic intestinal pseudo-obstruction (CIPO), which is a subtype of paraneoplastic syndromes called a paraneoplastic neurological syndrome (PNS). The second was Stauffer's syndrome, which is a unique paraneoplastic syndrome characterised by non-metastatic intrahepatic cholestasis associated with neoplasms. Here, we report the case of a 55-year-old man who presented with two concurrent paraneoplastic syndromes in the digestive system. The intestinal pseudo-obstruction and elevated biliary enzyme levels improved as the lung cancer responded to chemotherapy. In this case, CIPO as a PNS led to the detection of lung cancer. To our knowledge, this is the first report of Stauffer's syndrome caused by lung adenocarcinoma.

    DOI: 10.1136/bcr-2020-240161

    PubMed

    researchmap

  • Acute on chronicの新展開 当科における我が国の新診断基準でのAcute On Chronic Liver Failure症例の検討

    野尻 俊介, 土屋 淳紀, 阿部 聡司, 坂牧 僚, 上村 博輝, 上村 顕也, 高村 昌昭, 寺井 崇二

    肝臓   62 ( 2 )   107 - 107   2021年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge. 国際誌

    Hiroteru Kamimura, Takeki Sato, Kazuki Natsui, Takamasa Kobayashi, Tomoaki Yoshida, Kenya Kamimura, Atsunori Tsuchiya, Toshiko Murayama, Junji Yokoyama, Hirokazu Kawai, Masaaki Takamura, Shuji Terai

    International journal of molecular sciences   22 ( 3 )   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass and strength that occurs with aging or in association with various diseases. The condition is prevalent worldwide and occurs more frequently in patients with chronic diseases owing to the intrinsic relationship of muscles with glucose, lipid, and protein metabolism. Liver cirrhosis is characterized by the progression of necro-inflammatory liver diseases, which leads to fibrosis, portal hypertension, and a catabolic state, which causes loss of muscle tissue. Sarcopenia is of significant concern in the state of liver cirrhosis because sarcopenia has been associated with higher mortality, increased hospital admissions, worse post-liver transplant outcomes, decreased quality of life, and increased risk for other complications associated with cirrhosis. Therefore, sarcopenia is also an important feature of liver cirrhosis, representing a negative prognostic factor and influencing mortality. An increased understanding of sarcopenia could lead to the development of novel therapeutic approaches that could help improve the cognitive impairment of cirrhotic patients; therefore, we present a review of the mechanisms and diagnosis of sarcopenia in liver disease and existing therapeutic approaches.

    DOI: 10.3390/ijms22031425

    PubMed

    researchmap

  • Liver cirrhosis with ruptured splenic artery aneurysm leading to hepatitis c treatment: A case report

    Yuki Hojo, Hiroteru Kamimura, Takashi Owaki, Rika Kimura, Takahiro Iwasawa, Yusuke Watanabe, Masafumi Takatsuna, Satoshi Ikarashi, Masaaki Takamura, Toru Setsu, Yoshihisa Arao, Yosuke Horii, Tatsuhiko Sato, Shuji Terai

    Acta Hepatologica Japonica   62 ( 11 )   749 - 755   2021年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japan Society of Hepatology  

    A female patient in her 50s was diagnosed with hepatitis C virus infection, but she did not receive any treatment or was followed up. She was brought to the emergency room with complaints of abdominal pain and loss of consciousness, diagnosed as hemorrhagic shock due to a ruptured splenic artery aneurysm. Embolization of the splenic aneurysm was performed at our hospital, and the postoperative course was good. The patient was given direct-acting an-tiviral therapy, and a sustained viral response was achieved. Since there are still many untreated, unexamined, and unrecognized patients with hepatitis C in Japan, we report a literature review on splenic aneurysm in an attempt to identify patients with hepatitis.

    DOI: 10.2957/kanzo.62.749

    Scopus

    researchmap

  • Daily Monitoring of Serum Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein Is Useful for Predicting Therapeutic Effect of Tolvaptan in Cirrhotic Ascites.

    Masaaki Takamura, Akira Sakamaki, Yoshihisa Arao, Toru Setsu, Hiroteru Kamimura, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    The Tohoku journal of experimental medicine   252 ( 4 )   287 - 296   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Wisteria floribunda agglutinin (WFA) is a lectin that binds to the sugar chain of Mac-2 binding protein (M2BP), and WFA-positive M2BP (WFA+-M2BP) has been reported as a useful marker for assessing liver fibrosis in chronic liver disease. Tolvaptan (TLV), a selective vasopressin V2 receptor antagonist, is used for cirrhotic ascites in Japan, but good predictors of treatment efficacy remain to be established. Our aim was to investigate whether WFA+-M2BP monitoring before and after TLV administration can predict treatment efficacy in patients with cirrhotic ascites. Twenty patients (10 men), with a median age of 72 years, were enrolled. Cirrhosis was caused by hepatitis B virus (n = 3), hepatitis C virus (n = 4), alcohol (n = 8), and others (n = 5). Responders were defined as having a body weight loss of ≥ 1.5 kg/week after TLV administration. Serum WFA+-M2BP levels were measured at baseline and days 1, 3, and 7 after TLV treatment. Twelve patients (60%) were responders. Baseline WFA+-M2BP levels were correlated with serum albumin levels (r = -0.544, P = 0.013). The baseline furosemide dose was lower and platelet count was higher in responders than in non-responders (P < 0.05). The ratio of WFA+-M2BP levels on day 1 after TLV administration to baseline was lower in responders than in non-responders (P < 0.05). The decrease in the ratio discriminated responders from non-responders (AUC = 0.844, P < 0.05). In conclusion, monitoring serum WFA+-M2BP is helpful for predicting the efficacy of TLV treatment in patients with cirrhotic ascites.

    DOI: 10.1620/tjem.252.287

    PubMed

    researchmap

  • Monitoring chronological change by liver-to-spleen attenuation ratio for secondary hepatic steatosis for a short term. 査読

    Hiroteru Kamimura, Kunihiko Yokoyama, Shunsuke Nojiri, Yuko Komoro, Toshiko Murayama, Yu Koyama, Kenya Kamimura, Masaaki Takamura, Junji Yokoyama, Shuji Terai

    Clinical journal of gastroenterology   13 ( 6 )   1219 - 1224   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Parenteral nutrition-associated liver disease (PNALD) causes hepatic steatosis and moderate liver enzyme elevation due to lack of enteral nutrition and deficiency of some nutrients. However, the period for recovery from PNALD after a nutritional intervention is unknown with no report. Herein, we report a case of a 44-year-old Japanese woman with severe fatty infiltration of the liver due to malnutrition. Our nutritional support team administered appropriate total parenteral, especially fat and carnitine, nutrition to improve her malnutrition. Chronological changes in liver-to-spleen attenuation ratio were also considered because of her disease state. Computed tomography demonstrated improved attenuation of the liver, and the liver enzymes level normalized after 5 weeks from appropriate nutrition. Understanding the nutritional condition of a patient may help in elucidating an appropriate treatment strategy.

    DOI: 10.1007/s12328-020-01165-w

    PubMed

    researchmap

  • 急性腹症を契機にC型慢性肝炎が発見された1例

    北條 雄暉, 上村 博輝, 木村 莉菓, 大脇 崇史, 岩澤 貴宏, 渡邉 雄介, 高綱 将史, 荒生 祥尚, 薛 徹, 五十嵐 聡, 高村 昌昭, 寺井 崇二

    日本消化器病学会甲信越支部例会抄録集   67回   96 - 96   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    researchmap

  • Shear wave elastographyを用いたNAFLDにおける肝線維化の左右差の検討

    横尾 健, 杉田 萌乃, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    超音波医学   47 ( Suppl. )   S349 - S349   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本超音波医学会  

    researchmap

  • Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and its Role in Multidisciplinary Therapy. 国際誌

    Marina Ohkoshi-Yamada, Kenya Kamimura, Osamu Shibata, Shinichi Morita, Motoki Kaidu, Toshimichi Nakano, Katsuya Maruyama, Atsushi Ota, Hirotake Saito, Nobuko Yamana, Tomoya Oshikane, Yukiyo Goto, Natsumi Yoshimura, Satoshi Tanabe, Hisashi Nakano, Madoka Sakai, Yuto Tanaka, Yohei Koseki, Yoshihisa Arao, Hiroyuki Abe, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Hidefumi Aoyama, Shuji Terai

    Cancers   12 ( 10 )   2020年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    This study investigated the efficacy and safety of radiotherapy as part of multidisciplinary therapy for advanced hepatocellular carcinoma (HCC). Clinical data of 49 HCC patients treated with radiotherapy were assessed retrospectively. The efficacy of radiotherapy was assessed by progression-free survival, disease control rate, and overall survival. Safety was assessed by symptoms and hematological assay, and changes in hepatic reserve function were determined by Child-Pugh score and albumin-bilirubin (ALBI) score. Forty patients underwent curative radiotherapy, and nine patients with portal vein tumor thrombus (PVTT) underwent palliative radiotherapy as part of multidisciplinary therapy. Local disease control for curative therapy was 80.0% and stereotactic body radiotherapy was 86.7% which was greater than that of conventional radiotherapy (60.0%). Patients with PVTT had a median observation period of 651 days and 75% three-year survival when treated with multitherapy, including radiotherapy for palliative intent, transcatheter arterial chemoembolization, and administration of molecular targeted agents. No adverse events higher than grade 3 and no changes in the Child-Pugh score and ALBI score were seen. Radiotherapy is safe and effective for HCC treatment and can be a part of multidisciplinary therapy.

    DOI: 10.3390/cancers12102955

    PubMed

    researchmap

  • 健診受検者における年齢層別NAFLDの解析と高齢者の意識変化

    横尾 健, 佐藤 公俊, 丹羽 佑輔, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A671 - A671   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • mALBI score/gradeからみたNASH薬物治療に対する肝予備能への影響

    高村 昌昭, 横尾 健, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A691 - A691   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 2D-Shear Wave ElastographyとTransient Elastographyの乖離症例の特徴

    杉田 萌乃, 横尾 健, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A695 - A695   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis. 査読

    Akira Sakamaki, Kunihiko Yokoyama, Fusako Yamazaki, Hiroteru Kamimura, Kenya Kamimura, Masaaki Takamura, Junji Yokoyama, Shuji Terai

    Internal medicine (Tokyo, Japan)   59 ( 15 )   1849 - 1853   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A 66-year-old Japanese man was admitted to our hospital with grade 2 hepatic encephalopathy (HE). Abdominal computed tomography and laboratory examinations revealed decompensated liver cirrhosis. Intravenous administration of branched-chain amino acids immediately ameliorated the HE, and lactulose was initiated. However, a breath test revealed small intestinal bacterial overgrowth (SIBO); therefore, rifaximin was additionally initiated. The breath test was repeated after discharge, when no evidence of SIBO or overt HE was identified. This case suggested that a breath test is effective for the identification of SIBO and that the administration of a poorly absorbed antibiotic should be considered in SIBO-positive HE patients taking lactulose.

    DOI: 10.2169/internalmedicine.4593-20

    PubMed

    researchmap

  • 三次リンパ組織の臓器普遍性の解明

    鳥生 直哉, 佐藤 有紀, 上村 博輝, 田中 真生, 寺井 崇二, 柳田 素子

    日本腎臓学会誌   62 ( 4 )   262 - 262   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本腎臓学会  

    researchmap

  • 10年目を迎えた新潟県肝疾患相談センターの現況 査読

    上村 博輝, 薛 徹, 荒生 祥尚, 廣川 光, 澤栗 裕美, 渡邊 文子, 小師 優子, 坂牧 僚, 土屋 淳紀, 高村 昌昭, 五十嵐 正人, 青柳 豊, 菊田 玲, 渡辺 和仁, 中山 均, 田村 務, 寺井 崇二

    肝臓   61 ( 5 )   245 - 254   2020年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    平成21年に設立された新潟大学医歯学総合病院肝疾患相談センターは令和元年に10年目を迎え、236万人の新潟県民や医療従事者に対するウイルス性肝炎の情報の提供、啓発活動、助成制度のサポート等を新潟県健康対策課、厚生労働省健康局がん・疾病対策課肝炎対策室、国立国際医療センター肝炎情報センターとともに行ってきた。新潟県内の各種肝炎ウイルスの発生動向の報告、助成対象人数の把握や非受検者に対する啓発活動を各年度で行ってきた。C型肝炎については他県と同じく新規治療者数については減少段階にある。しかし、肝炎ウイルスは世界最大級の感染症であることにかわりなく、A型肝炎のエンデミック、B型肝炎ウイルスに対する耐性ウイルス発生や核酸アナログ製剤の長期利用による諸問題、E型肝炎の報告例の増加などについては今後も監視が必要である。また肝炎検査未受検者も多く、啓発活動を行う肝疾患相談センターの存在意義は今後も重要である。(著者抄録)

    DOI: 10.2957/kanzo.61.245

    CiNii Article

    researchmap

  • Ghrelin-insulin-like growth factor-1 axis is activated via autonomic neural circuits in the non-alcoholic fatty liver disease. 査読 国際誌

    Takuro Nagoya, Kenya Kamimura, Ryosuke Inoue, Masayoshi Ko, Takashi Owaki, Yusuke Niwa, Norihiro Sakai, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Yuka Nakamura, Masaki Ueno, Shuji Terai

    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society   32 ( 5 )   e13799   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The correlation of the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) with non-alcoholic fatty liver disease (NAFLD) has been reported in epidemiological studies. However, the mechanisms of molecular and inter-organ systems that render these factors to influence on NAFLD have not been elucidated. In this study, we examined the induction of ghrelin which is the GH-releasing hormone and IGF-1, and involvement of autonomic neural circuits, in the pathogenesis of NAFLD. METHODS: The expression of gastric and hypothalamic ghrelin, neural activation in the brain, and serum IGF-1 were examined in NAFLD models of choline-deficient defined l-amino-acid diet-fed, melanocortin 4 receptor knockout mice, and partial hepatectomy mice with or without the blockades of autonomic nerves to test the contribution of neural circuits connecting the brain, liver, and stomach. KEY RESULTS: The fatty changes in the liver increased the expression of gastric ghrelin through the autonomic pathways which sends the neural signals to the arcuate nucleus in the hypothalamus through the afferent vagal nerve which reached the pituitary gland to release GH and then stimulate the IGF-1 release from the liver. In addition, high levels of ghrelin expression in the arcuate nucleus were correlated with NAFLD progression regardless of the circuits. CONCLUSIONS: Our study demonstrated that the fatty liver stimulates the autonomic nervous signal circuits which suppress the progression of the disease by activating the gastric ghrelin expression, the neural signal transduction in the brain, and the release of IGF-1 from the liver.

    DOI: 10.1111/nmo.13799

    PubMed

    researchmap

  • Change in body composition in patients with achalasia before and after peroral endoscopic myotomy. 査読 国際誌

    Takeshi Mizusawa, Hiroki Sato, Kenya Kamimura, Satoru Hashimoto, Ken-Ichi Mizuno, Hiroteru Kamimura, Satoshi Ikarashi, Kazunao Hayashi, Masaaki Takamura, Junji Yokoyama, Shuji Terai

    Journal of gastroenterology and hepatology   35 ( 4 )   601 - 608   2020年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Patients with achalasia experience weight loss because of dysphagia caused by impaired relaxation of the lower esophageal sphincter. This study aimed to use dual bioelectrical impedance analysis (BIA) to determine the change in bodyweight and body composition in patients with achalasia before and after peroral endoscopic myotomy (POEM). METHODS: Patients with achalasia who underwent POEM from 2013 to 2018 (n = 72) were retrospectively analyzed for change in bodyweight before and after 3 months. Additionally, change in body composition was prospectively investigated in the final 10 of 72 patients using non-radiation dual BIA. RESULTS: Twenty patients (27.8%) were underweight (body mass index < 18.5) before undergoing POEM. No clinical parameters were identified to be associated with the underweight condition before POEM and be predictive of an increase in bodyweight after POEM. Low visceral fat volume observed on dual BIA correlated closely with the result obtained using computed tomography (Pearson correlation coefficient: r = 0.850, P < 0.01). Patients with achalasia had a statistically significant increase in visceral (P < 0.01) and subcutaneous fat volumes (P < 0.01) after POEM. Skeletal muscle mass index slightly increased (P = 0.02), although the value after POEM was still low. No blood biomarkers were indicators for low bodyweight or low visceral fat volume. CONCLUSIONS: Dual BIA is an effective non-invasive tool to evaluate the change in body composition of underweight patients with achalasia. Skeletal muscle volume was not enough after POEM, although a rapid increase in the intra-abdominal fat volume was observed. Additional studies are warranted to understand the pathological implications.

    DOI: 10.1111/jgh.14847

    PubMed

    researchmap

  • Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma. 査読 国際誌

    Kenya Kamimura, Takeshi Yokoo, Hiroyuki Abe, Norihiro Sakai, Takuro Nagoya, Yuji Kobayashi, Masato Ohtsuka, Hiromi Miura, Akira Sakamaki, Hiroteru Kamimura, Norio Miyamura, Hiroshi Nishina, Shuji Terai

    Cancers   12 ( 2 )   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatocellular carcinoma (HCC) is a major global malignancy, responsible for >90% of primary liver cancers. Currently available therapeutic options have poor performances due to the highly heterogeneous nature of the tumor cells; recurrence is highly probable, and some patients develop resistances to the therapies. Accordingly, the development of a novel therapy is essential. We assessed gene therapy for HCC using a diphtheria toxin fragment A (DTA) gene-expressing plasmid, utilizing a non-viral hydrodynamics-based procedure. The antitumor effect of DTA expression in HCC cell lines (and alpha-fetoprotein (AFP) promoter selectivity) is assessed in vitro by examining HCC cell growth. Moreover, the effect and safety of the AFP promoter-selective DTA expression was examined in vivo using an HCC mice model established by the hydrodynamic gene delivery of the yes-associated protein (YAP)-expressing plasmid. The protein synthesis in DTA transfected cells is inhibited by the disappearance of tdTomato and GFP expression co-transfected upon the delivery of the DTA plasmid; the HCC cell growth is inhibited by the expression of DTA in HCC cells in an AFP promoter-selective manner. A significant inhibition of HCC occurrence and the suppression of the tumor marker of AFP and des-gamma-carboxy prothrombin can be seen in mice groups treated with hydrodynamic gene delivery of DTA, both 0 and 2 months after the YAP gene delivery. These results suggest that DTA gene therapy is effective for HCC.

    DOI: 10.3390/cancers12020472

    PubMed

    researchmap

  • Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. 査読 国際誌

    Atsunori Tsuchiya, Suguru Takeuchi, Takahiro Iwasawa, Masaru Kumagai, Takeki Sato, Satoko Motegi, Yui Ishii, Youhei Koseki, Kei Tomiyoshi, Kazuki Natsui, Nobutaka Takeda, Yuki Yoshida, Fusako Yamazaki, Yuichi Kojima, Yusuke Watanabe, Naruhiro Kimura, Kentaro Tominaga, Hiroteru Kamimura, Masaaki Takamura, Shuji Terai

    Inflammation and regeneration   40   14 - 14   2020年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) and the ensuing worldwide pandemic. The spread of the virus has had global effects such as activity restriction, economic stagnation, and collapse of healthcare infrastructure. Severe SARS-CoV-2 infection induces a cytokine storm, leading to acute respiratory distress syndrome (ARDS) and multiple organ failure, which are very serious health conditions and must be mitigated or resolved as soon as possible. Mesenchymal stem cells (MSCs) and their exosomes can affect immune cells by inducing anti-inflammatory macrophages, regulatory T and B cells, and regulatory dendritic cells, and can inactivate T cells. Hence, they are potential candidate agents for treatment of severe cases of COVID-19. In this review, we report the background of severe cases of COVID-19, basic aspects and mechanisms of action of MSCs and their exosomes, and discuss basic and clinical studies based on MSCs and exosomes for influenza-induced ARDS. Finally, we report the potential of MSC and exosome therapy in severe cases of COVID-19 in recently initiated or planned clinical trials of MSCs (33 trials) and exosomes (1 trial) registered in 13 countries on ClinicalTrials.gov.

    DOI: 10.1186/s41232-020-00121-y

    PubMed

    researchmap

  • A case of primary hepatic actinomycosis difficult to distinguish from malignant hepatic tumors

    Hiroki Honda, Yujiro Nozawa, Masaaki Takamura, Hiroteru Kamimura, Atsunori Tsuchiya, Shuji Terai

    Acta Hepatologica Japonica   61 ( 3 )   109 - 115   2020年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japan Society of Hepatology  

    A 71-year-old man was diagnosed with elevated biliary enzyme levels by his previous doctor and visited the Niigata University Medical and Dental Hospital in June 2011. Abdominal computed tomography showed a 10 cm diameter mass, consisting of cystic and solid components in the right lobe with peripheral intrahepatic bile duct dilation. In addition, multiple lymph node swelling was observed around the aorta from the hilar region. It was considered to be intrahepatic cholangiocarcinoma or liver metastasis with abscess
    however, percutaneous liver biopsy was performed before chemotherapy because liver resection was contraindicated. Moreover, no tumor cells were observed. Therefore, liver abscess was treated with antibiotics, and percutaneous transhe-patic drainage was performed. Therefore, actinomycetes were detected from the liver tissue. When the antibiotics were changed to penicillin, the mass was remarkably reduced. Herein, we report a case of hepatic actino-mycosis that is difficult to distinguish from malignant hepatic tumors.

    DOI: 10.2957/kanzo.61.109

    Scopus

    researchmap

  • 有腹水肝硬変症例に対するtolvaptan投与前後のM2BPGiの経時的変化とその臨床的意義

    高村 昌昭, 坂牧 僚, 寺井 崇二, 上村 博輝, 土屋 淳紀, 薛 徹, 上村 顕也, 横尾 健

    肝臓   60 ( Suppl.3 )   A936 - A936   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 高齢者におけるFIB-4 indexの特徴

    横尾 健, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   60 ( Suppl.2 )   A696 - A696   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • NSTによる消化器内科病変の発見により自宅退院まで改善した症例

    小師 優子, 村山 稔子, 上村 博輝, 小山 諭, 寺井 崇二

    学会誌JSPEN   1 ( Suppl. )   1331 - 1331   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本臨床栄養代謝学会  

    researchmap

  • Usefulness of chemokine C-C receptor 7- /programmed cell death-1+ follicular helper T cell subset frequencies in the diagnosis of autoimmune hepatitis. 査読 国際誌

    Naruhiro Kimura, Satoshi Yamagiwa, Tomoyuki Sugano, Ryoko Horigome, Toru Setsu, Kentaro Tominaga, Hiroteru Kamimura, Masaaki Takamura, Shuji Terai

    Hepatology research : the official journal of the Japan Society of Hepatology   49 ( 9 )   1026 - 1033   2019年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: A significant concern for autoimmune hepatitis (AIH) patients is diagnostic specificity. Delayed treatment due to delayed diagnosis leads to poor survival. We recently reported that chemokine C-C receptor 7 (CCR7)- /programmed cell death-1 (PD-1)+ follicular helper T (Tfh) cells could be involved in AIH pathogenesis. We hypothesized that Tfh cell frequencies might contribute to AIH diagnosis. METHODS: Peripheral blood was collected from 12 patients with AIH from April 2013 to March 2016, as well as 24 patients with hepatitis B virus (HBV) infection and 44 healthy controls (HC). Mononuclear cells were separated using a Ficoll gradient, and surface markers were investigated using flow cytometry. RESULTS: The frequency of CCR7- PD-1+ Tfh cells was significantly higher in AIH patients (39.1 ± 8.6) compared to that in HC (25.1 ± 7.9%, P < 0.01) and HBV patients (22.7 ± 7.8, P < 0.01). The area under the receiver operating characteristic curve for the frequency of the CCR7- PD-1+ Tfh cell subset for AIH and HC and AIH and HBV was 0.905 and 0.927, respectively. The frequency of the CCR7- PD-1+ Tfh cell subset was not correlated with International Autoimmune Hepatitis Group (IAIHG) scoring, Simplified AIH scoring, or Japanese diagnostic guidelines (R = 0.10, 0.947; R = 0.0008, 0.180; and R = 0.348, 0.558, respectively). Therefore, these frequencies could diagnose AIH patients who were not diagnosed with the IAIHG or simplified AIH scores. CONCLUSIONS: The frequency of the peripheral CCR7- PD-1+ Tfh cell subset could be useful for diagnosing AIH even in patients who were not diagnosed with IAIHG or simplified AIH scores.

    DOI: 10.1111/hepr.13356

    PubMed

    researchmap

  • Rational arrangement of measuring shear wave speed in the liver. 査読 国際誌

    Takeshi Yokoo, Tsutomu Kanefuji, Takeshi Suda, Itsuo Nagayama, Takahiro Hoshi, Satoshi Abe, Shinichi Morita, Hiroteru Kamimura, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Kazuyoshi Yagi, Shuji Terai

    World journal of gastroenterology   25 ( 20 )   2503 - 2513   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Shear wave speed has been widely applied to quantify a degree of liver fibrosis. However, there is no standardized procedure, which makes it difficult to utilize the speed universally. AIM: To provide procedural standardization of shear wave speed measurement. METHODS: Point shear wave elastography (pSWE) was measured in 781 patients, and two-dimensional shear wave elastography (2dSWE) was measured on the same day in 18 cases. Regions-of-interest were placed at 12 sites, and the median and robust coefficient-of-variation (CVR) were calculated. A residual sum-of-square (Σdi2) was computed for bootstrap values of 1000 iterations in 18 cases with each assumption of 1 to 12 measurements. The proportion of the Σdi2 (%Σdi2) was calculated as the ratio of Σdi2 to pSWE after converting it based on the correlation between pSWE and 2dSWE. RESULTS: The CVR showed a significantly broader distribution in the left lobe (P < 0.0001), and the smallest CVR in the right anterior segment that covered 95% cases was 40.4%. pSWE was significantly higher in the left lobe than in the right lobe (1.63 ± 0.78 m/s vs 1.61 ± 0.78 m/s, P = 0.0004), and the difference between the lobes became further discrete when the subjects were limited to the cases with a CVR less than 40.4% in any segment (1.76 ± 0.80 m/s vs 1.70 ± 0.82 m/s, P < 0.0001). The highest values of the CVR in every 0.1 m/s interval were plotted in convex upward along pSWE and peaked at 1.93 m/s. pSWE and 2dSWE were significantly correlated (P < 0.0001, r = 0.95). In 216000 resamples from 18 cases, the %Σdi2 of 12 sites was 8.0% and gradually increased as the acquisition sites decreased to reach a significant difference with a %Σdi2 of 7 sites (P = 0.027). CONCLUSION: These data suggest that shear wave speed should be measured at 8 or more sites of spreading in both lobes.

    DOI: 10.3748/wjg.v25.i20.2503

    PubMed

    researchmap

  • Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. 査読 国際誌

    Kenya Kamimura, Akira Sakamaki, Hiroteru Kamimura, Toru Setsu, Takeshi Yokoo, Masaaki Takamura, Shuji Terai

    World journal of gastroenterology   25 ( 15 )   1817 - 1827   2019年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The aging of the organ function causes sensitivity to the disease progression and need careful consideration for the medical treatment. With the increase of aging population, the opportunity to provide medical treatment for people in very old age is rapidly increasing therefore, the understanding of the various physiological changes of cellular function, size and function of organs are essential for the decision of therapeutic options. Among the various chronic conditions seen in elderly people, we have focused on liver cirrhosis, since despite specific therapeutic options for many of liver diseases including direct acting antivirals for hepatitis C virus, nucleoside analogs for hepatitis B, and corticosteroids for autoimmune hepatitis, there is currently no standard therapy to treat liver cirrhosis, which is the final stage of these liver diseases. Therefore, management of the various symptoms of liver cirrhosis is essential, and aging-related parameters must be considered in the decision making for therapeutic strategies and dosage of the available medicine. In this mini-review, we have summarized the therapeutic options to manage various symptoms of liver cirrhosis, carefully considering the physiological changes of various organs associated with aging.

    DOI: 10.3748/wjg.v25.i15.1817

    PubMed

    researchmap

  • Mesenchymal stem cells cultured in hypoxic conditions had multi-directional effects on mice with liver cirrhosis through prostaglandin E2 and miR210 production

    Atsunori Tsuchiya, Yuichi Kojima, Masahiro Ogawa, Shunsuke Nojiri, Suguru Takauchi, Takayuki Watanabe, Hiroteru Kamimura, Masaaki Takamura, Shuji Terai

    JOURNAL OF HEPATOLOGY   70 ( 1 )   E443 - E444   2019年4月

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER  

    DOI: 10.1016/S0618-8278(19)30873-4

    Web of Science

    researchmap

  • Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH). 査読 国際誌

    Ryo Goto, Kenya Kamimura, Yoko Shinagawa-Kobayashi, Norihiro Sakai, Takuro Nagoya, Yusuke Niwa, Masayoshi Ko, Kohei Ogawa, Ryosuke Inoue, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Satoshi Abe, Hiroshi Nishina, Shuji Terai

    FEBS open bio   9 ( 4 )   643 - 652   2019年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested for its therapeutic effect on NASH; however, no studies to date have demonstrated the preventive effect of an SGLT2 inhibitor on the histological progression of steatosis and fibrosis in a sequential manner in animal models. In the present study, we examined the effect of the SGLT2 inhibitor, tofogliflozin (Tofo), on NASH liver tissue using medaka as an animal model, maintaining a feeding amount and drug concentration in all animal bodies. We generated a medaka NASH model by feeding d-rR/Tokyo medaka a high-fat diet and administered Tofo by dissolving the drug directly in the water of the feeding tank. Thereafter, the effects of Tofo on body weight (BW), liver weight, hepatotoxicity, fatty infiltration, and fibrotic changes in the liver were examined. We report here that SGLT2 is expressed in medaka fish and that Tofo inhibits the accumulation of fatty tissue and delays the progression of liver fibrosis in the medaka NASH model by inhibiting increases in blood sugar, serum lipids, and transaminase, irrespective of changes in BW. These results suggest that Tofo is effective for treating NASH and that the medaka model may be useful for developing new therapeutic drugs for this disease.

    DOI: 10.1002/2211-5463.12598

    PubMed

    researchmap

  • 当院における肝癌に対する放射線治療の検討

    柴田 理, 上村 顕也, 木村 成宏, 薛 徹, 横尾 健, 坂牧 僚, 上村 博輝, 土屋 淳紀, 高村 昌昭, 丸山 克也, 太田 篤, 海津 元樹, 青山 英史, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A456 - A456   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 高齢肝癌症例におけるソラフェニブの効果と有用性

    横尾 健, 森田 真一, 木村 成宏, 薛 徹, 坂牧 僚, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A413 - A413   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Different distribution of mucosal-associated invariant T cells within the human cecum and colon. 査読 国際誌

    Isamu Hama, Kentaro Tominaga, Satoshi Yamagiwa, Toru Setsu, Naruhiro Kimura, Hiroteru Kamimura, Toshifumi Wakai, Shuji Terai

    Central-European journal of immunology   44 ( 1 )   75 - 83   2019年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Introduction: Mucosal-associated invariant T (MAIT) cells are innate-like T cells that are involved in anti-bacterial immunity. MAIT cells are found in the intestines, but their role and distribution within the large intestine have not been fully elucidated. Therefore, we investigated the distribution of MAIT cells within the cecum and colon. Material and methods: Surgically resected tissues of the cecum and colon were obtained from 4 patients with cecal appendix cancer and 8 patients with colorectal cancer, respectively. Lymphocytes were isolated from the intestinal epithelium (intraepithelial lymphocytes - IELs) and the underlying lamina propria (lamina propria lymphocytes - LPLs), and then, MAIT cells were analyzed by flow cytometry. Results: Compared with the colon, the cecum showed a significantly increased frequency of MAIT cells among IELs (p < 0.01). CD69 expression on MAIT cells was significantly increased in the cecum and colon compared with that in the blood, and the frequency of natural killer group 2, member A+ cells among MAIT cells was significantly increased in the cecum. Conclusions: These results suggest that the distribution of MAIT cells was different between the cecum and colon and that MAIT cells were more likely to be activated, especially in the intestinal epithelium of the cecum than in the colon and blood.

    DOI: 10.5114/ceji.2019.84020

    PubMed

    researchmap

  • Effective prevention of sorafenib-related vascular damage induced adverse events and maintenance of hepatic function by dried bonito broth and histidine. 査読 国際誌

    Norihiro Sakai, Kenya Kamimura, Yoko Shinagawa-Kobayashi, Takuro Nagoya, Yusuke Niwa, Masayoshi Ko, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Satoshi Abe, Hiroteru Kamimura, Soichi Sugitani, Masahiko Yanagi, Shuji Terai

    Cancer management and research   11   4437 - 4448   2019年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Sorafenib (SOR) is an anti-angiogenic chemotherapeutic that prolongs the survival rates of patients with hepatocellular carcinoma. However, SOR also damages normal vasculature and causes associated adverse events, including hand-foot syndrome and hypertension (HT). We previously reported in an animal study that vascular damage resulted in the narrowing of the normal vascular dimension area in medaka fish (Oryzias), and histidine (HIS), a major amino acid contained in dried bonito broth (DBB), prevented these changes. Therefore, in the study, we analyzed the effects of DBB and HIS on SOR-related vascular damages and associated adverse events in patients. Materials and methods: Three-dimensional (3D) vascular images of abdominal regions reconstituted from computed tomography were assessed to compare vascular diameter prior to and following SOR administration in groups receiving SOR monotherapy, DBB+SOR, and HIS+SOR. The clinical courses of hand-foot syndrome and HT and the toxicities of SOR in biochemical assays were monitored and compared between the groups. Correlations between hepatic function and SOR-related changes in the portal venous area dimension were also assessed. Results: SOR-related vascular damage revealed narrowing of the normal abdominal vasculature in the human body, which was monitored using 3D images. The damage was ameliorated by DBB and HIS, however, HIS had a more marked effect, particularly on the renal arteries and portal vein (PV). Maintenance of blood flow contributed to the maintenance of total cholesterol, prothrombin time, albumin (ALB), and renal functions. Changes in the 3D vascular area dimension of the PV and level of serum ALB were significantly correlated. The occurrences of the clinical symptoms of hand-foot syndrome and HT were lower in the DBB- and HIS-treated groups. Conclusion: Our results clearly demonstrate that DBB and HIS prevented SOR-related abdominal vascular damage and effectively maintained hepatic function, and prevented clinical symptoms and toxicity. Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000025937 and UMIN000026898).

    DOI: 10.2147/CMAR.S201424

    PubMed

    researchmap

  • Classification of Heterogeneous Hepatocellular Carcinoma Using Four Hepatic Progenitor Cell Markers and Three Serum Tumor Markers

    Atsunori Tsuchiya, Satoshi Seino, Yuichi Kojima, Naruhiro Kimura, Toru Setsu, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Kenya Kamimura, Masaaki Takamura, Shuji Terai

    HEPATOLOGY   68   545A - 546A   2018年10月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • フレイルとサルコペニアについて 進行消化器癌における体組成と予後との関連

    川合 弘一, 小林 隆昌, 中野 応央樹, 五十嵐 聡, 河久 順志, 阿部 聡司, 上村 博輝, 坂牧 僚, 林 和直, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    新潟医学会雑誌   132 ( 10 )   350 - 352   2018年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    近年、様々な疾患で体組成が病態や予後と関連していることが報告されている。我々の検討で、経動脈的治療を行った進行肝細胞癌症例のうち、骨格筋の6ヵ月間変化率が-4.6%未満の症例は予後不良であることが明らかとなった。また低皮下脂肪量も予後不良因子の一つであることを見出した。膵癌非切除例においては、内臓脂肪量が1ヵ月間で大きく減少した群で予後不良だった。進行消化器癌においては体組成、特にその変化率と予後が密接に関連していることが示唆された。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J00990&link_issn=&doc_id=20200305060005&doc_link_id=%2Fdg3nigta%2F2018%2F013210%2F005%2F0350-0352%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg3nigta%2F2018%2F013210%2F005%2F0350-0352%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Diagnosis and management of fibromuscular dysplasia and segmental arterial mediolysis in gastroenterology field: A mini-review. 査読 国際誌

    Masayoshi Ko, Kenya Kamimura, Kohei Ogawa, Kentaro Tominaga, Akira Sakamaki, Hiroteru Kamimura, Satoshi Abe, Kenichi Mizuno, Shuji Terai

    World journal of gastroenterology   24 ( 32 )   3637 - 3649   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The vascular diseases including aneurysm, occlusion, and thromboses in the mesenteric lesions could cause severe symptoms and appropriate diagnosis and treatment are essential for managing patients. With the development and improvement of imaging modalities, diagnostic frequency of these vascular diseases in abdominal lesions is increasing even with the small changes in the vasculatures. Among various vascular diseases, fibromuscular dysplasia (FMD) and segmental arterial mediolysis (SAM) are noninflammatory, nonatherosclerotic arterial diseases which need to be diagnosed urgently because these diseases could affect various organs and be lethal if the appropriate management is not provided. However, because FMD and SAM are rare, the cause, prevalence, clinical characteristics including the symptoms, findings in the imaging studies, pathological findings, management, and prognoses have not been systematically summarized. Therefore, there have been neither standard diagnostic criteria nor therapeutic methodologies established, to date. To systematically summarize the information and to compare these disease entities, we have summarized the characteristics of FMD and SAM in the gastroenterological regions by reviewing the cases reported thus far. The information summarized will be helpful for physicians treating these patients in an emergency care unit and for the differential diagnosis of other diseases showing severe abdominal pain.

    DOI: 10.3748/wjg.v24.i32.3637

    PubMed

    researchmap

  • Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies. 査読 国際誌

    Takamasa Kobayashi, Hirokazu Kawai, Oki Nakano, Satoshi Abe, Hiroteru Kamimura, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai

    BMC cancer   18 ( 1 )   756 - 756   2018年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The impact of sarcopenia on the prognosis of patients with hepatocellular carcinoma (HCC) who receive transcatheter intra-arterial therapies, including transcatheter arterial chemoembolization and transcatheter arterial infusion chemotherapy, remains unclear. We investigated the prognostic value of skeletal muscle loss (SML) stratified by cutoffs for sarcopenia and rate of change in skeletal muscle mass over 6 months. METHODS: We retrospectively evaluated 102 patients with HCC treated with transcatheter intra-arterial therapies between 2005 and 2015. Computed tomography images of the third lumbar vertebra (L3) were analyzed to obtain the skeletal muscle area normalized for the height squared, defined as the skeletal muscle index at L3 (L3 SMI), before and 6 months after treatment. Low or high SMI was defined using cutoff values of 42 cm2/m2 in men and 38 cm2/m2 in women. The rate of change in skeletal muscle mass (ΔL3 SMI) over 6 months was calculated. Overall survival (OS) was compared in groups classified by baseline L3 SMI and ΔL3 SMI; prognostic significance was assessed with univariate and multivariate analyses, using Cox proportional hazards models. RESULTS: OS did not differ significantly between groups with low (n = 31) and high (n = 71) SMI at baseline (P = 0.172), but OS was significantly poorer in patients with SML (n = 41), defined as ΔL3 SMI < - 4.6% over 6 months than in those without SML (n = 61, P = 0.018). On multivariate analysis, SML (hazard ratio [HR], 1.675; 95% confidence interval [CI], 1.031-2.721; P = 0.037), serum alpha-fetoprotein ≥20 ng/mL (HR, 2.550; 95% CI, 1.440-4.515; P = 0.001), and maximum tumor diameter ≥ 30 mm (HR, 1.925; 95% CI, 1.166-3.179; P = 0.010) were independent predictors of poor OS. Baseline L3 SMI was not significantly associated with OS (HR, 1.405; 95% CI, 0.861-2.293; P = 0.174). CONCLUSIONS: ΔL3 SMI was an independent prognostic factor in patients with HCC treated with transcatheter intra-arterial therapies. Further study is required to reveal whether prevention of skeletal muscle depletion might be a new therapeutic strategy to contribute to improved clinical outcomes in patients with HCC.

    DOI: 10.1186/s12885-018-4673-2

    Web of Science

    PubMed

    researchmap

  • Renal Impairment in Chronic Hepatitis B: A Review. 査読 国際誌

    Hiroteru Kamimura, Toru Setsu, Naruhiro Kimura, Takeshi Yokoo, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai

    Diseases (Basel, Switzerland)   6 ( 2 )   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The liver plays a key role in the metabolism of proteins. Liver dysfunction affects many organs because it communicates with the spleen and all digestive organs through the portal vein. Additionally, the kidney is an organ that is closely related to the liver and is involved in liver diseases. Glomerulonephritis is an important extrahepatic manifestation of chronic hepatitis B virus (HBV) infection. Nucleos(t)ide analog (NA) therapy effectively suppresses HBV replication by inhibiting HBV polymerase, thus decreasing the levels of serum HBV-DNA and delaying the progression of cirrhosis. Although NA therapy is recommended for all patients with chronic HBV infection, regardless of the level of renal dysfunction, there is limited information on NA use in patients with chronic kidney disease. In addition, in patients with end-stage liver cirrhosis, hepatorenal syndrome can be fatal. Hence, we should take into account the stage of impaired renal function in patients with cirrhosis. The aims of this article are to review the epidemiology, clinical presentation, treatment, and prevention of HBV-associated nephropathy.

    DOI: 10.3390/diseases6020052

    PubMed

    researchmap

  • Persistent reduction of mucosal-associated invariant T cells in primary biliary cholangitis. 査読 国際誌

    Toru Setsu, Satoshi Yamagiwa, Kentaro Tominaga, Naruhiro Kimura, Hiroki Honda, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Shuji Terai

    Journal of gastroenterology and hepatology   33 ( 6 )   1286 - 1294   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Mucosal-associated invariant T (MAIT) cells constitute a novel subset of innate-like T lymphocytes characterized by a semi-invariant T-cell receptor repertoire capable of recognizing bacterial products. Considering the abundance of MAIT cells in the liver and the possible association between bacterial infections and primary biliary cholangitis (PBC), we aimed to analyze the involvement of MAIT cells in the immunopathogenesis of PBC. METHODS: Peripheral blood and liver biopsy specimens were collected from 25 patients with PBC and 19 patients with chronic viral hepatitis. Surgically removed liver tissues distant from tumors in patients with metastatic liver tumors were used as controls. Mononuclear cells were separated using Ficoll gradient, and the expression of various markers was investigated by flow cytometry. Cytokine production was investigated using blood MAIT cells after stimulation by anti-CD3/CD28-coupled beads with/without interleukin-7 (IL-7). RESULTS: Mucosal-associated invariant T cells were significantly reduced in both the blood and liver of PBC patients compared with those in controls. MAIT cells in the blood of PBC patients expressed significantly lower levels of activation markers and IL-7 receptor. Moreover, MAIT cells in the blood of PBC patients showed impaired production of cytokines, especially tumor necrosis factor alpha, after in vitro stimulation with IL-7. Interestingly, even after biochemical responses were achieved by ursodeoxycholic acid treatment, the frequencies of MAIT cells did not fully recover to normal levels. CONCLUSIONS: These findings suggested that MAIT cells were activated, exhausted, and persistently depleted in PBC patients even after ursodeoxycholic acid treatment, possibly as a consequence of persistent liver inflammation.

    DOI: 10.1111/jgh.14076

    Web of Science

    PubMed

    researchmap

  • Bleeding from a Small-Intestinal Ulcer Associated with Chronic Hepatitis C. 査読 国際誌

    Hiroteru Kamimura, Satoshi Yamagiwa, Iwasaki Tomohiro, Wataru Higuchi, Norio Ogata, Atsunori Tsuchiya, Kenya Kamimura, Masaaki Takamura, Hirokazu Kawai, Shuji Terai

    The American journal of case reports   19   234 - 237   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND Hepatitis C virus infection is probably the most common chronic viral infection and affects an estimated 180 million people worldwide. Extrahepatic manifestations are well recognized among patients with chronic HCV infection. CASE REPORT We report a case of melena occurring in a 69-year-old Japanese man who had been diagnosed with CHC and who was treated with antiviral therapy. CONCLUSIONS Finally, he was diagnosed with multiple small intestine ulcers in a short time. We herein report the case of HCV with rapidly developing small intestine ulcers.

    DOI: 10.12659/AJCR.908594

    Web of Science

    PubMed

    researchmap

  • Effect of a neural relay on liver regeneration in mice: activation of serotonin release from the gastrointestinal tract 査読 国際誌

    Ryosuke Inoue, Kenya Kamimura, Takuro Nagoya, Norihiro Sakai, Takeshi Yokoo, Ryo Goto, Kohei Ogawa, Yoko Shinagawa-Kobayashi, Yukari Watanabe-Mori, Akira Sakamaki, Satoshi Abe, Hiroteru Kamimura, Norio Miyamura, Hiroshi Nishina, Shuji Terai

    FEBS Open Bio   8 ( 3 )   449 - 460   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley Blackwell  

    The development of therapeutic options to promote hepatic regeneration following severe liver injury is essential. While humoral factors have been reported as mechanisms of liver regeneration, the contributions of interorgan communication to liver regeneration have not been reported. In this study, we examined the effect of a neural relay on liver regeneration via activation of serotonin release from the gastrointestinal (GI) tract. Our results demonstrated that the afferent visceral nerve from the liver activates the efferent vagus nerve from the brain, leading to activation of serotonin release from the GI tract and contributing to liver regeneration. While it is difficult to apply these results directly to human health, we believe that this study may represent a step toward developing essential therapeutics to promote liver regeneration.

    DOI: 10.1002/2211-5463.12382

    Web of Science

    Scopus

    PubMed

    researchmap

  • Possible involvement of chemokine C-C receptor 7−programmed cell death-1+ follicular helper T-cell subset in the pathogenesis of autoimmune hepatitis 査読

    Naruhiro Kimura, Satoshi Yamagiwa, Tomoyuki Sugano, Toru Setsu, Kentaro Tominaga, Hiroteru Kamimura, Masaaki Takamura, Shuji Terai

    Journal of Gastroenterology and Hepatology (Australia)   33 ( 1 )   298 - 306   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Blackwell Publishing  

    Background and Aim: Recent studies have demonstrated that B cells and follicular helper T (Tfh) cells, which are central regulators of humoral immune response, contribute to the development and progression of autoimmune diseases. Because Tfh cells can be divided into several subsets with distinct functional properties, this study aimed to examine the roles of different subsets of circulating Tfh cells in the immune pathogenesis of autoimmune hepatitis (AIH). Methods: Thirty-five patients with AIH, 28 patients with primary biliary cholangitis, 22 patients with chronic hepatitis B (CHB), and 44 health controls (HC) were enrolled. The frequencies of different Tfh subsets in the blood and liver were examined by flow cytometry and immunohistochemical staining. The function of circulating Tfh subsets was examined after in vitro stimulation. Results: In newly diagnosed AIH patients, the frequency of circulating chemokine C-C receptor 7−programmed cell death-1+ Tfh subset was significantly increased compared with that in CHB patients and HC, significantly correlated with clinical parameters, including serum IgG, prothrombin time and albumin levels, and significantly decreased after corticosteroid treatment. In the liver of AIH patients, the frequencies of activated Tfh subsets were significantly increased and positively correlated with those in the blood. Moreover, the ability to produce interleukin-21 and interleukin-17 from circulating Tfh cells was significantly increased in AIH patients compared with HC. Conclusions: These results significantly extend our understanding of Tfh subsets in AIH and suggest a potential role of dysregulated chemokine C-C receptor 7−programmed cell death-1+ Tfh subset in the pathogenesis and disease progression of AIH.

    DOI: 10.1111/jgh.13844

    Web of Science

    Scopus

    researchmap

  • Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. 査読 国際誌

    Takamasa Kobayashi, Hirokazu Kawai, Oki Nakano, Satoshi Abe, Hiroteru Kamimura, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai

    Cancer management and research   10   2231 - 2239   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Prognosis of patients with hepatocellular carcinoma (HCC) who undergo transcatheter intra-arterial therapies, including transcatheter arterial chemoembolization and transcatheter arterial infusion chemotherapy, is affected by many clinical factors including liver function and tumor progression. However, the effect of body composition such as skeletal muscle and visceral and subcutaneous adipose tissues (VAT and SAT, respectively) on the prognosis of these patients remains unclear. We investigated the prognostic value of body composition in HCC patients treated with transcatheter intra-arterial therapies. Patients and methods: This study retrospectively evaluated 100 HCC patients treated with transcatheter intra-arterial therapies between 2005 and 2015. Areas of skeletal muscle, VAT, and SAT were measured on computed tomography images at third lumbar vertebra level and normalized by the height squared to calculate the skeletal muscle index, VAT index, and SAT index (SATI). The visceral to subcutaneous adipose tissue area ratio was also calculated. Overall survival (OS) was compared between high- and low-index groups for each body composition. Furthermore, prognostic significance was assessed by univariate and multivariate analyses using Cox proportional hazards models. Results: Among the body composition indexes, only SATI could significantly differentiate OS (p=0.012). Multivariate analysis showed that SATI (low- vs. high-SATI: HR, 2.065; 95% CI, 1.187-3.593; p=0.010), serum albumin (<3.5 vs. ≥3.5 g/dL; HR, 2.007; 95% CI, 1.037-3.886; p=0.039), serum alpha-fetoprotein (<20 vs. ≥20 ng/mL; HR, 0.311; 95% CI, 0.179-0.540; p<0.001), and Modified Response Evaluation Criteria in Solid Tumors assessment (complete response+partial response+stable disease vs. progressive disease; HR, 0.392; 95% CI, 0.221-0.696; p=0.001) were indicated as independent prognostic factors for OS. Conclusion: High SAT volume is associated with better survival outcomes in HCC patients treated with transcatheter intra-arterial therapies. Elucidation of the mechanisms regulating SAT volume may offer a new therapeutic strategy for these patients.

    DOI: 10.2147/CMAR.S167417

    Web of Science

    PubMed

    researchmap

  • Specific gastric blood vessels in sinistral portal hypertension 査読

    Hiroteru Kamimura, Toru Ishikawa, Noriko Ishihara, Shuji Terai

    Internal Medicine   57 ( 7 )   1053 - 1054   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Society of Internal Medicine  

    DOI: 10.2169/internalmedicine.9699-17

    Web of Science

    Scopus

    PubMed

    researchmap

  • Effective prevention of sorafenib-induced hand-foot syndrome by dried-bonito broth. 査読 国際誌

    Kenya Kamimura, Yoko Shinagawa-Kobayashi, Ryo Goto, Kohei Ogawa, Takeshi Yokoo, Akira Sakamaki, Satoshi Abe, Hiroteru Kamimura, Takeshi Suda, Hiroshi Baba, Takayuki Tanaka, Yoshizu Nozawa, Naoto Koyama, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Yutaka Aoyagi, Shuji Terai

    Cancer management and research   10   805 - 813   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Sorafenib (SOR) is a molecular medicine that prolongs the survival of patients with hepatocellular carcinoma (HCC). Therefore, the management of side effects is essential for the longer period of continuous medication. Among the various side effects, hand-foot syndrome (HFS) is the most common, occurring in 30%-50% of patients, and often results in discontinuation of the SOR medication. However, its mechanism has not been clarified, and no effective prevention method has been reported for the symptoms. Therefore, this study aimed to analyze its mechanism and to develop an effective prevention regimen for the symptoms. Materials and methods: To assess the mechanism of SOR-induced HFS, the peripheral blood flow in the hand and foot was carefully monitored by Doppler ultrasound, thermography, and laser speckle flowgraphy in the cases treated with SOR and its contribution was assessed. Then, the effect of dried-bonito broth (DBB), which was reported to improve peripheral blood flow, on the prevention of the symptom was examined by monitoring its occurrence and the peripheral blood flow. Results: A total of 25 patients were enrolled in this study. In all, eight patients developed HFS, and all cases showed a significant decrease in the peripheral blood flow. DBB contributed to an increase in the flow (p = 0.009) and significantly decreased occurrence of HFS (p = 0.005) than control. Multivariable analysis showed that the ingestion of DBB is a significant independent contributor to HFS-free survival period (p = 0.035). Conclusion: The mechanism of SOR-induced HFS involves a decrease in the peripheral blood flow, and the ingestion of DBB effectively prevents the development of the syndrome by maintaining the flow.

    DOI: 10.2147/CMAR.S159370

    Web of Science

    PubMed

    researchmap

  • Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma 査読 国際誌

    Hiroki Honda, Masaaki Takamura, Satoshi Yamagiwa, Takuya Genda, Ryoko Horigome, Naruhiro Kimura, Toru Setsu, Kentaro Tominaga, Hiroteru Kamimura, Yasunobu Matsuda, Toshifumi Wakai, Yutaka Aoyagi, Shuji Terai

    SCIENTIFIC REPORTS   7 ( 1 )   15485 - 15485   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Cell motility plays an important role in intrahepatic metastasis of hepatocellular carcinoma (HCC), and predicts poor prognosis in patients. The present study investigated the role of a disintegrin and metalloproteinases (ADAMs) in HCC, since these proteins are known to be associated with cell motility. We confirmed the expression of 12 ADAMs with putative metalloproteinase activity in HCC cells, and established a KYN-2 HCC cell line stably expressing short interfering RNA against ADAM21 to investigate the effect of ADAM21 deficiency on HCC cell motility and metastasis in vitro and in vivo. We also examined ADAM21 expression in a cohort of 119 HCC patients by immunohistochemistry. ADAM21 was overexpressed in KYN-2 cells, and its knockdown reduced invasion, migration, proliferation, and metastasis relative to controls. In clinical specimens, ADAM21 positivity was associated with vascular invasion, large tumor size, high histological grade, and lower overall and recurrence-free survival as compared to cases that were negative for ADAM21 expression. A multivariate analysis revealed that ADAM21 positivity was an independent risk factor for overall (P = 0.003) and recurrence-free (P = 0.001) survival. These results suggest that ADAM21 plays a role in HCC metastasis and can serve as a prognostic marker for disease progression.

    DOI: 10.1038/s41598-017-15800-z

    Web of Science

    PubMed

    researchmap

  • Usefulness of follicular helper T cell subset frequencies in the diagnosis of autoimmune hepatitis 査読

    Naruhiro Kimura, Satoshi Yamagiwa, Ryoko Horigome, Hiroteru Kamimura, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Shuji Terai

    HEPATOLOGY   66   687A - 688A   2017年10月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Persistent reduction of mucosal-associated invariant T cells in primary biliary cholangitis 査読

    Toru Setsu, Satoshi Yamagiwa, Naruhiro Kimura, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Shuji Terai

    HEPATOLOGY   66   166A - 166A   2017年10月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • A Case of Hepatorenal Syndrome and Abdominal Compartment Syndrome with High Renal Congestion. 査読 国際誌

    Hiroteru Kamimura, Takayuki Watanabe, Tomoyuki Sugano, Nao Nakajima, Junji Yokoyama, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Takashi Kato, Gen Watanabe, Satoshi Yamagiwa, Shuji Terai

    The American journal of case reports   18   1000 - 1004   2017年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND Hepatorenal syndrome (HRS) is a reversible renal impairment that occurs in patients with acute liver failure and advanced liver cirrhosis. HRS is due to a renal vasoconstriction that results from extreme vasodilatation. It is therefore a functional disorder, not associated with structural kidney damage. On the other hand, end-stage liver diseases are often complicated by massive ascites. Massive ascites may cause abdominal compartment syndrome (ACS), which includes impairment of renal blood flow, but there are no reports indicating that kidney lesions caused by ACS may pathologically contribute to end-stage liver diseases. CASE REPORT A 40-year-old man with acute liver failure was admitted to our hospital. He was diagnosed with type 1 HRS and showed ACS at the same time. He died 30 days after admission. There were signs of congestion in the kidneys upon dissection and advanced erythroid fullness in the renal tubules. CONCLUSIONS We report an autopsy case with HRS and ACS diagnosed with a clinical and histopathological consideration of liver and kidney. Further clinical studies are needed to improve management of renal failure in patients with acute liver failure and advanced liver cirrhosis.

    DOI: 10.12659/AJCR.904663

    Web of Science

    PubMed

    researchmap

  • Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses 査読

    Kenya Kamimura, Takeshi Yokoo, Hiroteru Kamimura, Akira Sakamaki, Satoshi Abe, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    PLOS ONE   12 ( 6 )   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    Background and aim
    Among various symptoms accompanied with chronic liver disease, pruritus affects the quality of life of patients, causing physical and mental stress, and worsens hepatic function. Recently, kappa-opioid receptor agonist, nalfurafine hydrochloride was approved to treat central pruritus in patients with liver disease in Japan. This study aimed to assess the long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients.
    Methods
    A patient-reported outcome using questionnaire-based methods was used for 41 liver disease patients with or without pruritus symptoms. Nalfurafine hydrochloride (2.5 mu g/day) was orally administered to 18 patients suffering from pruritus symptoms and whose current treatment was not effective. The same questionnaires and visual analogue scales (VAS) were repeatedly followed up for the patients for the entire follow-up period, and biochemical analyses were performed to evaluate the safety of the treatment.
    Results
    Pruritus completely disappeared in seven of 18 cases, and VAS scores showed a decreasing trend over time from the start of nalfurafine hydrochloride administration in all patients who received the medication. Among 11 patients who were followed up for more than 12 weeks, nine patients showed continuous improvement of symptoms, and this progress was still apparent at &gt;= 20 weeks after starting administration (p &lt; 0.0001). The medication was discontinued in four patients because of progression of primary disease, high cost, oral dryness, and anemia. No significant toxicity was observed on the serum biochemical analyses.
    Conclusions
    Nalfurafine hydrochloride contributed to long-term suppression of pruritus without significant safety problems.

    DOI: 10.1371/journal.pone.0178991

    Web of Science

    researchmap

  • Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial 査読

    Kenya Kamimura, Takeshi Suda, Takeshi Yokoo, Hiroteru Kamimura, Tsutomu Kanefuji, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Nobuo Waguri, Satoshi Yamagiwa, Shuji Terai

    BMC CANCER   17   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: Based on promising results from a Phase I study of hepatic arterial infusion chemotherapy using a combination of miriplatin and cisplatin powder (DDP-H) for unresectable hepatocellular carcinoma (UMIN-CTR000003541), a multicenter, open-label, randomized phase II study was conducted to evaluate the efficacy and safety of the combination therapy versus miriplatin monotherapy.
    Methods: Nineteen patients, five and fourteen Barcelona-Clinic Liver Cancer staging classification A and B cases, respectively, were randomly assigned to receive either miriplatin monotherapy (n = 9) or miriplatin/DDP-H combination therapy (n = 10). DDP-H and/or miriplatin were administered through the hepatic arteries supplying the lobes of the liver containing tumors, and progression free survival was analyzed as a primary end point in addition to other secondary endpoints. The corresponding therapy was repeated unless disease progression or severe adverse events were recorded.
    Results: The monotherapy or combination therapy was performed for 15 or 36 sessions in total, respectively. Although there were no significant differences between the two groups for treatment intervals (p = 0.96) or the dose of miriplatin used in each session (p = 0.99), the progression free survival and overall disease control rate were significantly better in the combination therapy group (91 vs 423 days, p = 0.025; 40.0 vs 77.8%, p = 0.0025, respectively). Consistent with these observations, a trend of a significantly slower increase in des-gamma-carboxyprothrombin was observed, and the number of treatment sessions was nearly significantly larger in the combination therapy group (p &lt; 0.0001, p = 0.057, respectively). Conversely, the median survival time did not show a significant difference (706 days, monotherapy vs 733 days, combination therapy; p = 0.40). A significant decrease in cholinesterase was observed during the course of treatment only in patients receiving combination therapy (r = -0.86, p &lt; 0.0001). A few cases in both arms showed hematological and/or non-hematological toxicities that were categorized as grade 1 (NCI-CTCAE).
    Conclusions: The higher disease control effects with the combination of miriplatin and DDP-H indicate that it is a promising alternative treatment for cases with multiple HCCs, especially for those that can tolerate the treatment without experiencing a reduction in hepatic reserve.

    DOI: 10.1186/s12885-017-3320-7

    Web of Science

    researchmap

  • Tumor markers for early diagnosis for brain metastasis of hepatocellular carcinoma: A case series and literature review for effective loco-regional treatment 査読

    Kenya Kamimura, Yuji Kobayashi, Yoshifumi Takahashi, Hiroyuki Abe, Daisuke Kumaki, Takeshi Yokoo, Hiroteru Kamimura, Norihiro Sakai, Akira Sakamaki, Satoshi Abe, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    CANCER BIOLOGY & THERAPY   18 ( 2 )   79 - 84   2017年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:TAYLOR & FRANCIS INC  

    Intrahepatic lesions of hepatocellular carcinoma (HCC) have been controlled by significant advances in treatment using loco-regional therapies, including, surgery, ablative therapy, catheter-based chemotherapy, and embolization. Consequently, the number of patients with extrahepatic metastatic lesions has increased. Their prognosis remains poor with approximately &lt;1y of survival from the time of diagnosis. A molecularly targeted drug, sorafenib, have been used to treat extrahepatic lesions and shown the prolonged survival time. However, the therapeutic benefit for the brain metastasis remains unclear, since it causes intratumor bleeding leading to the severe brain damage. No guidelines for the brain metastasis of HCC have been developed to date due to the shortage of the experiences and evidences. Therefore, the development of standard therapy for brain metastasis following the early diagnosis is essential by accumulating the information of clinical courses and evidences. For this purpose, we reviewed cases of HCC brain metastasis reported to date and analyzed additional 8 cases from our hospital, reviewing 592 advanced HCC cases to estimate the possible metastatic lesions in the brain. With careful review of cases and literature, we suggest that the cases with lung metastasis with increase tendency of tumor markers within recent 3-6months have higher risks of brain metastasis. Therefore, they should be carefully followed by imaging modalities. In addition, the loco-regional treatment, including surgical resection and radiation therapy should be performed for better prognosis by preventing re-bleeding from the tumors.

    DOI: 10.1080/15384047.2016.1276134

    Web of Science

    researchmap

  • Possible involvement of mucosal-associated invariant T cells in the progression of inflammatory bowel diseases 査読

    Kentaro Tominaga, Satoshi Yamagiwa, Toru Setsu, Naruhiro Kimura, Hiroki Honda, Hiroteru Kamimura, Yutaka Honda, Masaaki Takamura, Junji Yokoyama, Kenji Suzuki, Toshifumi Wakai, Shuji Terai

    BIOMEDICAL RESEARCH-TOKYO   38 ( 2 )   111 - 121   2017年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMEDICAL RESEARCH PRESS LTD  

    munity. Recent studies have demonstrated that MAIT cells might be implicated in inflammatory bowel diseases (IBDs), but their precise function in IBD remains to be elucidated. We investigated the possible involvement of MAIT cells in the immunopathogenesis of IBDs. Heparinized peripheral blood and biopsy specimens of the colon were collected from 25 patients with ulcerative colitis (UC), 15 patients with Crohn's disease (CD), and 19 heathy individuals. Lymphocytes were isolated from the blood and colon, and then MAIT cells were analyzed by flow cytometry. The frequency of MAIT cells was significantly lower in the blood of IBD patients compared to healthy donors and significantly higher in the inflamed colons compared to healthy colons (P = 0.001). Among the IBD patients, the frequency of MAIT cells in the blood and colon was correlated with disease activities. In vitro activated MAIT cells from IBD patients secreted significantly more tumor necrosis factor-alpha and interleukin-17 than those from healthy donors. These findings indicate that MAIT cells are activated in IBD patients, and their accumulation in the inflamed mucosa is correlated with disease activities.

    DOI: 10.2220/biomedres.38.111

    Web of Science

    researchmap

  • Transhepatic arterial chemotherapy using a combination of miriplatin and CDDP powder in patients with hepatocellular carcinoma 査読

    Kenya Kamimura, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Nobuo Waguri, Toru Ishikawa, Takeshi Suda, Satoshi Yamagiwa, Shuji Terai

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   31   361 - 361   2016年11月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • Biological significance of a disintegrin and metalloproteinase 21 expression in hepatocellular carcinoma 査読

    Masaaki Takamura, Hiroki Honda, Satoshi Yamagiwa, Naruhiro Kimura, Toru Setsu, Kentaro Tominaga, Hiroteru Kamimura, Takuya Genda, Yasunobu Matsuda, Toshifumi Wakai, Shuji Terai

    HEPATOLOGY   64   639A - 639A   2016年10月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Platinum-based transhepatic arterial chemotherapy using a combination of miriplatin and CDDP powder in patients with hepatocellular carcinoma 査読

    Kohei Ogawa, Kenya Kamimura, Takeshi Suda, Takeshi Yokoo, Akira Sakamaki, Satoshi Abe, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Nobuo Waguri, Toru Ishikawa, Satoshi Yamagiwa, Shuji Terai

    HEPATOLOGY   64   652A - 652A   2016年10月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Effective prevention of hand-foot syndrome by the consumption of dried bonito broth 査読

    Kenya Kamimura, Yoko Shinagawa, Kohei Ogawa, Yuji Kobayashi, Hiroyuki Abe, Takeshi Yokoo, Hiroteru Kamimura, Hirokazu Kawai, Takeshi Suda, Satoshi Yamagiwa, Hiroshi Baba, Shuji Terai

    Japanese Journal of Cancer and Chemotherapy   43 ( 4 )   463 - 465   2016年4月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Journal of Cancer and Chemotherapy Publishers Inc.  

    To examine whether the consumption of dried bonito both is effective for the prevention of hand-foot syndrome (HFS), concentrated bonito broth was administered to 10 patients with HCC who were treated with sorafenib. Among the 10 patients, seven showed an increase in peripheral blood flow, as observed on Doppler ultrasonography. Only one patient showed Grade 1 HFS on day 14 after the initiation of sorafenib (10%)
    this incidence rate of HFS was significantly lower than that obtained in our previous studies and reported data. These results suggest that consumption of dried bonito broth contributes to the prevention of HFS by maintaining peripheral blood flow.

    Scopus

    PubMed

    researchmap

  • Possible involvement of activating follicular helper T cells in autoimmune hepatitis 査読

    Naruhiro Kimura, Satoshi Yamagiwa, Hiroki Honda, Toru Setsu, Kentaro Tominaga, Hiroteru Kamimura, Masaaki Takamura, Shuji Terai

    HEPATOLOGY   62   369A - 369A   2015年10月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • Diagnostic imaging of hepatic lymphoma 査読

    Hiroyuki Abe, Kenya Kamimura, Hirokazu Kawai, Hiroteru Kamimura, Koji Domori, Yuji Kobayashi, Minoru Nomoto, Yutaka Aoyagi

    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY   39 ( 4 )   435 - 442   2015年9月

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER MASSON  

    Hepatic lymphoma is a rare disease with poor prognosis because of delayed diagnosis. The disease comprises primary, metastatic, and intravascular hepatic lymphomas. The pathological characteristics of lymphomas differ contributing to difficulty in early diagnosis. Early diagnosis and appropriate treatment result in improved prognosis; therefore, diagnostic radiology and its development with various contrast agents are critical for improving disease outcomes. Herein, we review hepatic lymphomas and summarize the results of imaging studies in correlation with pathological characteristics. The information provided will help physicians in early diagnosis and thereby improving prognosis. (C) 2014 Published by Elsevier Masson SAS.

    DOI: 10.1016/j.clinre.2014.11.001

    Web of Science

    researchmap

  • Advances in understanding and treating liver diseases during pregnancy: A review 査読

    Kenya Kamimura, Hiroyuki Abe, Hirokazu Kawai, Hiroteru Kamimura, Yuji Kobayashi, Minoru Nomoto, Yutaka Aoyagi, Shuji Terai

    WORLD JOURNAL OF GASTROENTEROLOGY   21 ( 17 )   5183 - 5190   2015年5月

     詳細を見る

    記述言語:英語   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    Liver disease in pregnancy is rare but pregnancy-related liver diseases may cause threat to fetal and maternal survival. It includes pre-eclampsia; eclampsia; haemolysis, elevated liver enzymes, and low platelets syndrome; acute fatty liver of pregnancy; hyperemesis gravidarum; and intrahepatic cholestasis of pregnancy. Recent basic researches have shown the various etiologies involved in this disease entity. With these advances, rapid diagnosis is essential for severe cases since the decision of immediate delivery is important for maternal and fetal survival. The other therapeutic options have also been shown in recent reports based on the clinical trials and cooperation and information sharing between hepatologist and gynecologist is important for timely therapeutic intervention. Therefore, correct understandings of diseases and differential diagnosis from the pre-existing and co-incidental liver diseases during the pregnancy will help to achieve better prognosis. Therefore, here we review and summarized recent advances in understanding the etiologies, clinical courses and management of liver disease in pregnancy. This information will contribute to physicians for diagnosis of disease and optimum management of patients.

    DOI: 10.3748/wjg.v21.i17.5183

    Web of Science

    researchmap

  • Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging 査読

    Tsutomu Kanefuji, Toru Takano, Takeshi Suda, Kouhei Akazawa, Takeshi Yokoo, Hiroteru Kamimura, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Hidefumi Aoyama, Minoru Nomoto, Shuji Terai

    WORLD JOURNAL OF GASTROENTEROLOGY   21 ( 15 )   4583 - 4591   2015年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    AIM: To establish a prognostic formula that distinguishes non-hypervascular hepatic nodules (NHNs) with higher aggressiveness from less hazardous one.
    METHODS: Seventy-three NHNs were detected in gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging (Gd-EOB-DTPA-MRI) study and confirmed to change 2 mm or more in size and/or to gain hypervascularity. All images were interpreted independently by an experienced, board-certified abdominal radiologist and hepatologist; both knew that the patients were at risk for hepatocellular carcinoma development but were blinded to the clinical information. A formula predicting NHN destiny was developed using a generalized estimating equation model with thirteen explanatory variables: age, gender, background liver diseases, Child-Pugh class, NHN diameter, T1-weighted imaging/T2-weighted imaging detectability, fat deposition, lower signal intensity in arterial phase, lower signal intensity in equilibrium phase, alpha-fetoprotein, des-gamma-carboxy prothrombin, alpha-fetoprotein-L3, and coexistence of classical hepatocellular carcinoma. The accuracy of the formula was validated in bootstrap samples that were created by resampling of 1000 iterations.
    RESULTS: During a median follow-up period of 504 d, 73 NHNs with a median diameter of 9 mm (interquartile range: 8-12 mm) grew or shrank by 68.5% (fifty nodules) or 20.5% (fifteen nodules), respectively, whereas hypervascularity developed in 38.4% (twenty eight nodules). In the fifteen shrank nodules, twelve nodules disappeared, while 11.0% (eight nodules) were stable in size but acquired vascularity. A generalized estimating equation analysis selected five explanatories from the thirteen variables as significant factors to predict NHN progression. The estimated regression coefficients were 0.36 for age, 6.51 for lower signal intensity in arterial phase, 8.70 or 6.03 for positivity of hepatitis B virus or hepatitis C virus, 9.37 for des-gamma- carboxy prothrombin, and -4.05 for fat deposition. A formula incorporating the five coefficients revealed sensitivity, specificity, and accuracy of 88.0%, 86.7%, and 87.7% in the formulating cohort, whereas these of 87.2% +/- 5.7%, 83.8% +/- 13.6%, and 87.3% +/- 4.5% in the bootstrap samples.
    CONCLUSION: These data suggest that the formula helps Gd-EOB-DTPA-MRI detect a trend toward hepatocyte transformation by predicting NHN destiny.

    DOI: 10.3748/wjg.v21.i15.4583

    Web of Science

    researchmap

  • Successful management of severe intrahepatic cholestasis of pregnancy: report of a first Japanese case 査読

    Kenya Kamimura, Hiroyuki Abe, Naomi Kamimura, Masayuki Yamaguchi, Maiko Mamizu, Kanna Ogi, Yoshifumi Takahashi, Ken-ichi Mizuno, Hiroteru Kamimura, Yuji Kobayashi, Manabu Takeuchi, Kunihiko Yoshida, Kyoko Yamada, Takayuki Enomoto, Koichi Takakuwa, Minoru Nomoto, Miki Obata, Yoshinori Katsuragi, Yukio Mishima, Ryo Kominami, Tomoteru Kamimura, Yutaka Aoyagi

    BMC GASTROENTEROLOGY   14   2014年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: Intrahepatic cholestasis of pregnancy (ICP) is a cholestasis condition caused by elevated levels of serum bile acids that mainly occurs in the third trimester of pregnancy. Maternal symptoms include pruritus; elevation of transaminases, biliary enzymes, and bilirubin levels; and abnormal liver function tests. Fetal symptoms include spontaneous preterm labor, fetal distress, and intrauterine death. It is more prevalent in the Caucasians and is rarely found in Asian countries, including Japan. The etiology of ICP has been reported as involving various factors such as, environmental factors, hormone balance, and genetic components. The genetic factors include single-nucleotide polymorphisms (SNPs) in the genes of canalicular transporters, including ABCB4 and ABCB11. It has also been reported that the combination of these SNPs induces severe cholestasis and liver dysfunction.
    Case presentation: Here, we report for the first time a 24-year Japanese case of severe ICP diagnosed by typical symptoms, serum biochemical analysis, and treated with the administration of ursodeoxycholic acid which improved cholestasis and liver injury and prevented fetal death. The sequence analysis showed SNPs reported their association with ICP in the ABCB11 (rs2287622, V444A) and ABCB4 (rs1202283, N168N) loci.
    Conclusion: The risk of ICP has been reported to be population-specific, and it is rare in the Japanese population. Our case was successfully treated with ursodeoxycholic acid and the genetic sequence analysis has supported the diagnosis. Because genetic variation in ABCB4 and ABCB11 has also been reported in the Japanese population, we need to be aware of potential ICP cases in pregnant Japanese women although further studies are necessary.

    DOI: 10.1186/1471-230X-14-160

    Web of Science

    researchmap

  • Imbalance between CD56(+bright) and CD56(+dim) natural killer cell subsets in the liver of patients with recurrent hepatitis C after liver transplantation 査読

    Satoshi Yamagiwa, Yoshinobu Sato, Takafumi Ichida, Toru Setsu, Kentaro Tominaga, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Yasunobu Matsuda, Yutaka Aoyagi

    BIOMEDICAL RESEARCH-TOKYO   35 ( 3 )   177 - 184   2014年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMEDICAL RESEARCH PRESS LTD  

    Progressive liver fibrosis remains a major problem for patients with recurrent chronic hepatitis C (CHC) after liver transplantation (LT). However, the involvement of natural killer (NK) and natural killer T (NKT) cells, which predominate in the liver, in recurrent CHC after LT remains unclear. In the present study, we investigated the status of NK and NKT cells in the liver and peripheral blood obtained from 10 patients with recurrent CHC after LT (LT-C), 15 patients with CHC, and 7 normal donors for living donor LT. CD56(+) NK cells were separated into two subsets: CD56(+bright) subset, which is identified as major NK cytokine producer, and CD56(+dim) subset, which has greater spontaneous cytotoxicity. We found a significant decrease in the CD56(+bright) subset in the liver of patients with LT-C compared to patients with CHC (P &lt; 0.01) and normal donors (P = 0.03). The expression of inhibitory NK cell receptor NKG2A was significantly increased on intrahepatic CD56(+bright) subset in LT-C patients, and activated CD69(+)CD56(+dim) NK cell subset was significantly increased. in the liver of LT-C patients. Our results suggest that a significant imbalance between CD56(+bright) and CD56(+dim) NK cell subsets in the liver may contribute to the progression of recurrent CHC after LT.

    DOI: 10.2220/biomedres.35.177

    Web of Science

    researchmap

  • Value of shear wave velocity measurements for the risk assessment of hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease 査読

    Masaaki Takamura, Tsutomu Kanefuji, Takeshi Suda, Takeshi Yokoo, Hiroteru Kamimura, Atsunori Tsuchiya, Kenya Kamimura, Yasushi Tamura, Masato Igarashi, Hirokazu Kawai, Satoshi Yamagiwa, Minoru Nomoto, Yutaka Aoyagi

    HEPATOLOGY INTERNATIONAL   8 ( 2 )   240 - 249   2014年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    To evaluate the value of measuring shear wave velocity evoked by acoustic radiation force impulse (VTTQ) for the risk assessment of hepatocellular carcinoma (HCC) development in patients with nonalcoholic fatty liver disease (NAFLD).
    VTTQ was measured three times in each of the four liver segments in 163 NAFLD patients, including 14 HCC cases; the results were statistically evaluated.
    The VTTQ was 3.04 +/- A 0.17 m/s (median +/- A median absolute deviation) and 1.27 +/- A 0.25 m/s in patients with and without HCC, respectively, and was significantly higher in HCC cases (p &lt; 0.001). When the patients were classified as F0-F4 based on VTTQ cutoff values, VTTQ was significantly higher in the left lobe than in the right lobe for F0 (p &lt; 0.0001) and for F1 and F2 combined (p &lt; 0.0001), but not significantly higher for F3 and F4 combined (p = 0.070). The robust coefficient of variation was significantly higher in the left than in the right (p = 0.018) and significantly increased as VTTQ increased (p = 0.0002). Multivariate analysis showed that total bilirubin concentration {p = 0.014, 38.9 (2.08-727) [odds ratio (95 % confidence interval)]} and VTTQ [p = 0.006, 113 (3.91-3245)] were the only independent explanatory factors for HCC presence among the seven variables identified by univariate analysis. The area under the receiver-operating characteristic curve in the differentiation of HCC from non-HCC was 0.943 for VTTQ and was comparable to that for other noninvasive markers such as Fib-4 (0.964) or higher than that in BARD (0.838).
    These results suggest that fibrosis occurs heterogeneously throughout the liver and that VTTQ measurements are useful in HCC risk evaluation in a NAFLD cohort.

    DOI: 10.1007/s12072-014-9517-9

    Web of Science

    researchmap

  • Autoantibodies in primary biliary cirrhosis: Recent progress in research on the pathogenetic and clinical significance 査読

    Satoshi Yamagiwa, Hiroteru Kamimura, Masaaki Takamura, Yutaka Aoyagi

    WORLD JOURNAL OF GASTROENTEROLOGY   20 ( 10 )   2606 - 2612   2014年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBL GRP CO LTD  

    Primary biliary cirrhosis (PBC) is a chronic progressive cholestatic liver disease characterized by immune-mediated destruction of the small-and medium-sized intrahepatic bile ducts and the presence of antimitochondrial antibodies (AMA) in the serum. AMA are detected in over 90% of patients with PBC, whereas their prevalence in the general population is extremely low, varying from 0.16% to 1%. Previous studies have shown that the unique characteristics of biliary epithelial cells undergoing apoptosis may result in a highly direct and very specific immune response to mitochondrial autoantigens. Moreover, recent studies have demonstrated that serum from AMA-positive PBC patients is reactive with a number of xenobiotic modified E2 sub-units of the pyruvate dehydrogenase complex, which is not observed in the serum of normal individuals. These findings indicate that chemicals originating from the environment may be associated with a breakdown in the tolerance to mitochondrial autoantigens. While it is currently generally accepted that AMA are the most specific serological markers of PBC, more than 60 autoantibodies have been investigated in patients with PBC, and some have previously been considered specific to other autoimmune diseases. This review covers the recent progress in research on the pathogenetic and clinical significance of important autoantibodies in PBC. Determining the pathogenic role of those autoantibodies in PBC remains a priority of basic and clinical research. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

    DOI: 10.3748/wjg.v20.i10.2606

    Web of Science

    researchmap

  • Presence of Antibodies against Self Human Leukocyte Antigen Class II Molecules in Autoimmune Hepatitis 査読

    Satoshi Yamagiwa, Hiroteru Kamimura, Masaaki Takamura, Takuya Genda, Takafumi Ichida, Minoru Nomoto, Yutaka Aoyagi

    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES   11 ( 9 )   850 - 856   2014年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:IVYSPRING INT PUBL  

    Autoimmune hepatitis (AIH) can arise de novo after liver transplantation (LT) for non-autoimmune liver diseases. Considering the identical features of de novo AIH after LT and classical AIH, as well as the importance of anti-human leukocyte antigen (HLA) antibodies in graft rejection, we investigated the presence of circulating anti-HLA class II antibodies in the sera of 35 patients with AIH, 30 patients with primary biliary cirrhosis (PBC), and 30 healthy donors using fluorescent dye-impregnated beads bound to HLA molecules. We then investigated the allele specificity of the antibodies and identified the HLA alleles in each patient using DNA-based HLA typing. We also examined HLA class II expression in liver samples using immunohistochemistry. Anti-HLA class II antibodies were detected significantly more frequently in the patients with AIH (88.1%) than in the patients with PBC (33.3%) or in the healthy donors (13.3%) (both P &lt; 0.01). We confirmed that the anti-HLA class II antibodies in the AIH patients showed specificity for several HLA class II alleles, including self HLA class II alleles. Moreover, positive reactivity with anti-self HLA class II antibodies was associated with higher serum transaminase levels. In conclusion, we demonstrated, for the first time, that antibodies against self HLA class II alleles were detectable in patients with AIH. Our results suggest that an antibody-mediated immune response against HLA class II molecules on hepatocytes may be involved in the pathogenesis or acceleration of liver injury in AIH.

    DOI: 10.7150/ijms.8633

    Web of Science

    researchmap

  • Distinctive phenotypic features of human mucosal-associated invariant T cells in the liver 査読

    Kentaro Tominaga, Toru Setsu, Satoshi Yamagiwa, Naruhiro Kimura, Hiroki Honda, Hiroteru Kamimura, Masaaki Takamura, Minoru Nomoto

    HEPATOLOGY   60   506A - 506A   2014年

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • Possible impairment of mucosal-associated invariant T cells in the liver of patients with primary biliary cirrhosis 査読

    Toru Setsu, Satoshi Yamagiwa, Kentaro Tominaga, Naruhiro Kimura, Hiroki Honda, Hiroteru Kamimura, Masaaki Takamura, Minoru Nomoto

    HEPATOLOGY   60   357A - 358A   2014年

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • Increased Susceptibility to Severe Chronic Liver Damage in CXCR4 Conditional Knock-Out Mice 査読

    Atsunori Tsuchiya, Michitaka Imai, Hiroteru Kamimura, Masaaki Takamura, Satoshi Yamagiwa, Tatsuki Sugiyama, Minoru Nomoto, Toshio Heike, Takashi Nagasawa, Tatsutoshi Nakahata, Yutaka Aoyagi

    DIGESTIVE DISEASES AND SCIENCES   57 ( 11 )   2892 - 2900   2012年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    The chemokine SDF-1 and its receptor CXCR4 are essential for the proper functioning of multiple organs. In the liver, cholangiocytes and hepatic progenitor cells (HPCs) are the main cells that produce SDF-1, and SDF-1 is thought to be essential for HPC-stimulated liver regeneration.
    In this study, CXCR4 conditionally targeted mice were used to analyze the role of SDF-1 in chronically damaged liver.
    Chronic liver damage was induced in MxCre CXCR4(f/null) mice and the control MxCre CXCR4(f/wt) mice by CCl4. Serum markers were analyzed to assess liver function and damage, the number of cytokeratin-positive cells as a measure of HPCs, and the extent of liver fibrosis. Additional parameters relating to liver damage, such as markers of HPCs, liver function, MMPs, and TIMPs were measured by real-time PCR.
    Serum ALT was significantly higher in MxCre CXCR4(f/null) mice than MxCre CXCR4(f/wt) mice. The number of cytokeratin-positive cells and the area of fibrosis were also increased in the MxCre CXCR4(f/null) mice. The expression of mRNAs for several markers related to hepatic damage and regeneration was also increased in the liver of MxCre CXCR4(f/null) mice, including primitive HPC marker prominin-1, MMP9, TNF-alpha, and alpha-SMA.
    MxCre CXCR4(f/null) mice were susceptible to severe chronic liver damage, suggesting that SDF-1-CXCR4 signals are important for liver regeneration and preventing the progression of liver disease. Modulation of SDF-1 may therefore be a promising treatment strategy for patients with chronic liver disease.

    DOI: 10.1007/s10620-012-2239-8

    Web of Science

    researchmap

  • Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence 査読

    Hiroteru Kamimura, Satoshi Yamagiwa, Atsunori Tsuchiya, Masaaki Takamura, Yasunobu Matsuda, Shogo Ohkoshi, Makoto Inoue, Toshifumi Wakai, Yoshio Shirai, Minoru Nomoto, Yutaka Aoyagi

    JOURNAL OF HEPATOLOGY   56 ( 2 )   381 - 388   2012年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE BV  

    Background 82 Aims: The activating receptor natural killer group 2, member D (NKG2D) and its ligands play a crucial role in immune response to tumors. NKG2D ligand expression in tumors has been shown to be associated with tumor eradication and superior patient survival, but the involvement of NKG2D ligands in the immune response against hepatocellular carcinoma (HCC) still remains to be elucidated.
    Methods: We investigated the expression of NKG2D ligands in HCC tissues collected from 54 patients and HCC cell lines. We also examined the proteasome expression and the effect of inhibition of proteasome activity on NKG2D ligand expression in HCC tissues and cell lines.
    Results: In dysplastic nodules (DN), well-differentiated (well-HCC), and moderately-differentiated HCCs (mod-HCC), UL16-binding protein (ULBP) 1 was expressed predominantly in tumor cells, but not in poorly-differentiated HCCs (poor-HCC). Remarkably, recurrence-free survival of patients with ULBP1-negative HCC was significantly shorter than that of patients with ULBP1-positive HCC (p = 0.006). Cox regression analysis revealed that loss of ULBP1 expression was an independent predictor of early recurrence (p = 0.008). We confirmed that ULBP1 was expressed in the well- and mod-HCC cell lines, but not in the poor-HCC cell line KYN-2. However, inhibition of proteasome activity resulted in significant up-regulation of ULBP1 expression in KYN-2. Moreover, we found that 20S proteasome expression was more abundant in KYN-2 than that in the well- and mod-HCC cell lines.
    Conclusions: ULBP1 is prevalently expressed in DN to mod-HCC, but loss of its expression correlates with tumor progression and early recurrence. (C) 2011 European Association for the Study of the Liver. Published by Elsevier By. All rights reserved.

    DOI: 10.1016/j.jhep.2011.07.008

    Web of Science

    researchmap

  • Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. 招待

    Kamimura Hiroteru, Yamagiwa Satoshi, Tsuchiya Atsunori, Takamura Masaaki, Matsuda Yasunobu, Ohkoshi Shogo, Inoue Makoto, Wakai Toshifumi, Shirai Yoshio, Nomoto Minoru, Aoyagi Yutaka

    J Hepatol   56 ( 2 )   381 - 388   2012年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND &amp; AIMS: The activating receptor natural killer group 2, member D (NKG2D) and its ligands play a crucial role in immune response to tumors. NKG2D ligand expression in tumors has been shown to be associated with tumor eradication and superior patient survival, but the involvement of NKG2D ligands in the immune response against hepatocellular carcinoma (HCC) still remains to be elucidated. METHODS: We investigated the expression of NKG2D ligands in HCC tissues collected from 54 patients and HCC cell lines. We also examined the proteasome expression and the effect of inhibition of proteasome activity on NKG2D ligand expression in HCC tissues and cell lines. RESULTS: In dysplastic nodules (DN), well-differentiated (well-HCC), and moderately-differentiated HCCs (mod-HCC), UL16-binding protein (ULBP) 1 was expressed predominantly in tumor cells, but not in poorly-differentiated HCCs (poor-HCC). Remarkably, recurrence-free survival of patients with ULBP1-negative HCC was significantly shorter than that of patients with ULBP1-positive HCC (p=0.006). Cox regression analysis revealed that loss of ULBP1 expression was an independent predictor of early recurrence (p=0.008). We c

    DOI: 10.1016/j.jhep.2011.06.017

    PubMed

    researchmap

  • REDUCED NKG2D LIGAND EXPRESSION IN HEPATOCELLULAR CARCINOMA CORRELATES WITH EARLY RECURRENCE 査読

    Satoshi Yamagiwa, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Yasunobu Matsuda, Yoshio Shirai, Yutaka Aoyagi

    HEPATOLOGY   54   1100A - 1101A   2011年10月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM 査読

    Atsunori Tsuchiya, Hiroteru Kamimura, Yasushi Tamura, Masaaki Takamura, Satoshi Yamagiwa, Takeshi Suda, Minoru Nomoto, Yutaka Aoyagi

    CANCER LETTERS   309 ( 1 )   95 - 103   2011年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER IRELAND LTD  

    We analyzed hepatocellular carcinoma (HCC) with progenitor cell features using hepatic stem/progenitor cell marker neural cell adhesion molecule (NCAM). Approximately 8.3% of the operated HCC cases expressed NCAM, and 22.3% of the HCC patients had soluble NCAM levels &gt;1000 ng/ml (the "highly soluble" NCAM group). Soluble NCAM status was a significant independent factor predictive of long-term survival in patients with HCC, and high levels of soluble NCAM were significantly related to intrahepatic metastasis. The 140-kDa NCAM isoform was specifically detected in the "highly soluble" NCAM group of HCC patients and its related signals are potential drug targets for NCAM+ HCC. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

    DOI: 10.1016/j.canlet.2011.05.021

    Web of Science

    researchmap

  • Loss of liver-intestine cadherin in human intrahepatic cholangiocarcinoma promotes angiogenesis by up-regulating metal-responsive transcription factor-1 and placental growth factor 査読

    Masaaki Takamura, Satoshi Yamagiwa, Toshifumi Wakai, Yasushi Tamura, Hiroteru Kamimura, Takashi Kato, Atsunori Tsuchiya, Yasunobu Matsuda, Yoshio Shirai, Takafumi Ichida, Yoichi Ajioka, Yutaka Aoyagi

    INTERNATIONAL JOURNAL OF ONCOLOGY   36 ( 1 )   245 - 254   2010年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    Liver-intestine cadherin (LI-cadherin) represents a novel type of cadherin within the cadherin superfamily that comprises seven cadherin repeats and a short cytoplasmic domain. In this study, we first examined LI-cadherin expression immunohistochemically in 34 specimens of human intrahepatic cholangiocarcinoma (ICC). LI-cadherin expression was positive (defined as positivity in &gt;= 10% of cells) in 18 of the ICCs (52.9%). LI-cadherin negativity was significantly correlated with tumor dedifferentiation (P=0.026) and vascular invasion (P=0.015). The cumulative survival rate of patients with LI-cadherin-negative ICC was significantly shorter than that of patients with LI-cadherin-positive ICC (P=0.021). Multivariate analysis identified the extent of LI-cadherin staining as an independent prognostic factor for ICC survival (P=0.027). Next, to elucidate the mechanism of loss of LI-cadherin-mediated aggressiveness in ICC, we knocked down LI-cadherin expression in an ICC cell line using small interfering RNA (siRNA) technology, and screened for genes that were expressed differentially between these cells and ICC cells transfected with scrambled siRNA using microarray analysis with real-time polymerase chain reaction confirmation. Among 21 identified genes, we focused on metal-responsive transcription factor-1 (MTF-1), whose target genes might contribute to tumor aggressiveness. Expression of placental growth factor (PIGF), one of the MTF-1 target genes, was up-regulated in the ICC cells transfected with LI-cadherin siRNA. Likewise, PIGF expression was up-regulated in LI-cadherin-negative ICC specimens. There was a significant inverse relationship between these expressions (P=0.033). Furthermore, the microvessel density of LI-cadherin-negative ICC specimens was higher than that of LI-cadherin-positive specimens. These findings suggest that loss of LI-cadherin in ICC is associated with tumor dedifferentiation and vascular invasion, and thus poor prognosis. Loss of LI-cadherin results in up-regulation of MTF-1 and PIGF, thereby regulating angiogenesis in ICC.

    DOI: 10.3892/ijo_00000495

    Web of Science

    researchmap

  • Clinicopathological analysis of CD133+and NCAM+ human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas 査読

    Atsunori Tsuchiya, Hiroteru Kamimura, Masaaki Takamura, Satoshi Yamagiwa, Yasunobu Matsuda, Yoshinobu Sato, Minoru Nomoto, Takafumi Ichida, Yutaka Aoyagi

    HEPATOLOGY RESEARCH   39 ( 11 )   1080 - 1090   2009年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL PUBLISHING, INC  

    Aim:
    Hepatic stem cells are capable of dramatically changing and differentiating to form mature hepatocytes in acute and chronically damaged livers; however, the clinicopathological characteristics of these heterogeneous cell populations have not been sufficiently analyzed.
    Methods:
    In this study, cells in tissue sections from 12 cases of acute damaged livers and 31 cases of hepatocellular carcinomas (HCC), and the surrounding chronically damaged liver tissues, were analyzed by immunohistochemistry using the previously reported hepatic stem/progenitor cell marker CD133 (AC133) and the neural cell adhesion molecule (NCAM) marker.
    Results:
    In both the acute and chronically damaged livers, CD133+ cells and NCAM+ cells were present in ductular reactions (DR), which include hepatic stem/progenitor cells, and became more apparent in proportion to the degree of fibrosis or histological damage. Analysis of their distribution and morphological similarities revealed that the NCAM+ cell population included cells that were closer to, and morphologically more similar to, hepatocytes than were CD133+ cells. Analysis of HCC using these markers revealed that 9.7% of HCC expressed NCAM (two cases had abundant NCAM+ cells), while CD133+ HCC were not detected.
    Conclusion:
    These results suggest that CD133 and NCAM can be employed to enrich for hepatic stem/progenitor cells and that DR can be distinguished in greater detail using these markers. NCAM+ HCC were detected, but their function remains unresolved. Expression of CD133, a potent stem cell marker, may be extremely rare in the common human HCC examined.

    DOI: 10.1111/j.1872-034X.2009.00559.x

    Web of Science

    researchmap

  • Oral Branched-Chain Amino Acids Administration Improves Impaired Liver Dysfunction after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma 査読

    Toru Ishikawa, Imai Michitaka, Hiroteru Kamimura, Kazuo Higuchi, Tomoyuki Kubota, Kei-ichi Seki, Hironobu Ohta, Toshiaki Yoshida, Tomoteru Kamimura

    HEPATO-GASTROENTEROLOGY   56 ( 94-95 )   1491 - 1495   2009年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:H G E UPDATE MEDICAL PUBLISHING S A  

    Background/Aims: Radiofrequency ablation (RFA) is a new modality for hepatocellular carcinoma (HCC). However, the effects of RFA on hepatic reserve have not yet been thoroughly studied. In the present study, it was evaluated the effect of branched chain amino acid (BCAA) administration after RFA.
    Methodology: Fifty-seven patients with initial, single HCC lesions measuring not more than 30mm in whom RFA was selected in first-line therapy were enrolled. Twenty-eight patients with the Child-Pugh B/C grade who received RFA therapy were divided into two groups: 11 who received a BCAA-enriched nutrient mixture, and 17 who did not. Changes in serum albumin were evaluated before RFA and 1, 6 and 12 months after RFA.
    Results: Multivariate analysis showed that the Child-Pugh grading is the most important factor related to intrahepatic distant recurrence following by RFA. Serum albumin levels decreased I month after RFA. Although a tendency toward recover), was noted 6 months after RFA, a decreasing tendency was noted again one year after RFA compared to the pre-RFA baseline. However, a tendency toward improvement was noted in Child-Pugh B grade patients who received BCAA mixture.
    Conclusions: BCAA mixture made it possible to maintain serum albumin levels and hepatic reserve.

    Web of Science

    researchmap

  • Successful treatment of multiple lung metastases of hepatocellular carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil 査読

    Atsunori Tsuchiya, Michitaka Imai, Hiroteru Kamimura, Tadayuki Togashi, Kouji Watanabe, Kei-ichi Seki, Toru Ishikawa, Hironobu Ohta, Toshiaki Yoshida, Tomoteru Kamimura

    WORLD JOURNAL OF GASTROENTEROLOGY   15 ( 14 )   1779 - 1781   2009年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:W J G PRESS  

    We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year-old man was diagnosed with multiple lung metastases of HCC 7 mo after partial hepatectomy for HCC. Oral UFT-E was given daily and docetaxel and CDDP were given intra-arterially (administered just before the bronchial arteries) every 2 wk via a subcutaneous injection port. One month after starting chemotherapy, levels of tumor marker, protein induced by vitamin K absence II (PIVKA-II), decreased rapidly, and after a further month, chest X-ray and computed tomography revealed the complete disappearance of multiple liver metastases. Two years after the combined chemotherapy, HCC recurred in the liver and was treated but no pulmonary recurrence occurred. In the absence of a standardized highly effective therapy, this combined chemotherapy with docetaxel, CDDP and UFT-E may be an attractive option for multiple lung metastases of HCC. (C) 2009 The WJG Press and Baishideng. All rights reserved.

    DOI: 10.3748/wjg.15.1779

    Web of Science

    researchmap

  • Natural killer cell receptors and their ligands in liver diseases 査読

    Satoshi Yamagiwa, Hiroteru Kamimura, Takafumi Ichida

    MEDICAL MOLECULAR MORPHOLOGY   42 ( 1 )   1 - 8   2009年3月

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER TOKYO  

    The liver is a distinctive immune organ with predominant innate immunity, being rich in innate immune cells such as natural killer (NK) cells. In humans, NK cells comprise about 30%-50% of intrahepatic lymphocytes, whereas peripheral blood lymphocytes contain about 5%-20% NK cells. Accumulating evidence suggests that NK cells play an important role not only in host defense against invading microorganisms and tumor transformation in the liver but also in liver injury and repair. In recent years, significant progress has been made in terms of understanding how NK cells recognize their target cells and carry out their effector functions. It is now clear that NK cells are strictly regulated by numerous activating and inhibitory NK cell receptors that recognize various classes of cell surface ligands, some of which are expressed by normal healthy cells. Therefore, to further elucidate the involvement of NK cells in the pathogenesis of liver diseases, an understanding of recent advances in NK cell biology is crucial. This review provides an overview of recent advances in our knowledge of human NK cell receptors and their ligands in the context of liver diseases.

    DOI: 10.1007/s00795-008-0434-7

    Web of Science

    researchmap

  • Therapeutic Efficacy of Continuous Arterial Infusion of the Protease Inhibitor and the Antibiotics and via Celiac and Superior Mesenteric Artery for Severe Acute Pancreatitis-Pilot Study 査読

    Toru Ishikawa, Michitaka Imai, Hiroteru Kamimura, Takashi Ushiki, Atsunori Tsuchiya, Tadayuki Togashi, Kouji Watanabe, Kei-ichi Seki, Hironobu Ohta, Toshiaki Yoshida, Tomoteru Kamimura

    HEPATO-GASTROENTEROLOGY   56 ( 90 )   524 - 528   2009年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:H G E UPDATE MEDICAL PUBLISHING S A  

    Background/Aims: Severe acute pancreatitis is poor prognosis. Continuous regional arterial infusion of protease inhibitors and antibiotics were developed in Japan. We evaluated whether arterial infusion both celiac artery and superior mesenteric artery for this disease would reduce mortality.
    Methodology: Seventeen patients were treated arterial infusion of protease inhibitor and antibiotics via both celiac artery and superior mesenteric artery. Changes of Acute Physiology and Chronic Health Evaluation II score and mortality were evaluated.
    Results: Arterial infusion via two routes reduced the mortality rate and improved Acute Physiology and Chronic Health Evaluation II score. The overall mortality rate was 11.8%. The mortality rate in patients in whom were treated within Mays after the onset was significantly lower than that in patients in whom were treated without 3days after the onset
    Conclusions: Arterial infusion via superior mesenteric artery might prevent both bacterial translocation and non-occlusive mesenteric ischemia. Continuous arterial infusion both celiac artery and superior mesenteric artery might be effective for reducing mortality and preventing the development of pancreatitis, especially when initiated within Mays after the onset. Further prospective randomized studies using a larger number of patients are required.

    Web of Science

    researchmap

  • A successful Balloon-occluded retrograde transvenous obliteration (B-RTO) for the gastric varices with double balloon obliteration using micro balloon catheter together 査読

    Toru Ishikawa, Michitaka Imai, Kazuo Higuchi, Hiroteru Kamimura, Kouji Watanabe, Keiichi Seki, Hironobu Ohta, Toshiaki Yoshida, Tomoteru Kamimura

    Acta Hepatologica Japonica   50 ( 2 )   65 - 70   2009年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 43-year-old woman with alcoholic liver cirrhosis was hospitalized with gastric varices, which brought about transient bleeding 1 week ago. Enhanced CT and esophago-gastro duodenoscopy revealed gastric fundal varices with some gastrorenal shunt. Balloon-occluded retrograde transvenous obliteration (B-RTO) was offered as the treatment A 6.0-Fr balloon was introduced from the right internal jugular vein into the gastro-renal shunt. However, the main gastro-renal shunt could not completely blocked with a 6.0-Fr balloon catheter because another small shunt that branched from the gastro-renal shunt developed and drained the blood flow into the left renal vein. Therefore, a 6.0-Fr catheter was introduced from the right femoral vein to left renal vein and 3.2Fr balloon catheter was inserted into the 6.0-Fr catheter and positioned in the small gastrorenal shunt described above. Inflation of the two balloons resulted in occlusion of the both gastrorenal shunts. After occulusion of these shunts, B-RTO was performed. One-week after the treatment, follow-up CT scans revealed thrombosed gastric varices. Simultaneously blocking of the branched gastro-renal shunt occluded successfully the blood flow into the renal vein, resulting in complete sclerosis of fundal gastric varices. © 2009 The Japan Society of Hepatology.

    DOI: 10.2957/kanzo.50.65

    Scopus

    researchmap

  • THE BALANCE BETWEEN CD56(+BRIGHT) AND CD56(+DlM) NATURAL KILLER CELL SUBSETS IN THE LIVER OF PATIENTS WITH RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION 査読

    Satoshi Yamagiwa, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Yasunobu Matsuda, Yoshinobu Sato, Takafumi Ichida, Yutaka Aoyagi

    HEPATOLOGY   48 ( 4 )   769A - 770A   2008年10月

     詳細を見る

    記述言語:英語   出版者・発行元:JOHN WILEY & SONS INC  

    Web of Science

    researchmap

  • 顕微鏡的多発血管炎(microscopic polyangiitis)にreversible posterior leukoencephalopathy syndrome(RPLS)を併発した1例

    高嶋 修太郎, 上村 博輝, 佐藤 正久

    日本内科学会雑誌   97 ( 2 )   448 - 449   2008年

     詳細を見る

    記述言語:日本語   出版者・発行元:The Japanese Society of Internal Medicine  

    DOI: 10.2169/naika.97.448

    CiNii Article

    researchmap

  • Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer 査読

    Toru Ishikawa, Hiroteru Kamimura, Atsunori Tsuchiya, Tadayuki Togashi, Kouji Watanabe, Kei-ichi Seki, Hironobu Ohta, Toshiaki Yoshida, Keiko Takeda, Tomoteru Kamimura

    HEPATO-GASTROENTEROLOGY   54 ( 80 )   2378 - 2382   2007年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:H G E UPDATE MEDICAL PUBLISHING S A  

    Background/Aims: To deliver anticancer drugs more selectively into cancer tissues and to improve survival time, we have developed a new method of intra-arterial chemotherapy for unresectable pancreatic cancer.
    Methodology: From April 2002 to June 2006, twenty patients with pancreatic cancer with liver metastases were given intra-arterial infusions consisting of gemcitabine, 5-FU, and cisplatin mixed with angiotensin-II with the intent of increasing the blood flow into the tumor tissue but decreasing that to the non-tumor tissues. Simultaneously, tegafur/uracil was administered. A tumor marker and computed tomography (CT) findings were used to evaluate the efficacy of this chemotherapy.
    Results: The median survival was 365 days, and 6-months and 1-year survival rates were 80.0% and 44.7%, respectively. In 12 of 20 cases, the tumor marker level was decreased after this chemotherapy. In 10 of 20 cases, computed tomography showed a decrease in the tumor size. In 6 patients, back pain was the chief complaint and was reduced to a self-controlled level in 20 patients. No major complications were encountered.
    Conclusions: Compared with the previously reported data in traditional chemotherapies, our method of intra-arterial chemotherapy appears to be quite useful not only for prolonging patient survival but also for improving the quality of life. Intra-arterial regional chemotherapy including changes in distribution of blood flow induced by angiotensin-II appears to be an effective palliative treatment for advanced pancreatic cancer.

    Web of Science

    researchmap

  • Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: A pilot study 査読

    Toru Ishikawa, Michitaka Imai, Hiroteru Kamimura, Atsunori Tsuchiya, Tadayuki Togashi, Kouji Watanabe, Kei-ichi Seki, Hironobu Ohta, Toshiaki Yoshida, Tomoteru Kamimura

    WORLD JOURNAL OF GASTROENTEROLOGY   13 ( 41 )   5465 - 5470   2007年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:W J G PRESS  

    AIM: To investigate the poor prognosis of HCC with PVTT, we evaluated the efficacy by a new combination chemotherapy for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
    METHODS: From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil.
    RESULTS: The mean course of chemotherapy was 14.4 (range, 9-21) mo. One patient showed complete response (CR) with disappearance of HCC and PVTT after treatment, and the two patients showed partial response (PR), response rate (CR + PR/All cases 30%). The median survival time after the therapy was 457.2 d. The one-year survival rate was 70%. Adverse reactions were tolerable.
    CONCLUSION: Although the prognosis of most patients with Stage IVA HCC by PVTT is poor, our combination chemotherapy may induces long-term survival and is an effective treatment and produced anti-tumor activity with tolerable adverse effects in patients for advanced Stage IVA HCC accompanied by PVTT. (C) 2007 W-7G. All rights reserved.

    DOI: 10.3748/wjg.v13.i41.5465

    Web of Science

    researchmap

  • A resected case of fibrolamellar hepatocellular carcinoma with chronic hepatitis (type B) 査読

    Toru Ishikawa, Hiroteru Kamimura, Atsunori Tsuchiya, Kouji Watanabe, Keiichi Seki, Hironobu Ohta, Toshiaki Yoshida, Nobuyuki Musya, Toshihiro Tsubono, Yasuo Sakai, Keiko Takeda, Noriko Ishihara, Tomoteru Kamimura

    Japanese Journal of Gastroenterology   104 ( 7 )   1076 - 1081   2007年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    We report a case of a 34-year-old woman who tested positive for HBs Ag with fibrolamellar hepatocellular carcinoma of the liver. The sister of this patient, who was also positive for HBs Ag, died of hepatocellular carcinoma (HCC). The patient showed elevation of alpha-fetoprotein. Abdominal CT scan showed a tumor in the posterior segment of the liver and hepatic angiography revealed marked neovascularity in the tumor. Partial resection of the liver was performed, and the histological diagnosis was fibrolamellar hepatocellular carcinoma. The patient is now tumor free and doing well 20 months after the operation.

    Scopus

    PubMed

    researchmap

  • Angiotensin-II administration is useful for the detection of liver metastasis from pancreatic cancer during pharmacoangiographic computed tomography 査読

    Toru Ishikawa, Takashi Ushiki, Hiroteru Kamimura, Tadayuki Togashi, Atsunori Tsuchiya, Kouji Watanabe, Kei-ichi Seki, Hironobu Ohta, Toshiaki Yoshida, Keiko Takeda, Tomoteru Kamimura

    WORLD JOURNAL OF GASTROENTEROLOGY   13 ( 22 )   3080 - 3083   2007年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:W J G PRESS  

    AIM: To improve the preoperative diagnosis of liver metastasis from pancreatic cancer, we estimated computed tomography during arterial angiography (CTA) with/without administration of angiotensin-II (AT-II).
    METHODS: Thirty-five patients with pancreatic cancer were examined in this study. After conventional CTA was performed, pharmacoangiographic CTA was performed with a 1-3 microgram/5 mL solution of angiotensin II injected through a catheter into the celiac artery during spiral computed tomography. We prospectively analyzed the relative region of interest (ROI) ratio of tumor to liver with/without AT-II.
    RESULTS: In all patients, the relative ratio of each computed tomography (CT) number in the ROI was larger at pharmacoangiographic CT than at conventional angiographic CT. Administration of angiotensin-II enhanced the metastatic liver tumor as compared with normal tissue. Intratumoral blood flow increased in all patients with malignant tumors due to the pressure effect of AT-II. Furthermore, the metastatic lesions in the liver of three patients were represented by only pharmacoangiographic CT, not by conventional CT and conventional CT angiography. In even peripheral and central areas of metastatic liver tumor, the lesions were enhanced after administration of AT-II.
    CONCLUSION: These results support that high detection rate of liver metastasis revealed by pharmacoangiographic CT suggests the improvement of diagnosis on preoperative staging. Moreover, chemotherapy under AT-II induced hypertension may have a better effect on the treatment of metastatic liver tumors. (c) 2007 The WJG Press. All rights reserved.

    Web of Science

    researchmap

  • Comparison of a new aspiration needle device and the quick-core biopsy needle for transjugular liver biopsy 査読

    Toru Ishikawa, Hiroteru Kamimura, Atsunori Tsuchiya, Tadayuki Togashi, Kouji Watanabe, Kei-ichi Seki, Hironobu Ohta, Toshiaki Yoshida, Noriko Ishihara, Tomoteru Kamimura

    WORLD JOURNAL OF GASTROENTEROLOGY   12 ( 39 )   6339 - 6342   2006年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:W J G PRESS  

    AIM: To evaluate sample adequacy, safety, and needle passes of a new biopsy needle device compared to the Quick-Core biopsy needle for transjugular liver biopsy in patients affected by liver disease.
    METHODS: Thirty consecutive liver-disease patients who had major coagulation abnormalities and/or relevant ascites underwent transjugular liver biopsy using either a new needle device (18 patients) or the Quick-Core biopsy needle (12 patients). The length of the specimens was measured before fixation. A pathologist reviewed the histological slides for sample adequacy and pathologic diagnoses. The two methods' specimen adequacy and complication rates were assessed.
    RESULTS: Liver biopsies were technically successful in all 30 (100%) patients, with diagnostic histological core specimens obtained in 30 of 30 (100%) patients, for an overall success rate of 100%. With the new device, 18 specimens were obtained, with an average of 1.1 passes per patient. Using the Quick-Core biopsy needle, 12 specimens were obtained, with an average of 1.8 passes per patient. Specimen length was significantly longer with the new needle device than with the QuickCore biopsy needle (P &lt; 0.05). The biopsy tissue was not fragmented in any of the specimens with the new aspiration needle device, but tissue was fragmented in 3 of 12 (25.0%) specimens obtained using the Quick Core biopsy needle. Complications included cardiac arrhythmia in 3 (10.0%) patients, and transient abdominal pain in 4 (13.3%) patients. There were no cases of subcapsular hematoma, hemoperitoneum, or sepsis, and there was no death secondary to the procedure. In particular, no early or delayed major procedure-related complications were observed in any patient.
    CONCLUSION: Transjugular liver biopsy is a safe and effective procedure, and there was significant difference in the adequacy of the specimens obtained using the new needle device compared to the QuickCore biopsy needle. Using the new biopsy needle device, the specimens showed no tissue fragmentation and no increment in major procedure-related complications was observed. (c) 2006 The WJG Press. All rights reserved.

    DOI: 10.3748/wjg.v12.i39.6339

    Web of Science

    researchmap

▶ 全件表示

MISC

  • 新規簡易ポリソノグラフィーを用いた肝硬変患者の睡眠障害の特徴

    上村博輝, 内山敦司, 登内孝文, 三井田秀, 丸山弘貴, 土屋淳紀, 大藏倫博, 寺井崇二

    日本消化器病学会雑誌(Web)   121   2024年

     詳細を見る

  • EUS-FNAが診断に有用であった原発性舌下腺癌に合併した多発膵腫瘍の1例

    渡邊 誠, 五十嵐 聡, 渡邊 浩太朗, 山崎 駿, 酒井 規裕, 渡邉 雄介, 冨永 顕太郎, 高橋 一也, 上村 博輝, 寺井 崇二

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   73回・95回   68 - 68   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    researchmap

  • 【肝疾患とサルコペニア】総論 肝疾患とサルコペニア 未来のリハビリテーション医療 楽しくないと続かない

    寺井 崇二, 上村 博輝

    日本消化器病学会雑誌   120 ( 9 )   701 - 708   2023年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    骨格筋は運動機能に関わる運動器としてだけでなく,さまざまなホルモン様の生理活性物質を分泌する内分泌臓器としての役割も果たしている.肝における代謝を考える場合に,臓器間ネットワークの視点から肝の代謝をとらえることはきわめて重要で,糖・脂質代謝には,肝,脂肪組織(内臓・皮下),筋肉(骨格筋)のネットワークのなかでとらえていく必要がある.2022年10月より日本肝臓学会の社会保険委員会にて肝臓リハビリテーションワーキンググループが作られ,その指針が2023年4月に公開された.サルコペニアにともなう,肝臓疾患における身体的・精神的影響を軽減させ,症状を調整し,生命予後を改善するため,今後この分野は肝臓分野のなかでも注視される領域である.(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J01118&link_issn=&doc_id=20230921450001&doc_link_id=%2Fck8syokb%2F2023%2F012009%2F001%2F0701-0708%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fck8syokb%2F2023%2F012009%2F001%2F0701-0708%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 消化器病に対する低侵襲治療 切除不能肝内胆管癌に対して肝動脈化学塞栓療法(TACE)および重粒子線治療を行った1例

    内山 敦司, 上村 博輝, 木村 莉菓, 佐藤 千紘, 木村 究, 渡邉 雄介, 高橋 一也, 五十嵐 聡, 寺井 崇二

    ENDOSCOPIC FORUM for digestive disease   39 ( 1 )   37 - 37   2023年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • 門脈圧亢進症に対する診断・治療における新たな挑戦 機械学習を用いた慢性心不全に続発した肝臓への障害(Cardiac Hepatopathy)の画像解析

    三井田 秀, 上村 博輝, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増大会 )   A640 - A640   2022年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 機械学習を用いた上部内視鏡施行時の咽頭老化の予測

    上村 博輝, 小島 雄一, 高橋 一也, 高綱 将史, 平野 正明, 政二 文明, 水野 研一, 横山 純二, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増大会 )   A812 - A812   2022年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 【1ページでわかる内科疾患の診療ノート-"あたりまえ"のなかにある大事な視点】(第7章)肝・胆・膵 非代償性肝硬変

    上村 博輝, 寺井 崇二

    内科   129 ( 4 )   867 - 871   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)南江堂  

    <文献概要>肝硬変は慢性肝疾患の終着点であり,「肝細胞がんに進行することはあっても肝硬変が戻ることはない」というのが従来の考え方であるが,原因とそれに伴う慢性炎症をきちんとコントロールできた場合には,肝硬変/肝線維化の少なくとも一部は可逆性であるという視点から,まず原因の治療,抗炎症療法が重要である.ただし,これらの治療が有効な症例においても肝線維化が改善するには年余の期間が必要である(新犬山分類の線維化の程度が1段階下降するには通常4~5年かかる).この期間,肝硬変患者は常に合併症や発がんのリスクにさらされている.したがって,これらの対策も並行して進める必要がある.さらに原因治療や抗炎症療法に不応性の症例では,肝不全対策や発がん対策(発がんスクリーニングを含む)がいっそう重要となる.詳細は文献1)を参照されたい.

    researchmap

    その他リンク: https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J00974&link_issn=&doc_id=20220401100086&doc_link_id=issn%3D0022-1961%26volume%3D129%26issue%3D4%26spage%3D867&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0022-1961%26volume%3D129%26issue%3D4%26spage%3D867&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

  • FALD(フォンタン術後肝障害)の疫学・病態・臨床-診療ガイドラインの確立を目指して 先天性心疾患術後の肝線維化進展に影響を及ぼす因子の解析

    山崎 文紗子, 上村 博輝, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A192 - A192   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝疾患の小児・成人移行期医療の課題-全人的ケアの確立を目指して 成人外来へ受診する可能性をもつ小児脂肪肝の特徴

    上村 博輝, 上村 顕也, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A169 - A169   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 【肝疾患エキスパートブック 栄養管理に活かすための最新情報】(Part 1)肝硬変 肝硬変に対する運動療法について

    上村 博輝, 寺井 崇二, 眞田 菜緒, 小師 優子

    臨床栄養   139 ( 4 )   445 - 451   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:医歯薬出版(株)  

    <Key Point>・これまで安静が基本とされていた肝硬変患者の運動については、サルコペニア対策からも最近はレジスタンス運動を含む、積極的な運動介入が推奨される傾向にある。・患者の状態(静脈瘤、腹水、肝肺症候群、サルコペニアなどの合併)に注意しながら、運動介入程度を決定していく。・"FITT"を構築して行うことが基本となるが、個人の状況に応じた継続可能な日常活動を、医師の外来診療、管理栄養士の栄養指導の際に医療機関側からアドバイスして背中を押してあげることも重要になってくる。(著者抄録)

    researchmap

  • 門脈圧亢進症と臓器相関 心、肝、肺、腎、脾 当院における心不全に伴う肝臓への影響(Cardiac Hepatopathy)の解析

    上村 博輝, 寺井 崇二, 猪又 孝文, 三井田 秀, 山崎 文紗子, 柏村 健, 藤木 信也, 渡邊 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 坂牧 僚, 横尾 健

    日本門脈圧亢進症学会雑誌   27 ( 3 )   109 - 109   2021年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • 併存する疾患のあることが多い高齢者における上部消化管疾患のマネージメント 地域病院における消化器サルコペニア疾患診療の有用性

    上村 博輝, 小島 雄一, 高橋 一也, 高綱 将史, 平野 正明, 政二 文明, 藤田 一, 辻村 恭憲, 小林 太一, 寺井 崇二

    日本消化器病学会甲信越支部例会抄録集   68回   52 - 52   2021年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    researchmap

  • 肝疾患移行期医療の現状と問題点 先天性心疾患術後に肝線維化悪化に影響を及ぼす因子の解析

    山崎 文紗子, 上村 博輝, 寺井 崇二

    肝臓   62 ( Suppl.1 )   A167 - A167   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝疾患におけるビックデータとAI(人工知能)の臨床応用 ディープラーニングを活用したPBC多施設データから予測する高齢者PBCの介入の必要性の検討

    上村 博輝, 高村 昌昭, 寺井 崇二

    肝臓   62 ( Suppl.1 )   A208 - A208   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 消化器疾患診療におけるディープラーニングの有用性の検証

    上村 博輝, 野中 尋史, 寺井 崇二

    日本消化器病学会雑誌   118 ( 臨増総会 )   A354 - A354   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 【小児期発症慢性肝疾患における移行期医療の現状と課題-小児と成人のダイアログ-】NAFLD Pediatric fatty liver disease(PeFLD)における概説と成人との比較(肝組織学的検討を含めて) 小児と成人の相違

    上村 博輝, 山崎 文紗子, 佐藤 毅昂, 薛 徹, 土屋 淳紀, 上村 顕也, 高村 昌昭, 寺井 崇二, 長崎 啓祐, 斎藤 昭彦, 梅津 哉

    肝胆膵   82 ( 3 )   425 - 440   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • 地域病院健診時の消化器サルコペニア疾患診療の有用性

    上村 博輝, 小島 雄一, 寺井 崇二

    日本消化器病学会雑誌   118 ( 臨増総会 )   A345 - A345   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 短期間に急速な肝脂肪沈着と栄養・運動介入による肝機能の改善を確認できたアスリートの一例

    上村 博輝, 木村 莉菓, 北條 雄暉, 渡邊 雄介, 高綱 将史, 五十嵐 聡, 佐野 正和, 真田 奈緒, 武田 安永, 小師 優子, 高村 昌昭, 寺井 崇二

    日本消化器病学会甲信越支部例会抄録集   67回   97 - 97   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    researchmap

  • mALBI score/gradeからみたNASH薬物治療に対する肝予備能への影響

    高村 昌昭, 横尾 健, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A691 - A691   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 2D-Shear Wave ElastographyとTransient Elastographyの乖離症例の特徴

    杉田 萌乃, 横尾 健, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A695 - A695   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 健診受検者における年齢層別NAFLDの解析と高齢者の意識変化

    横尾 健, 佐藤 公俊, 丹羽 佑輔, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A671 - A671   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 三次リンパ組織の臓器普遍性の解明

    鳥生 直哉, 佐藤 有紀, 上村 博輝, 田中 真生, 寺井 崇二, 柳田 素子

    日本腎臓学会誌   62 ( 4 )   262 - 262   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本腎臓学会  

    researchmap

  • 当院における心疾患に合併する遠隔期肝合併症における右心負荷系因子の重要性

    上村 博輝, 高村 昌昭, 寺井 崇二

    日本消化器病学会雑誌   117 ( 臨増総会 )   A252 - A252   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 自己免疫性肝炎における赤血球容量粒度分布幅変動係数の臨床的意義

    高村 昌昭, 高綱 将史, 薛 徹, 上村 博輝, 土屋 淳紀, 寺井 崇二

    肝臓   61 ( Suppl.1 )   A433 - A433   2020年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝疾患における移行期医療 小児NAFLD患者の背景疾患と移行医療への課題

    上村 博輝, 上村 顕也, 寺井 崇二

    肝臓   61 ( Suppl.1 )   A142 - A142   2020年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝悪性腫瘍との鑑別に苦慮した原発性肝放線菌症の1例

    本田 博樹, 野澤 優次郎, 高村 昌昭, 上村 博輝, 土屋 淳紀, 寺井 崇二

    肝臓   61 ( 3 )   109 - 115   2020年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    症例は71歳男性。近医で胆道系酵素の上昇を指摘され、2011年6月に新潟大学医歯学総合病院消化器内科を紹介受診した。腹部CTでは、肝右葉に10cm大の嚢胞成分と充実成分からなる腫瘤が指摘され、末梢の肝内胆管拡張を伴っていた。また肝門部から大動脈周囲に多発するリンパ節腫大がみられた。肝膿瘍を併発した肝内胆管癌を考えたが、外科的切除の適応外であり、化学療法導入前の組織学的診断のため、2011年8月経皮経肝的肝生検を施行したが腫瘍細胞は認められなかった。その後肝膿瘍に対する抗生剤治療および経皮経肝的ドレナージ術を行ったが、膿瘍腔の十分な縮小には至らなかった。後日、肝病理組織から放線菌を確認し、肝放線菌症と診断して抗生剤をペニシリンに変更したところ、病変の著明な縮小を認めた。肝悪性腫瘍と鑑別を要した肝放線菌症の一例を経験したので報告する。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00263&link_issn=&doc_id=20200310120008&doc_link_id=10.2957%2Fkanzo.61.109&url=https%3A%2F%2Fdoi.org%2F10.2957%2Fkanzo.61.109&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 【難治性腹水の対策】肝腎症候群

    薛 徹, 荒生 祥尚, 上村 博輝, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    消化器・肝臓内科   7 ( 2 )   169 - 174   2020年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • 表在型食道癌再発患者における飲酒習慣と体組成変化の検討

    水澤健, 橋本哲, 上村博輝, 高村昌昭, 寺井崇二

    アルコールと医学生物学   39   2020年

     詳細を見る

  • 表在型食道癌再発患者における飲酒習慣と体組成変化の検討

    水澤健, 橋本哲, 上村博輝, 高村昌昭, 寺井崇二

    アルコール医学生物学研究会学術集会プログラム・抄録集(Web)   39th   2020年

     詳細を見る

  • 表在型食道癌患者における禁酒後の体組成変化の検討

    水澤 健, 橋本 哲, 上村 博輝, 高村 昌昭, 寺井 崇二

    アルコールと医学生物学   38   54 - 54   2019年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)響文社  

    researchmap

  • 心窩部痛、肝障害を契機に発見されたcholedochoceleの一例

    岩澤 貴宏, 五十嵐 聡, 林 和直, 大脇 崇史, 上村 博輝, 橋本 哲, 寺井 崇二

    ENDOSCOPIC FORUM for digestive disease   35 ( 2 )   152 - 152   2019年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • Antiprogramed cell death-1 therapy with microspheres for metastatic liver tumors. 国際誌

    Hiroteru Kamimura, Nobutaka Takeda, Takashi Owaki, Takeshi Mizusawa, Takahiro Iwasawa, Satoshi Ikarashi, Satoru Hashimoto, Masaaki Takamura, Shuji Terai

    JGH open : an open access journal of gastroenterology and hepatology   3 ( 6 )   542 - 543   2019年12月

     詳細を見る

    記述言語:英語  

    Anti-programmed cell death-1 therapy with microspheres is an effective treatment for metastatic liver tumors.

    DOI: 10.1002/jgh3.12213

    PubMed

    researchmap

  • 肝硬度測定を用いたICG検査の代替の試み

    熊谷 優, 横尾 健, 佐藤 毅昂, 茂木 聡子, 川田 雄三, 薛 徹, 水野 研一, 木村 成宏, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増大会 )   A849 - A849   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 高齢者表在型食道癌患者における内視鏡的粘膜下層剥離術後の体組成変化の検討

    水澤 健, 橋本 哲, 上村 博輝, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増大会 )   A811 - A811   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 当県における非専門科対策を中心とした肝疾患診療体制の確立

    上村 博輝, 薛 徹, 荒生 祥尚, 高村 昌昭, 寺井 崇二

    肝臓   60 ( Suppl.2 )   A665 - A665   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝臓病理の臨床への貢献と次世代への飛躍を目指して 小児NAFLD患者の臨床スコアの動態とSerial Biopsyによる知見

    上村 博輝, 上村 顕也, 寺井 崇二

    肝臓   60 ( Suppl.2 )   A607 - A607   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 門亢症を伴う肝硬変に対する薬物療法の進歩〜腹水・脳症・血栓など〜 肝硬変を背景とした門脈血栓に対する治療戦略の検討

    茂木 聡子, 横尾 健, 熊谷 優, 薛 徹, 坂牧 僚, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    日本門脈圧亢進症学会雑誌   25 ( 3 )   71 - 71   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    J-GLOBAL

    researchmap

  • 新潟県における肝疾患診療体制の現状

    上村博輝, 菊田玲, 渡辺和仁, 薛徹, 堀井淳一, 寺井崇二

    肝臓   60 ( Supplement 1 )   A283   2019年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 当院における高齢発症原発性胆汁性胆管炎患者の予後予測マーカーについて

    高村昌昭, 木村成宏, 薛徹, 上村博輝, 坂牧僚, 横尾健, 土屋淳紀, 上村顕也, 松田康伸, 寺井崇二

    肝臓   60 ( Supplement 1 )   A407   2019年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 当院における肝炎医療コーディネーターの活動実態と今後の課題

    廣川光, 廣川光, 堀恵子, 薛徹, 薛徹, 上村博輝, 上村博輝, 上村博輝, 金子奨太, 小師優子, 鶴田恵, 澤栗裕美, 寺井崇二, 寺井崇二, 寺井崇二

    肝臓   60 ( Supplement 1 )   A258   2019年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 肝性脳症治療の変遷 肝臓と消化管―腸・肝・脳相関をベースに―各種肝疾患における腸内細菌叢の変化

    上村顕也, 坂牧僚, 薛徹, 横尾健, 上村博輝, 阿部聡司, 高村昌昭, 寺井崇二

    肝胆膵   78 ( 3 )   441‐446   2019年3月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 高齢肝癌症例におけるソラフェニブの効果と有用性

    横尾 健, 森田 真一, 木村 成宏, 薛 徹, 坂牧 僚, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A413 - A413   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 当院における肝癌に対する放射線治療の検討

    柴田 理, 上村 顕也, 木村 成宏, 薛 徹, 横尾 健, 坂牧 僚, 上村 博輝, 土屋 淳紀, 高村 昌昭, 丸山 克也, 太田 篤, 海津 元樹, 青山 英史, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A456 - A456   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 【肝性脳症治療の変遷】肝臓と消化管 腸・肝・脳相関をベースに 各種肝疾患における腸内細菌叢の変化

    上村 顕也, 坂牧 僚, 薛 徹, 横尾 健, 上村 博輝, 阿部 聡司, 高村 昌昭, 寺井 崇二

    肝・胆・膵   78 ( 3 )   441 - 446   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • 肝疾患におけるサルコペニア サルコペニア研究の最前線

    吉田智彰, 横山純二, 冨永顕太郎, 上村博輝, 坂牧僚, 高村昌昭, 寺井崇二

    月刊消化器・肝臓内科   5 ( 1 )   120‐126   2019年1月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • サルコペニア研究の最前線 (特集 肝疾患におけるサルコペニア)—Frontiers of sarcopenia research

    吉田 智彰, 横山 純二, 冨永 顕太郎, 上村 博輝, 坂牧 僚, 高村 昌昭, 寺井 崇二

    消化器・肝臓内科 = Gastroenterology & hepatology / 消化器・肝臓内科編集委員会 編   5 ( 1 )   120 - 126   2019年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:科学評論社  

    CiNii Article

    researchmap

    その他リンク: https://search.jamas.or.jp/link/ui/2019099693

  • 乳癌手術24年後に消化管,リンパ節,皮膚,骨に多発転移をきたした1例

    大脇崇史, 橋本哲, 岩澤貴宏, 水澤健, 五十嵐聡, 上村博輝, 高村昌昭, 周啓亮, 松本吉史, 梅津哉, 寺井崇二

    Endoscopic Forum for Digestive Disease   35 ( 2 )   2019年

     詳細を見る

  • 高齢者表在型食道癌患者における内視鏡的粘膜下層剥離術後の体組成変化の検討

    水澤健, 橋本哲, 上村博輝, 寺井崇二

    日本消化器病学会雑誌(Web)   116   2019年

     詳細を見る

  • 手足症候群に対するヒスチジンの効果

    上村 顕也, 品川 陽子, 後藤 諒, 横尾 健, 坂牧 僚, 上村 博輝, 阿部 聡司, 寺井 崇二

    The Liver Cancer Journal   10 ( Suppl.2 )   25 - 26   2018年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)メディカルレビュー社  

    researchmap

  • HCV陽性腎移植レシピエントに対し直接作用型抗ウイルス薬(DAA)で抗ウイルス療法を行った二例

    岩澤貴宏, 高村昌昭, 大脇崇史, 竹内卓, 五十嵐聡, 上村博輝, 橋本哲, 寺井崇二

    肝臓   59 ( Supplement 3 )   A982   2018年11月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 単一県下におけるウイルス性肝炎への残された課題への取り組み

    上村博輝, 坂牧僚, 寺井崇二

    肝臓   59 ( Supplement 3 )   A787   2018年11月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 肝動脈化学塞栓療法が奏効した眼球原発悪性黒色腫の肝転移の3例

    武田信峻, 水澤健, 上村博輝, 野尻俊介, 五十嵐聡, 橋本哲, 高村昌昭, 寺井崇二

    肝臓   59 ( Supplement 3 )   A999   2018年11月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 超高齢者の肝臓診療 超高齢者における肝硬変診療

    上村顕也, 坂牧僚, 木村成広, 薛徹, 上村博輝, 横尾健, 阿部聡司, 寺井崇二

    月刊消化器・肝臓内科   4 ( 4 )   344‐347   2018年10月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 高齢者原発性胆汁性胆管炎に対する治療選択と長期予後

    上村博輝, 寺井崇二

    肝臓   59 ( Supplement 2 )   A632   2018年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • B型肝炎由来肝細胞癌に関与するNKG2L,NAAsの検討

    上村博輝, 薛徹, 寺井崇二

    肝臓   59 ( Supplement 2 )   A629   2018年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 消化器内科医とNSTによる新たな疾患介入と病院内高齢者サルコペニア対策

    小師優子, 上村博輝, 上村博輝, 寺井崇二, 寺井崇二

    日本消化器がん検診学会雑誌   56 ( Supplement )   918 - 918   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器がん検診学会  

    J-GLOBAL

    researchmap

  • Acute on chronic―慢性病態の急性増悪―総論 Acute‐on‐chronic liver failureの病態―感染症,循環障害の焦点をあてて―

    寺井崇二, 上村博輝, 坂牧僚, 高村昌昭

    肝胆膵   76 ( 6 )   995‐1000   2018年6月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 新潟県におけるウイルス性肝炎の動向と各啓発活動状況

    上村博輝, 坂牧僚, 寺井崇二

    肝臓   59 ( Supplement 1 )   A537 - A537   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • 新潟県における肝炎検査の未受検者に対する肝炎啓発の取り組み

    坂牧僚, 上村博輝, 寺井崇二

    肝臓   59 ( Supplement 1 )   A537 - A537   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • 唾液中HBVウイルス量と潜血測定による水平感染リスクの評価と歯科連携

    上村博輝, 山際訓, 寺井崇二

    肝臓   59 ( Supplement 1 )   A245   2018年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 当院における循環器疾患が肝臓へ与える影響の指標の解析

    上村博輝, 高村昌昭, 寺井崇二

    肝臓   59 ( Supplement 1 )   A179   2018年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 内臓脂肪面積と生活習慣病、胆膵疾患、膵脂肪変性に関する検討

    河久 順志, 五十嵐 聡, 林 和直, 高橋 一也, 冨永 顕太郎, 水野 研一, 橋本 哲, 上村 博輝, 高村 昌昭, 横山 純二, 川合 弘一, 寺井 崇二

    日本消化器病学会雑誌   115 ( 臨増総会 )   A393 - A393   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • うっ血性肝硬変の診療における諸問題〜肝臓内科医が避けられない移行期医療を含めて〜 当院における循環器疾患が肝臓へ与える影響の指標の解析

    上村 博輝, 高村 昌昭, 寺井 崇二

    肝臓   59 ( Suppl.1 )   A179 - A179   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝炎ウイルスの新規感染や再活性化の現状とその対策 唾液中HBVウイルス量と潜血測定による水平感染リスクの評価と歯科連携

    上村 博輝, 山際 訓, 寺井 崇二

    肝臓   59 ( Suppl.1 )   A245 - A245   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 内臓脂肪面積と生活習慣病、胆膵疾患、膵脂肪変性に関する検討

    河久 順志, 五十嵐 聡, 林 和直, 高橋 一也, 冨永 顕太郎, 水野 研一, 橋本 哲, 上村 博輝, 高村 昌昭, 横山 純二, 川合 弘一, 寺井 崇二

    日本消化器病学会雑誌   115 ( 臨増総会 )   A393 - A393   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 自己免疫性肝疾患の最新知見 自己免疫性肝疾患の治療方針決定における経時的肝生検の有用性

    上村 博輝, 山際 訓, 寺井 崇二

    日本消化器病学会雑誌   115 ( 臨増総会 )   A166 - A166   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 当院におけるIFN Based TherapyとDAA治療後の発癌因子の検討

    上村 博輝, 坂牧 僚, 寺井 崇二

    日本消化器病学会雑誌   115 ( 臨増総会 )   A345 - A345   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 内臓脂肪面積と生活習慣病,胆膵疾患,膵脂肪変性に関する検討

    河久順志, 五十嵐聡, 林和直, 高橋一也, 冨永顕太郎, 水野研一, 橋本哲, 上村博輝, 高村昌昭, 横山純二, 川合弘一, 寺井崇二

    日本消化器病学会雑誌(Web)   115   2018年

     詳細を見る

  • 世界的動向から考える消化器内科医として注意すべき薬剤耐性

    上村博輝, 上村博輝, 山際訓, 寺井崇二

    日本消化器がん検診学会雑誌   55 ( Supplement )   940   2017年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 消化器内視鏡のリスクマネージメント 医療事故調査委員会の現状から 世界的動向から考える消化器内科医として注意すべき薬剤耐性

    上村 博輝, 山際 訓, 寺井 崇二

    日本消化器がん検診学会雑誌   55 ( Suppl. )   940 - 940   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器がん検診学会  

    researchmap

  • 消化器内視鏡のリスクマネージメント 医療事故調査委員会の現状から 世界的動向から考える消化器内科医として注意すべき薬剤耐性

    上村 博輝, 山際 訓, 寺井 崇二

    Gastroenterological Endoscopy   59 ( Suppl.2 )   1968 - 1968   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • Serial liver biopsiesで確定診断に至った自己免疫性急性肝不全の一例

    上村 博輝, 山際 訓, 中島 尚, 菅野 智之, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 野本 実, 梅津 哉, 岩崎 友洋, 小方 則夫, 寺井 崇二

    肝臓   58 ( 6 )   373 - 374   2017年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 慢性肝疾患の掻痒症に対するナルフラフィン塩酸塩の長期的効果と安全性の検証

    上村顕也, 横尾健, 上村博輝, 坂牧僚, 阿部聡司, 土屋淳紀, 高村昌昭, 川合弘一, 山際訓, 寺井崇二

    肝臓   58 ( Supplement 1 )   A462   2017年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 慢性肝疾患のそう痒症に対するナルフラフィン塩酸塩の長期的効果と安全性の検証

    上村 顕也, 横尾 健, 上村 博輝, 坂牧 僚, 阿部 聡司, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   58 ( Suppl.1 )   A462 - A462   2017年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 進行肝細胞癌に対するアイエーコールとミリプラの併用肝動注療法の意義・多施設共同研究による第II相試験

    上村顕也, 横尾健, 坂牧僚, 阿部聡司, 上村博輝, 兼藤努, 土屋淳紀, 高村昌昭, 川合弘一, 山際訓, 須田剛士, 和栗暢生, 石川達, 寺井崇二

    肝臓   57 ( Supplement 2 )   A560 - A560   2016年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • ソラフェニブによる手足症候群に対する“濃厚鰹だし”の予防効果

    上村顕也, 品川陽子, 小川光平, 阿部寛幸, 小林雄司, 横尾健, 坂牧僚, 阿部聡司, 上村博輝, 土屋淳紀, 高村昌昭, 川合弘一, 山際訓, 寺井崇二

    肝臓   57 ( Supplement 1 )   A218 - A218   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • ラジオ波焼灼術を施行した肝細胞癌患者に対するNomogramを用いた生命予後予測モデルの開発と術前ICG‐PDR測定の臨床的意義

    安住基, 須田剛士, 横尾健, 上村博輝, 土屋淳紀, 上村顕也, 高村昌昭, 川合弘一, 松田康伸, 山際訓, 寺井崇二

    肝臓   57 ( Supplement 1 )   A158 - A158   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • 肝細胞癌におけるa disintegrin and metalloprotease 21発現の生物学的意義に関する検討

    本田 博樹, 高村 昌昭, 山際 訓, 玄田 拓哉, 木村 成宏, 薛 徹, 冨永 顕太郎, 上村 博輝, 松田 康伸, 若井 俊文, 寺井 崇二

    肝臓   57 ( Suppl.1 )   A247 - A247   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 鰹だしの末梢血流増加作用を利用した手足症候群の予防効果の検証

    上村 顕也, 品川 陽子, 小川 光平, 小林 雄司, 阿部 寛幸, 横尾 健, 上村 博輝, 川合 弘一, 須田 剛士, 山際 訓, 馬場 洋, 寺井 崇二

    癌と化学療法   43 ( 4 )   463 - 465   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    鰹だしの末梢血流増加作用を利用した手足症候群(HFS)の予防効果について検討した。ソラフェニブ(SFN)内服開始のために入院した肝細胞癌症例10例を対象とした。濃厚鰹だしを飲用せず、SFNを内服した対照群3例では、足底血管のtime averaged mean blood flow velocity(TAMEAN)の平均値はSFN内服開始1週後に前値に比較して低下を認め、2例にGrade 1、2のHFSを認めた。濃厚鰹だしを飲用した10例中7例でTAMEAN値が内服開始前後(1週)で上昇を認め、2例では33.5%の低下を認め、1例では著変を認めなかった。各症例における濃厚鰹だし飲用前後の血流変化は、飲用群で対照群に比較して有意に血流増加を認めた。血流増加を認めた症例ではサーモグラフィを施行すると手足末梢温が維持、改善していた。血流低下を認めたうちの1例のみでGrade 1のHFSを内服開始14日目に発症した(発症率10%)。経過中、濃厚鰹だしによる副作用を認めなかった。

    researchmap

  • 【腎機能を悪化させない日常診療】 肝疾患における腎機能のみかたと対策

    上村 博輝, 山際 訓, 高村 昌昭, 横尾 健, 土屋 淳紀, 上村 顕也, 川合 弘一, 寺井 崇二

    成人病と生活習慣病   46 ( 3 )   370 - 375   2016年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)東京医学社  

    肝臓は蛋白質の合成・代謝と物質の解毒・排泄などの重要な役割を担っている。また、門脈を介してすべての消化器(消化管、胆道、膵臓)と網内系臓器である脾臓と連携しているため肝臓の機能低下は多くの臓器に影響を与える。抗ウイルス療法の進歩によりC型肝炎患者の肝硬変への進展が抑えられることが予想されるが、いまだ肝硬変、肝細胞癌患者の治療対象者数は多い。そのため肝細胞癌早期発見のための造影MRI使用やプラチナ製剤による抗癌剤治療の選択に腎予備能を考慮しなければいけない機会が多い。本企画の意図に則り、肝疾患診療で遭遇する慢性肝炎に合併する腎疾患、肝硬変が進行した場合の腎病態、トルバプタン承認後の難治性腹水に対しての最新の利尿薬治療について解説する。(著者抄録)

    researchmap

  • 【コランギオパチー】 免疫介在性コランギオパチー 原発性硬化性胆管炎

    山際 訓, 木村 成宏, 本田 博樹, 上村 博輝, 高村 昌昭, 寺井 崇二

    肝・胆・膵   71 ( 5 )   839 - 844   2015年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • B-RTOの止血効果に対するリスク因子解析

    渡邉 雄介, 盛田 景介, 林 和直, 兼藤 努, 上村 博輝, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 須田 剛士, 鈴木 健司, 野本 実, 寺井 崇二

    新潟医学会雑誌   129 ( 10 )   628 - 628   2015年10月

  • 効率的なDrug-eluting beadsの調整法

    横尾 健, 兼藤 努, 須田 剛士, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 野本 実, 寺井 崇二

    新潟医学会雑誌   129 ( 10 )   628 - 628   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • クームス陰性自己免疫性溶血性貧血(AIHA)を合併した急性肝不全の1例

    中島 尚, 菅野 智之, 上村 博輝, 横山 純二, 山際 訓, 野本 実, 寺井 崇二, 梅津 哉, 佐藤 聡史, 岩崎 友洋, 小方 則夫

    新潟医学会雑誌   129 ( 10 )   630 - 630   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 当科における門脈圧亢進症を伴った骨髄増殖性疾患症例の予後に関する検討

    清野 智, 川合 弘一, 横尾 健, 佐藤 裕樹, 本田 穣, 兼藤 努, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 山際 訓, 須田 剛士, 野本 実, 寺井 崇二, 増子 正義, 田中 研介, 柳 雅彦, 佐藤 直子, 矢野 敏雄

    新潟医学会雑誌   129 ( 10 )   631 - 632   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 各種肝疾患における肝細胞ロゼット形成の臨床的意義

    野本 実, 上村 博輝, 土屋 淳紀, 寺井 崇二, 松田 康伸

    新潟医学会雑誌   129 ( 10 )   632 - 633   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 重複癌に合併した多血性肝腫瘍の1例

    渡邉 貴之, 菅野 智之, 中島 尚, 上村 博輝, 横山 純二, 山際 訓, 野本 実, 寺井 崇二, 梅津 哉, 佐藤 聡史, 岩崎 友洋, 小方 則夫

    新潟医学会雑誌   129 ( 10 )   613 - 613   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • B型慢性肝炎における核酸アナログ投与後の発癌因子とキャリアにおける水平感染リスクの評価

    上村 博輝, 山際 訓, 高村 昌昭, 横尾 健, 兼藤 努, 上村 顕也, 土屋 淳紀, 川合 弘一, 須田 剛士, 野本 実, 寺井 崇二, 小方 則夫, 大越 章吾, 渡辺 順, 高木 律男

    肝臓   56 ( Suppl.2 )   A763 - A763   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 当科における門脈圧亢進症を伴った骨髄増殖性疾患症例の臨床的特徴と予後に関する検討

    清野 智, 川合 弘一, 横尾 健, 兼藤 努, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 山際 訓, 須田 剛士, 野本 実, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A863 - A863   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 慢性腎臓病合併肝細胞癌の予後解析

    木村 成宏, 川合 弘一, 上村 博輝, 兼藤 努, 土屋 淳紀, 上村 顕也, 高村 昌昭, 山際 訓, 須田 剛士, 野本 実, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A870 - A870   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝細胞癌の予後に影響する栄養学因子

    兼藤 努, 須田 剛士, 横尾 健, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A872 - A872   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Drug-eluting beadsの調整法の検討

    横尾 健, 兼藤 努, 須田 剛士, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A903 - A903   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 自己免疫性肝炎の病理形態像と臨床像の比較検討

    野本 実, 上村 博輝, 寺井 崇二

    肝臓   56 ( Suppl.2 )   A770 - A770   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • ハイドロダイナミック細胞内遺伝子送達システムの開発

    上村 顕也, 阿部 寛幸, 小林 雄司, 兼藤 努, 横尾 健, 須田 剛士, 上村 博輝, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   56 ( Suppl.2 )   A776 - A776   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 先天性心疾患における器質的な肝障害に関連する因子の同定

    須田 剛士, 杉本 愛, 横尾 健, 上村 博輝, 兼藤 努, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 白石 修一, 渡邉 マヤ, 文 智勇, 高橋 昌, 寺井 崇二

    肝臓   56 ( Suppl.2 )   A784 - A784   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 当科と関連施設に於けるC型慢性肝炎に対するIFN治療後発癌の現状

    薛 徹, 山際 訓, 横尾 健, 上村 博輝, 兼藤 努, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 須田 剛士, 石川 達, 阿部 聡司, 吉田 俊明, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A860 - A860   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 薬剤師が知っておくべき臓器別画像解析の基礎知識 肝臓分野 肝膿瘍の画像診断

    上村 博輝, 山際 訓, 横尾 健, 土屋 淳紀, 上村 顕也, 高村 昌昭, 川合 弘一, 青柳 豊, 寺井 崇二

    医薬ジャーナル   51 ( 8 )   1847 - 1852   2015年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)医薬ジャーナル社  

    肝・胆道感染症は適切な治療が選択できない場合、敗血症へと進展しやすい緊急性の高い疾患である。肝膿瘍は「肝内に細菌、真菌、原虫などが侵入・増殖し、肝組織が融解・壊死を起こして形成された膿瘍」と定義される。総胆管結石などに対する内視鏡的治療が進歩し、胆管炎に伴う肝膿瘍の発生頻度は減少しているが、肝細胞癌に対するラジオ波治療後に肝膿瘍を併発する症例もあり、特徴的画像所見や鑑別ポイントの把握は依然として重要である。(著者抄録)

    researchmap

  • 難治性胸・腹水の治療法とその適応 肝細胞癌合併難治性胸腹水症例に対する治療戦略と有効性

    上村 博輝, 山際 訓, 高橋 俊作, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 寺井 崇二

    日本門脈圧亢進症学会雑誌   21 ( 3 )   86 - 86   2015年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • 薬剤師が知っておくべき臓器別画像解析の基礎知識(56)9.肝臓分野(8)肝膿瘍の画像診断

    上村 博輝, 山際 訓, 横尾 健

    医薬ジャーナル   51 ( 8 )   5 - 10   2015年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:医薬ジャーナル社  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015323865

  • メチオニン・コリン欠乏食(MCD)誘発性脂肪肝炎に対するDPP-4阻害薬の効果

    山際 訓, 木村 成宏, 本田 博樹, 薛 徹, 冨永 顕太郎, 上村 博輝, 高村 昌昭, 寺井 崇二

    肝臓   56 ( Suppl.1 )   A549 - A549   2015年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 自己免疫性肝炎における肝内および末梢血中濾胞性ヘルパーT細胞の検討

    木村 成宏, 山際 訓, 本田 博樹, 薛 徹, 冨永 顕太郎, 上村 博輝, 高村 昌昭, 寺井 崇二

    肝臓   56 ( Suppl.1 )   A295 - A295   2015年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Virtual Touch Quantificationによる肝硬度測定における伝搬速度の測定部位ならびに測定ポイント数の検討

    横尾 健, 兼藤 努, 須田 剛士, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 野本 実, 寺井 崇二

    肝臓   56 ( Suppl.1 )   A429 - A429   2015年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Shear Wave(SW)とVirtual Touch Tissue Quantification(VTTQ)の相関性に基づいたせん断弾性波速度(SWV)方式肝硬度測定における適正測定回数の検討

    兼藤 努, 須田 剛士, 川合 弘一, 横尾 健, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 山際 訓, 野本 実

    日本消化器病学会雑誌   112 ( 臨増総会 )   A417 - A417   2015年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 自己免疫性肝炎に合併した胸腺腫 画像上の注意点と免疫担当細胞の解析による液性免疫への関与について

    上村 博輝, 山際 訓, 野本 実

    肝臓   55 ( Suppl.3 )   A789 - A789   2014年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 当科における非B非C型肝細胞癌の臨床的特徴

    川合 弘一, 上村 顕也, 上村 博輝, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 山際 訓, 須田 剛士, 野本 実, 青柳 豊

    肝臓   55 ( Suppl.2 )   A633 - A633   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 当科で経験したCombined HCC/CCCに関して新しいWHO分類、HCC with progenitor featureも含めて

    小島 雄一, 土屋 淳紀, 安住 基, 横尾 健, 山本 幹, 上村 博輝, 兼藤 努, 上村 顕也, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊, 若井 俊文

    新潟医学会雑誌   128 ( 9 )   475 - 476   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 臨床にフィードバックできる基礎研究を目指して 癌関連遺伝子Bel11bの肝腫瘍における発現解析研究

    阿部 寛幸, 上村 顕也, 熊木 大輔, 上村 博輝, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊, 三嶋 行雄, 木南 凌, 廣瀬 雄己, 大橋 拓, 若井 俊文

    新潟医学会雑誌   128 ( 9 )   477 - 477   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 肝硬度測定のピットフォール

    須田 剛士, 廣瀬 奏恵, 高村 昌昭, 杉本 愛, 兼藤 努, 横尾 健, 上村 博輝, 土屋 淳紀, 上村 顕也, 田村 康, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 高橋 昌, 青柳 豊

    新潟医学会雑誌   128 ( 9 )   479 - 480   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 新WHO分類に基づく混合型肝癌再分類でのAFP-L3、臨床経過の違いの考察

    土屋 淳紀, 小島 雄一, 安住 基, 横尾 健, 山本 幹, 上村 博輝, 兼藤 努, 上村 顕也, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊

    日本消化器病学会雑誌   111 ( 臨増大会 )   A930 - A930   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝細胞癌に対するミリプラとアイエーコール肝動注の併用効果に関する検討

    上村 顕也, 須田 剛士, 上村 博輝, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊, 和栗 暢生, 石川 達

    新潟医学会雑誌   128 ( 9 )   472 - 472   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 当科における肝炎・肝癌治療の現状

    上村 博輝, 上村 顕也, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊

    新潟医学会雑誌   128 ( 9 )   472 - 473   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 音響放射圧を用いた肝内せん断弾性波速度測定による非アルコール性脂肪肝疾患の肝細胞癌発癌リスク評価

    高村 昌昭, 須田 剛士, 兼藤 努, 横尾 健, 上村 博輝, 土屋 淳紀, 上村 顕也, 田村 康, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊

    新潟医学会雑誌   128 ( 9 )   480 - 480   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 肝細胞癌に対するミリプラとアイエーコール肝動注の併用効果に関する検討

    上村 顕也, 須田 剛士, 上村 博輝, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊, 和栗 暢生, 石川 達

    肝臓   55 ( Suppl.2 )   A612 - A612   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 慢性腎臓病合併肝細胞癌の予後解析

    木村 成宏, 川合 弘一, 上村 博輝, 兼藤 努, 土屋 淳紀, 上村 顕也, 田村 康, 高村 昌昭, 五十嵐 正人, 山際 訓, 須田 剛士, 野本 実, 青柳 豊

    肝臓   55 ( Suppl.2 )   A616 - A616   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • ソラフェニブの手足症候群に対する、濃厚鰹だしの有効性の検証

    上村 顕也, 須田 剛士, 上村 博輝, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊

    肝臓   55 ( Suppl.1 )   A394 - A394   2014年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • エネルギー代謝状態によるNAFLDの病態選別と治療候補分子の動態評価

    須田 剛士, 横尾 健, 兼藤 努, 上村 博輝, 上村 顕也, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊

    日本消化器病学会雑誌   111 ( 臨増総会 )   A333 - A333   2014年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 消化器癌に対する腹水濾過濃縮再静注療法(CART)のQOLと抗腫瘍効果に対する再評価

    上村 博輝, 山際 訓, 高村 昌昭, 岩崎 友洋, 林 和直, 小方 則夫, 廣瀬 慎太郎, 沢津橋 孝拓, 森岡 伸浩, 中塚 英樹, 清水 孝王, 宮下 薫, 青柳 豊

    新潟県医師会報   ( 764 )   8 - 10   2013年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟県医師会  

    researchmap

  • 自己免疫性肝疾患の基礎・臨床の最前線 自己免疫性肝炎の肝細胞傷害におけるMHC class II分子の関与

    上村 博輝, 山際 訓, 青柳 豊

    肝臓   54 ( Suppl.2 )   A487 - A487   2013年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Peg-IFN+RBV治療を導入した自己免疫性肝炎合併C型慢性肝炎の1例

    上村 博輝, 青柳 智也, 小方 則夫, 野本 実, 本間 信之

    新潟医学会雑誌   126 ( 11 )   635 - 636   2012年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 自己免疫性肝炎 自己免疫性肝炎急性発症時における抗HLA class II抗体出現と肝細胞傷害への関与

    山際 訓, 高村 昌昭, 上村 博輝, 玄田 拓哉, 市田 隆文, 石川 達, 高橋 達, 野本 実, 青柳 豊

    肝臓   53 ( Suppl.1 )   A285 - A285   2012年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝炎ウイルス持続感染および肝細胞癌発癌とNK細胞機能

    山際 訓, 上村 博輝, 青柳 豊

    新潟県医師会報   ( 741 )   2 - 7   2011年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟県医師会  

    researchmap

  • 肝細胞癌におけるNK細胞活性化レセプターリガンド発現低下とその臨床的意義

    山際 訓, 上村 博輝, 土屋 淳紀, 高村 昌昭, 松田 康伸, 白井 良夫, 野本 実, 青柳 豊

    肝臓   52 ( Suppl.2 )   A624 - A624   2011年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肺転移を伴わず多発肝転移を形成し肝細胞癌との鑑別診断に苦慮した肉腫化腎細胞癌の1剖検例

    上村 博輝, 石川 達, 樋口 和男, 今井 径卓, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝, 武田 敬子, 石原 法子, 野本 実, 青柳 豊

    肝臓   52 ( 9 )   607 - 616   2011年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    症例は60代男性。200X年肝機能障害にて当院へ紹介された。肝胆道系酵素の上昇を認め、腹部造影CTで肝S8濃度低下、左腎下極に低吸収域を認めた。腹部MRIにて肝両葉に小結節の散在が認められ、腫瘍生検にて肝細胞癌あるいは腎細胞癌肝転移と診断されたが確定診断には至らなかった。肝細胞癌に準じた治療を施行するも進行早く第22病日死亡。剖検所見では上皮成分の腎淡明細胞癌が肉腫様変性を生じ、肺転移を形成せずに広汎な壊死を伴った急速な多発肝転移を呈した腎細胞癌肝転移と診断された。非典型的な画像所見とその転移様式の考察に剖検所見が有用であった。(著者抄録)

    DOI: 10.2957/kanzo.52.607

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: https://jlc.jst.go.jp/DN/JALC/00378119182?from=CiNii

  • 肝細胞癌におけるLiver-intestine(LI)-cadherinの発現とその臨床病理学的意義

    高村 昌昭, 山際 訓, 若井 俊文, 上村 博輝, 土屋 淳紀, 松田 康伸, 白井 良夫, 青柳 豊

    肝臓   52 ( Suppl.1 )   A324 - A324   2011年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 胃静脈瘤に対するB-RTO後のコリンエステラーゼ(ChE)活性変動に対する検討

    今井 径卓, 上村 博輝, 石川 達, 樋口 和男, 関 慶一, 吉田 俊明, 上村 朝輝

    肝臓   51 ( Suppl.3 )   A783 - A783   2010年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 非蛋白性呼吸商の治療侵襲に対する耐容性指標としての有用性

    山田 一樹, 須田 剛士, 大崎 暁彦, 上村 博輝, 土屋 淳紀, 矢野 雅彦, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 松田 康伸, 大越 章吾, 野本 実, 青柳 豊

    肝臓   51 ( Suppl.1 )   A306 - A306   2010年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝細胞癌における分子標的としてのNK細胞活性化レセプターリガンドとその発現調節による抗腫瘍効果

    上村 博輝, 山際 訓, 土屋 淳紀, 高村 昌昭, 松田 康伸, 井上 真, 若井 俊文, 白井 良夫, 野本 実, 青柳 豊

    肝臓   51 ( Suppl.1 )   A167 - A167   2010年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝内胆管癌におけるLI-cadherinの発現消失はMTF-1およびPlGFの発現を上昇することにより血管新生を誘導する

    高村 昌昭, 山際 訓, 若井 俊文, 田村 康, 井上 真, 上村 博輝, 加藤 卓, 土屋 淳紀, 松田 康伸, 白井 良夫, 市田 隆文, 味岡 洋一, 青柳 豊

    日本消化器病学会雑誌   107 ( 臨増総会 )   A266 - A266   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • C型肝炎 ウイルス感染の分子免疫機構 C型肝炎の持続感染と抗腫瘍免疫機構からの逃避に関与するNK細胞活性化レセプターリガンド

    上村 博輝, 山際 訓, 青柳 豊

    日本消化器病学会雑誌   107 ( 臨増総会 )   A104 - A104   2010年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝癌に対する腫瘍免疫

    上村 博輝, 山際 訓, 青柳 豊

    新潟県医師会報   ( 716 )   8 - 9   2009年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟県医師会  

    researchmap

  • 肝性脳症に対しB-RTOが奏効した1例

    上村 博輝, 牛木 隆志, 富樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝, 武田 敬子

    新潟医学会雑誌   123 ( 8 )   434 - 435   2009年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 急性間欠性ポルフィリン症2例の遺伝子解析

    諏佐 真治, 上村 博輝, 樋口 和男, 柄澤 繁, 和田 輝里子, 亀田 亘, 大泉 俊英, 大門 真, 加藤 丈夫

    日本内分泌学会雑誌   85 ( 1 )   373 - 373   2009年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内分泌学会  

    researchmap

  • 胃静脈瘤を伴った自己免疫性膵炎の1例

    渡辺 孝治, 今井 径卓, 上村 博輝, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝, 武田 敬子

    新潟医学会雑誌   123 ( 3 )   146 - 146   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 副流出路に対しマイクロバルーンカテーテル併用によるダブルバルーン下逆行性経静脈的塞栓術が有用であった孤立性胃穹窿部静脈瘤の1例

    石川 達, 今井 径卓, 樋口 和男, 上村 博輝, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝臓   50 ( 2 )   71 - 74   2009年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    症例は43歳女性。2005年8月飲酒後、吐血し、救急車にて某院搬送入院。上部消化管内視鏡にて孤立性胃穹窿部静脈瘤からの出血を認めたが、自然止血にて経過観察していた。再出血の可能性を認め、バルーン下逆行性経静脈的塞栓術目的に当院へ紹介転院となった。造影CTにて胃内腔へ突出する胃静脈瘤とそれに連続する胃腎短絡路を認めた。胃腎短絡路の存在からバルーン下逆行性経静脈的塞栓術可能と判断し、血管造影施行。右内頸静脈により6Frバルーンカテーテルを胃腎短絡路に挿入、逆行性造影を施行したところ、造影剤は通常より左側の細い胃腎短絡路より流出し、胃静脈瘤本体への造影剤の停滞は不十分であった。そこで、右大腿静脈から6Frシェファードフックカテーテルを左腎静脈に挿入し、マイクロバルーンカテーテルを細い短絡路に挿入し、閉塞下に造影したところ、十分な静脈瘤血行路の描出が得られ、閉塞が可能となり、2ヶ所の閉塞により胃静脈瘤への造影剤の停滞が十分であると判断し、5%EOIを注入し塞栓可能となった。術後CTにても短絡路は消失し、胃静脈瘤は消失した。(著者抄録)

    researchmap

  • NBI内視鏡システムを用いて観察し得た胆管癌の1例

    樋口 和夫, 関 慶一, 今井 径卓, 上村 博輝, 渡辺 孝治, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝, 中塚 英樹, 坪野 俊広, 酒井 靖夫, 石原 法子

    ENDOSCOPIC FORUM for digestive disease   24 ( 2 )   136 - 136   2008年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • 臍ヘルニアより噴出性腹水流出をきたした難治性腹水に対してTIPSが奏功した一例

    上村 博輝, 石川 達, 樋口 和男, 今井 径卓, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝, 武田 敬子

    肝臓   49 ( Suppl.3 )   A720 - A720   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • これからの肝癌治療 肝細胞癌に対する経皮的ラジオ波焼灼療法後のSecondary PreventionとしてのInterferon療法の臨床的意義

    石川 達, 上村 博輝, 今井 径卓, 樋口 和男, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本癌治療学会誌   43 ( 2 )   371 - 371   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • 傍臍静脈より右大腿静脈への門脈大循環短絡路に対し、B-RTOが著効したC型肝硬変肝性脳症の1例

    石川 達, 今井 径卓, 樋口 和男, 上村 博輝, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝臓   49 ( Suppl.3 )   A720 - A720   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 多量に増殖するCD133+,NCAM+肝幹前駆細胞の分化階層性の解析を行った劇症肝炎亜急性型の一例

    今井 径卓, 石川 達, 樋口 和男, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝, 上村 博輝, 土屋 淳紀, 佐藤 好信

    肝臓   49 ( Suppl.3 )   A726 - A726   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • マイクロバルーンカテーテル(Micro Balloon Catheter)併用によるB-RTOを施行しえた胃静脈瘤の1例

    石川 達, 今井 径卓, 樋口 和男, 上村 博輝, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 武田 敬子, 上村 朝輝

    IVR: Interventional Radiology   23 ( 4 )   413 - 413   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本インターベンショナルラジオロジー学会  

    researchmap

  • 当院における頭頸部癌肝転移症例の検討

    上村 博輝, 石川 達, 樋口 和男, 今井 径卓, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本消化器病学会雑誌   105 ( 臨増大会 )   A862 - A862   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 多発性肝転移を呈した肺非定型的カルチノイドの一例

    今井 径卓, 石川 達, 樋口 和男, 上村 博輝, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝, 石原 法子

    日本消化器病学会雑誌   105 ( 臨増大会 )   A871 - A871   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Y型二口弁シースを用いたCT angiographyの現状

    石川 達, 上村 博輝, 今井 径卓, 樋口 和男, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本消化器病学会雑誌   105 ( 臨増大会 )   A834 - A834   2008年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Mass reductionを目的として経皮的ラジオ波焼灼療法(RFA)とDSM-TAE、肝動注化学療法を施行した大腸癌転移性大型肝癌の1例

    上村 博輝, 石川 達, 樋口 和男, 今井 径卓, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝, 酒井 靖夫, 武者 信行, 坪野 俊広

    医学と薬学   60 ( 1 )   60 - 64   2008年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)自然科学社  

    症例は30歳代女性で、9ヵ月ほど前から腹部膨満感を自覚し近医にて内服薬を処方されたが軽快せず、1ヵ月前から嘔気症状に続き、発熱・咳も出現したため精査目的で入院となった。入院時、腫瘍マーカーはCEA・CA19-9が著明な高値を示し、腹部造影CTではS状結腸からRsにかけて壁肥厚と腫瘍穿破による膿瘍形成・肝両葉に多発する腫瘤影を認めた。大腸ファイバーにて同部位に全周性肥厚を認め、ファイバーが通過しなかったため経肛門的イレウスチューブを留置した。第10病日に外科的手術を施行、臨床診断はSi(ileum)P1H3N4M(-)、stage IV,H(+)、P(+)で遺残があり根治度Cであった。肝右葉を中心とした多発肝転移巣が予後規定因子と考え、全身化学療法と肝転移巣に対する治療を主治療とする方針とした。全身化学療法はホリナート・テガフール・ウラシル療法を開始し、12×10cm大の肝右葉巨大転移病巣に対し肝動注療法(5-FU・マイトマイシン+DMS)を4〜6週の間隔で開始し、その間に追加ラジオ波焼灼術(RFA)として1回4セッション以上として継続併行治療した。その結果、腫瘍マーカーは漸減し画像所見では腫瘍は完全嚢胞化し腫瘍サイズも縮小して門脈右枝の再拡張、咳症状は消失し、7ヵ月後のRECISTガイドラインによるCT評価ではPRと判定した。8ヵ月後から再度腫瘍マーカーの上昇をきたし、造影CTにて大腸原発巣腹膜播種性病変の増大を認めFOLFOX6による全身化学療法を主体とする治療を施行したが、原発巣の増大を制御できず、残存腹膜播種結節の再増大と後腹膜リンパ節腫大による腎水腫・腹水の悪化のため12ヵ月後に死亡した。

    researchmap

  • 骨髄腫、アミロイドーシスから肝不全となった透析患者の1例

    田崎 和之, 広瀬 慎太郎, 鈴木 靖, 上村 博輝, 石原 法子

    日本透析医学会雑誌   41 ( Suppl.1 )   640 - 640   2008年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本透析医学会  

    researchmap

  • 閉塞性黄疸を呈した胆管浸潤肝細胞癌に対し、RFAが有効であった1例

    今井 径卓, 石川 達, 太田 宏信, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 吉田 俊明, 上村 朝輝, 武田 敬子, 石原 法子

    日本消化器病学会雑誌   105 ( 臨増総会 )   A364 - A364   2008年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 消化管出血をきたした膵癌の一例

    上村 博輝, 樋口 和男, 今井 径卓, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝, 石原 法子

    日本消化器病学会雑誌   105 ( 臨増総会 )   A344 - A344   2008年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Letters to the Editor

    高嶋 修太郎, 上村 博輝, 佐藤 正久

    日本内科学会雑誌   97 ( 2 )   448 - 449   2008年2月

     詳細を見る

  • 当院における転移性肝癌に対する経皮的ラジオ波焼灼療法の現況

    石川 達, 今井 径卓, 上村 博輝, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    医学と薬学   59 ( 2 )   186 - 188   2008年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)自然科学社  

    経皮的ラジオ波焼灼療法(RFA)を施行した転移性肝癌26例118結節を対象に現況を検討した。大腸癌肝転移において、RFA腫瘍径3cm以内、3結節以内とした適応症例は全例生存中であった。原発が大腸癌である11例中8例はmass reductionが目的であったが、抗癌剤一時無効症例においてもRFA後、腫瘍マーカーの低下とともに抗癌剤の効果発現を認めた症例も認められた。また、大腸癌肝転移症例においては抗癌剤との併用群の予後は良好であった。膵癌肝転移においては抗癌剤併用にもかかわらず、予後不良であったが、肺癌肝転移および乳癌肝転移は抗癌剤併用の有無にかかわらず、予後良好であった。合併症は1例にBiloma、1例に肝膿瘍を認めたが、いずれも多発症例であり、抗生剤投与により対処可能であった。

    researchmap

  • 肝細胞癌局所療法後のBCAA含有経腸栄養剤の投与意義

    石川 達, 今井 径卓, 上村 博輝, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本内科学会雑誌   97 ( Suppl. )   177 - 177   2008年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    researchmap

  • 主膵管の完全途絶を呈し、膵癌との鑑別診断に苦慮した自己免疫性膵炎の1手術例

    石川 達, 上村 博輝, 土屋 淳紀, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝, 石原 法子

    Gastroenterological Endoscopy   50 ( 2 )   234 - 241   2008年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    57歳男。左下腿浮腫で受診した。腹部超音波検査で左水腎症を疑われ、CTで膵尾部の腫大、脾静脈不明瞭化で閉塞所見、胃大網静脈の拡張、左腎盂杯尿管の拡張と左総腸骨動脈前面での尿管の不明瞭化、終末大動脈から左総腸骨動脈、内外腸骨動脈分岐部直下まで周囲に軟部影を認め、後腹膜線維症を伴う膵腫瘍性病変の診断で入院とした。MRCPでは主膵管は尾部で描出されず、MRIでは膵尾部は全体に腫脹し、T1で低信号、T2で等信号、造影で周囲線維化を示唆する造影遅延は認めなかった。ERCPでは膵尾部は途絶して描出されず、膵液細胞診はClass IIであった。膵管癌が否定できず、膵尾部及び脾合併切除術を行った。病理所見にて、膵管周囲と膵小葉に高度のリンパ球、形質細胞の浸潤と線維化を認め、後腹膜線維症を伴った自己免疫性膵炎と診断された。術後、Prednisolone投与で後腹膜線維症は改善した。

    DOI: 10.11280/gee1973b.50.234

    researchmap

  • 胃壁内転移をきたした食道表在癌の1例

    関 慶一, 太田 宏信, 上村 博輝, 今井 径卓, 石川 達, 渡辺 孝治, 吉田 俊明, 上村 朝輝, 若井 淳宏, 武者 信行, 石原 紀子

    ENDOSCOPIC FORUM for digestive disease   23 ( 2 )   163 - 163   2007年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • 【肝胆膵がんと化学療法のすべて】 肝疾患 薬剤からみた化学療法 作用機序、理論と投与方法、成績、副作用 UFT-E(Enteric-coated tegafur/uracil)

    石川 達, 今井 径卓, 上村 博輝, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝・胆・膵   55 ( 5 )   881 - 888   2007年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • 顕微鏡的多発血管炎(miroscopic polyangiitis)にreversible posterior leukoencephalopathy syndrome(RPLS)を併発した1例

    上村 博輝, 広瀬 慎太郎, 田崎 和之, 鈴木 靖, 佐藤 正久

    日本内科学会雑誌   96 ( 11 )   2532 - 2535   2007年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    症例は20歳女性で、1ヵ月ほど前から両眼充血を呈して眼科を受診、上強膜炎と診断されたが、CRP高度上昇とタンパク質尿・血尿・尿細管障害をきたしていたため精査加療目的で紹介入院となった。入院後の腎生検にてcellular circular cresentic formationを認める壊死性半月体形成性腎炎の所見であり、急性進行性腎炎・胸膜炎・MPO-ANCA陽性・CRP陽性・タンパク質尿・血尿の出現により主要症候2項目・主要検査所見3項目以上を満たしていることからmicroscopic polyangiitis(MPA)と診断した。ステロイドパルス(デキサメタゾン)100mgを2回投与後にプレドニゾロン(PSL)40mg/日内服の開始により、CRP改善、P-ANCAが軽減したためPSL35mg/日となった第50病日に退院となった。退院後、深夜に頭痛を訴え救急外来を受診、神経内科外来待合室にて強直性痙攣発作が出現し、ジアゼパム・フェニトインの静注により痙攣は消失したが精査加療目的で再入院となった。頭部MRI FLAIR画像にて橋中央に単一ほぼ左右対称の高信号域、左前頭葉にも高信号域を認め、当初は後頭葉白質病変はMPAによる脳血管炎と考え、PSLを30mgから60mg/日に増量したところその後は症状の再発は認めなかった。しかし、臨床経過と画像所見からreversible posterior leukoencephalopathy syndrome(RPLS)が強く疑われ、RPLSの原因がMPA又はステロイド療法による可能性も考慮して、免疫抑制薬のシクロフォスファミド大量間欠静注療法への切り替えを行った。シクロフォスファミド大量間欠静注療法2コース終了・PSL30mg/日内服で退院となり、その後外来にてシクロフォスファミド大量間欠静注療法15コースを施行、PSLは6mg/日にて継続している。9ヵ月後の頭部MRIでは病変部は完全消失し、更に6ヵ月後にはMPO-ANCAも陰転化した。

    DOI: 10.2169/naika.96.2532

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: https://jlc.jst.go.jp/DN/JALC/00303170301?from=CiNii

  • 急性腹症として発生した肝梗塞の一例

    上村 博輝, 今井 径卓, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本消化器病学会雑誌   104 ( 臨増大会 )   A707 - A707   2007年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • B型慢性肝炎に合併したFibrolamellar hepatocellular carcinoma(FLC)の1切除例

    石川 達, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 武者 信行, 坪野 俊広, 酒井 靖夫, 武田 敬子, 石原 法子, 上村 朝輝

    日本消化器病学会雑誌   104 ( 7 )   1076 - 1081   2007年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    Fibrolamellar hepatocellular carcinoma(FLC)の1切除例を経験したので報告する。症例は34歳、女性。姉がB型慢性肝炎合併肝細胞癌にて死亡。精査目的に来院し、肝腫瘍を指摘され、入院。腹部CT,MRI、血管造影などの画像所見からFibrolamellar hepatocellular carcinoma(FLC)を疑い、肝部分切除術施行。病理組織学的にもFLCと診断した。現在術後、2年6ヵ月経過観察中である。B型慢性肝炎に合併したFLCはまれであり、若干の文献的考察を加えて報告する。(著者抄録)

    DOI: 10.11405/nisshoshi.104.1076

    researchmap

  • 初発単発30mm以下肝細胞癌症例に対する経皮的ラジオ波焼灼療法(RFA)後の局所再発と異所性再発形式の検討

    石川 達, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝臓   48 ( Suppl.1 )   A92 - A92   2007年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 昇圧動注化学療法は高齢者切除不能膵癌に対して内科的治療戦略となりうるか

    石川 達, 今井 径卓, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本高齢消化器病学会誌   8-9 ( 2 )   103 - 107   2007年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本高齢消化器病学会  

    昇圧動注化学療法を行った切除不能膵癌20例を65歳以上の高齢者群10例と非高齢者群10例に分け、治療成績を比較検討した。その結果、1)50%生存期間は非高齢者群372日、高齢者群301日で有意差を認めなかった。2)高齢者群の8例(80%)に症状緩和効果を認め、全例外来治療に移行できた。3)有害事象として、非高齢者群3例、高齢者群3例にGrade 2の血液毒性、非血液毒性を認めたが、Grade 3/4の副作用は認めなかった。4)昇圧動注化学療法は高齢者であっても副作用の軽減が得られ、高い治療効果が認められ、切除不能膵癌症例の積極的緩和治療として有用と考えられた。

    researchmap

  • 経皮経肝的胆管内視鏡(PTCS)下に胆道鏡下電気水圧式衝撃波(EHL)と乳頭バルーン拡張術を用いて巨大胆管結石の排石を認めた一例

    上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本消化器病学会雑誌   104 ( 臨増総会 )   A230 - A230   2007年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 高齢者C型慢性肝炎に対するIFNβ先行投与後PegIFN製剤の有用性

    石川 達, 今井 径卓, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本消化器病学会雑誌   104 ( 臨増総会 )   A138 - A138   2007年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 重症急性膵炎に伴う急性肺障害に対する好中球エラスターゼ阻害薬(sivelestat sodium)の有用性

    石川 達, 牛木 隆志, 今井 径卓, 上村 博輝, 土屋 淳紀, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    Progress in Medicine   27 ( 2 )   409 - 412   2007年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)ライフ・サイエンス  

    症例1:56歳男。心窩部痛が増悪し、ショック状態を来たした。検査所見で白血球数、amylaseなどの上昇、CTで両側傍腎腔の液体貯留などを認め、急性膵炎、Grade Vと診断し、APACHE II scoreも11点であったため、蛋白分解酵素阻害薬および抗菌薬の動注療法を行った。加療開始後改善傾向を認めたが、全身性炎症反応症候群に伴う急性肺障害を合併したため、人工呼吸管理と同時にsivelestat sodium、利尿薬、アルブミン製剤の投与を開始した。病態は改善し6日間で抜管でき、内科的治療の継続により退院となった。症例2:27歳男。腹痛が増悪し、ショック状態となった。CTで膵融解像、膵・腎周囲滲出液を認め、急性膵炎、Grade IV、APACHE II score 8点と診断し、動注療法および持続血液濾過透析を施行した。更に、PaO2/FIO2比の低下傾向を認めたため、急性呼吸窮迫症候群の危険性を考えsivelestat sodiumを併用した。その結果、早期改善を認め、発症23日で退院した。

    researchmap

  • 転移性肝癌に対する経皮的ラジオ波焼灼療法の検討

    石川 達, 今井 径卓, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本内科学会雑誌   96 ( Suppl. )   106 - 106   2007年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    researchmap

  • 動注用アイエーコールによる腫瘍壊死を病理学的に確認しえた肝細胞癌切除例

    石川 達, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 坪野 俊広, 武田 敬子, 石原 法子, 上村 朝輝

    肝臓   48 ( 1 )   27 - 32   2007年

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    症例は61歳女性。54歳時クモ膜下出血にて入院の際に、HCV抗体陽性を指摘され、以後、某病院にて経過観察されていた。平成14年より肝障害持続し、C型慢性肝炎に対しInterferon療法施行するもうつ症状にて中止。経過観察中に腹部CTにて肝細胞癌の出現を認め平成17年1月20日入院。2月1日腹部血管造影を施行し、左肝動脈より動注用アイエーコールを動注後、2月9日に肝部分切除を施行した。腫瘍部は全体が壊死に陥り、腫瘍被膜下にわずかにvividな腫瘍組織を認めるのみであった。CDDPは癌細胞内DNA鎖と結合、DNA合成とそれに続く癌細胞分裂を阻害することで殺細胞効果を示すが、動注用アイエーコールはCDDPを動注内投与に適した微粉末にした新規剤型の抗癌剤であり、従来の静注用CDDPと比較して濃度依存性殺細胞効果が高まることが期待されている。今回我々は動注用アイエーコールによる腫瘍壊死を病理学的に確認できた1例を経験したので報告した。(著者抄録)

    DOI: 10.2957/kanzo.48.27

    Scopus

    researchmap

  • B型慢性肝炎に合併したFibrolamellar hepatocellular carcinoma(FLC)の1切除例

    石川 達, 今井 径卓, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 武者 信行, 坪野 俊広, 酒井 靖夫, 武田 敬子, 石原 法子, 上村 朝輝

    肝臓   47 ( Suppl.3 )   589 - 589   2006年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • サイトメガロウイルス(CMV)感染性腸炎の2例

    関 慶一, 渡辺 孝治, 石川 達, 土屋 淳紀, 上村 博輝, 太田 宏信, 吉田 俊明, 広瀬 慎太郎, 石原 紀子, 上村 朝輝

    ENDOSCOPIC FORUM for digestive disease   22 ( 2 )   165 - 165   2006年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • IFN療法著効後に肝細胞癌が発生したC型慢性肝炎の2例

    石川 達, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 石原 法子, 上村 朝輝

    肝臓   47 ( Suppl.3 )   549 - 549   2006年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Docetaxel動注を主体とした多剤併用化学療法により完全消失をみた肝細胞癌術後多発肺転移の一例

    土屋 淳紀, 石川 達, 今井 径卓, 上村 博輝, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝臓   47 ( Suppl.3 )   589 - 589   2006年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 急激な臨床経過をたどった転移性肝癌の一剖検例

    上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝臓   47 ( Suppl.3 )   594 - 594   2006年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝性脳症に対しB-RTOが奏功した肝硬変の一例

    上村 博輝, 今井 径卓, 土屋 淳紀, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝臓   47 ( Suppl.3 )   615 - 615   2006年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 【肝がん治療のすべて】 肝細胞癌 化学療法 肝細胞癌に対する全身化学療法の現況 経口抗癌剤投与の臨床的意義

    石川 達, 上村 博輝, 土屋 淳紀, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝・胆・膵   53 ( 5 )   713 - 721   2006年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • 上腸間膜静脈・門脈血栓症を伴うIPHと考えられた一例

    上村 博輝, 牛木 隆志, 冨樫 忠之, 渡邉 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 武者 信行, 坪野 俊広, 酒井 靖夫, 石原 法子, 武田 敬子, 上村 朝輝

    ENDOSCOPIC FORUM for digestive disease   22 ( 1 )   72 - 72   2006年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • 胃静脈瘤に対するB-RTO後の食道静脈瘤の経過に関する検討

    石川 達, 上村 博輝, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    Gastroenterological Endoscopy   48 ( Suppl.1 )   759 - 759   2006年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 肝細胞癌に対するRITA社ハンドピースModel-90展開型RFAニードルの使用経験

    石川 達, 上村 博輝, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本内科学会雑誌   95 ( Suppl. )   174 - 174   2006年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    researchmap

▶ 全件表示

受賞

  • 新潟大学プロジェクト推進受賞

    2013年   新潟大学  

    上村博輝

     詳細を見る

  • 若手研究支援受賞

    2013年   新潟大学  

    上村博輝

     詳細を見る

  • 特別研究費受賞

    2012年   独立行政法人労働者健康福祉機構  

    上村博輝

     詳細を見る

  • 市田賞

    2011年   新潟大学消化器内科  

    上村博輝

     詳細を見る

  • 新潟県医師会研究奨励賞

    2009年   新潟県医師会  

    上村博輝

     詳細を見る

共同研究・競争的資金等の研究

  • 心不全による進行性うっ血性肝不全を制御する細胞外小胞の解明

    研究課題/領域番号:23K07372

    2023年4月 - 2026年3月

    制度名:科学研究費助成事業

    研究種目:基盤研究(C)

    提供機関:日本学術振興会

    上村 博輝, 寺井 崇二, 柏村 健, 土屋 淳紀

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • 次世代型サルコペニア対策を可能にする肝筋臓器連関における細胞外小胞の解明

    研究課題/領域番号:20K08326

    2020年4月 - 2023年3月

    制度名:科学研究費助成事業 基盤研究(C)

    研究種目:基盤研究(C)

    提供機関:日本学術振興会

    上村 博輝, 寺井 崇二, 土屋 淳紀

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    高齢化が進む我が国において、加齢に伴い医療・介護費を増加させる病態であるサルコペニア(筋肉の量・機能低下)への対策は喫緊の課題である。肝不全では早期にサルコペニアが出現する事が注目されているが、本研究ではその病態を解明するためのモデル動物の作成、早期の段階で介入の指標となるバイオマーカーの確立を目指す。
    肝不全サルコペニアモデルや臨床検体からプロテオミクス、miRNA解析を行い、モデル動物の結果と照合し、肝不全時に筋肉を臓器不全へ陥らせるサルコペニアのEVバイオマーカーを確立し、次世代型サルコペニア対策へと結び付ける。
    第一段階として,初年度は老化促進モデルマウス+肝傷害等の組み合わせを行い,肝不全とサルコペニアを同時に評価できる新規モデル動物の構築を行った。
    肝疾患併発サルコペニア対象モデルマウスについては,Melanocortin-4 Receptor(MC4R)ノックアウト(KO)マウスに対して,Dextran sulfate sodium (DSS) 誘導性による腸炎を併発した脂肪肝由来のサルコペニアモデルマウスを開発して運動解析を行った。握力とともに,オープンフィールドの実験を行い,個別の運動解析を行った。当該マウスより、血清,肝臓,心臓,大腿四頭筋,ヒラメ筋の摘出を行い,これらのマイオカインと肝発癌、NASスコアについて解析を継続している。肝硬変サルコペニア患者について、マイオカインの網羅的測定を行った。

    researchmap

  • 肝内リンパ濾胞と肝星細胞活性化との排除の機序解明による組織線維化対策

    研究課題/領域番号:17H06691

    2017年8月 - 2019年3月

    制度名:科学研究費助成事業 研究活動スタート支援

    研究種目:研究活動スタート支援

    提供機関:日本学術振興会

    上村 博輝, 薛 徹, 上村 顕也, 高村 昌昭, 寺井 崇二

      詳細を見る

    配分額:2730000円 ( 直接経費:2100000円 、 間接経費:630000円 )

    肝内に形成されたリンパ濾胞組織は慢性C型肝炎の組織においてみられることが多かったが、肝炎ウイルス排除のための研究・臨床が第一義であったため、これまで肝リンパ濾胞組織と組織線維化について行われた研究はなかった。炎症の源を形成する 肝内でのリンパ濾胞組織と間質細胞への細胞間コミュニケーションを解明し、革新的組織線維化対策に寄与することを目的として本研究を開始させて頂いた。慢性C型肝炎の診療で採取され、当科で冷所保存しているFFPE検体について、リンパ濾胞を有する組織で分化したと考えらえる周囲インターフェイス領域の各種免疫担当細胞の解析を行った。

    researchmap

  • 抗MICA抗体による抗体関連型拒絶反応を応用した肝細胞癌に対する新規治療法の開発

    研究課題/領域番号:26860497

    2014年4月 - 2016年3月

    制度名:科学研究費助成事業 若手研究(B)

    研究種目:若手研究(B)

    提供機関:日本学術振興会

    上村 博輝

      詳細を見る

    配分額:1560000円 ( 直接経費:1200000円 、 間接経費:360000円 )

    慢性肝炎由来の肝細胞癌発癌症例について、MICAの発現を確認し、保存血清を利用して抗MICA抗体の測定をLABScreen MICA Single Antigen testsを行った。また血清対応型SSOでHLAタイピング検査を行ったが自己アリルとは同一のものが存在しなかった。抗MICA抗体については抗腫瘍抗体として出現した自己抗体ではない可能性が考慮された。
    抗MICA抗体測定と同時に行ったsMICAに関してはB型慢性肝炎については核酸アナログ導入前後のsMICAの濃度はは多変量解析によりHCC発癌と関連する最も有意な因子であり,核酸アナログ導入後の発癌予測マーカーとなる可能性が示唆された。

    researchmap